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INTRODUCTION 
 
G-protein-coupled receptors (GPCRs) are physiologically important membrane proteins 
that sense signaling molecules such as hormones and neurotransmitters, and are the 
targets of several prescribed drugs. Recently, the process of heterodimerization among 
GPCRs has attracted attention because of its potential to generate the diversity in the 
regulatory machinery of signaling. Since the mechanism of GPCR signaling in yeast is 
similar to that in mammalian cells and various GPCRs have been successfully expressed 
in yeast Saccharomyces cerevisiae, the yeast is an attractive host organism for the study 
of human GPCRs. In this thesis, we developed microbial yeast biosensors to monitor 
signal transmission and heterodimer formation for human GPCRs. Because these 
biosensors permitted the facile detection of GPCR dimerizations as well as the 
convenient monitoring of the signal activation, it is applicable to the identification of 
obscured heterodimer partners and the screening of new agonistic and antagonistic 
peptides for target human GPCRs. Additionally, we integrated these two detection 
systems into a single yeast strain to enable the simultaneous detections of dimerization 
and signaling of human GPCRs. The constructed yeast biosensors will assist the 
elucidation of mechanisms and roles of GPCR dimerizations, and promote the discovery 
of new GPCR heterodimer pairs and lead peptides as potential therapeutic targets. 
 
G-protein-coupled receptor 
G-protein-coupled receptors (GPCRs) are located in the plasma membrane and 
transmit external signals into the cell. GPCRs constitute the largest family of membrane 
proteins and are involved in the majority of signal transduction. The common  
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Fig. 1. (A) Characteristics of G-protein-coupled receptor. (B) Molecular targets of 
known drugs. 
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architecture of GPCRs has a seven transmembrane domain structure (Fredriksson et al., 
2003; Takeda et al., 2002) that responds to a remarkable range of stimuli, including 
neurotransmitters, hormones, and ions (Lefkowitz and Shenoy, 2005). GPCRs transduce 
signals by activating heterotrimeric guanine nucleotide-binding proteins (G-proteins, 
Gilman, 1987) (Figure 1). GPCRs are the most important research target in 
biomolecular and medical sciences because they are the most common targets of 
therapeutic drugs (Gudermann et al., 1995; Heilker et al., 2009). Due to their excellent 
potential for drug discovery, GPCR targets represent up to 30% of the portfolio of many 
pharmaceutical companies (Klabunde and Hessler, 2002). Although the human genome 
contains 720‒800 GPCRs (Siehler, 2008), it is still less than 50 GPCRs that are the 
targets of commercially available drugs (Eglen et al., 2007). Thus, GPCRs are attractive 
proteins not only for basic understandings of physiological and biological actions but 
also for commercial targets in medicinal and pharmaceutical area. 
 
GPCR dimerization 
Protein‒protein interactions have fundamental roles in a variety of biological 
functions, and are of central importance for virtually every process in a living cell. It is 
now clear that GPCRs interact with a range of proteins, including other GPCRs 
(Bockaert et al., 2010; Ferré and Franco, 2010; Ritter and Hall, 2009). Identifying and 
elucidating the function of such interactions will significantly enhance our 
understanding of cellular control systems, with the promise of new and improved 
pharmaceuticals. Evidence suggests that oligomerization (dimerization, including 
homo-dimerization and hetero-dimerization) of GPCRs is important for their trafficking 
to and from the plasma membrane (Benkirane et al., 1997; Grosse et al., 1997; Jordan et  
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Fig. 2. Schematic illustration of the pheromone signaling pathway. (A) In the absence of 
α-factor, heterotrimeric G-protein is unable to activate the pheromone signaling pathway. 
(B) Binding of α-factor to Ste2p receptor activates the pheromone signaling pathway 
through heterotrimeric G-protein. Sequestered Ste4p–Ste18p complex from Gpa1p 
activates effectors and subsequent kinases that constitute the MAPK cascade, resulting 
in phosphorylation of Far1p and Ste12p. Phosphorylation of Far1p leads to cell cycle 
arrest. Phosphorylation of Ste12p induces global changes in transcription. Sst2p 
stimulates hydrolysis of GTP to GDP on Gpa1p, and helps to inactivate pheromone 
signaling. 
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al., 2001; Margeta-Mitrovic et al., 2000), for agonist binding activity (Jordan and Devi, 
1999; Mijares et al., 2000; Potter et al., 1991), for signal transduction (AbdAlla et al., 
2000; Hebert et al., 1996), and for down-regulation of receptor expression (Cvejic and 
Devi, 1997; Yesilaltay and Jenness, 2000). 
Currently, the ascendancy of GPCRs as molecular targets has gradually decreased 
among newly developed Food and Drug Administration (FDA)-approved drugs (Drews, 
2000; Overington et al., 2006), in part because conventional screening trials have been 
exhausted. Therefore, new screening trials, such as heterodimer-targeted ligand 
screening, are required for further drug discovery. Notably, dimerization has increased 
the potential diversity in regulation and modulation of GPCR signaling, and thus the 
specific evaluation of signaling properties among variously dimerized receptors will 
offer important implications for the development of new drugs as well as the 
understanding of signaling networks (Jordan and Devi, 1999). 
 
Yeast Saccharomyces cerevisiae 
The budding yeast Saccharomyces cerevisiae is one of the simplest unicellular 
eukaryotes, and is often used as a eukaryotic model organism for cellular and molecular 
biology (Lushchak, 2006; Schneiter, 2007; Sychrová, 2004; Wang and Dohlman, 2006; 
Winderickx et al., 2008). Yeast has several benefits, including the possession of 
eukaryotic secretory machinery, post-translational modifications, rapid cell growth, and 
well-established and versatile genetic techniques.  
In addition, the S. cerevisiae is a useful microbial host organism for studying 
GPCRs as monomolecular models (Ishii et al., 2010; Minic et al., 2005). All eukaryotes 
conserve heterotrimeric G-proteins that comprise Gα-, Gβ- and Gγ-subunits. 
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Mammalian cells possess several types of G-proteins on the inner leaflets of plasma 
membranes. These G-proteins enable to regulate diverse physiological responses 
through coupling with a variety of transmembrane GPCRs (Hur and Kim, 2002). 
However, this diversity makes it difficult to identify which G-protein is responsible for 
controlling the specific signals (Ishii et al., 2010). Because haploid S. cerevisiae 
expresses one type of GPCR (either the a-cell specific pheromone receptor, Ste2p, or 
the α-cell specific pheromone receptor, Ste3p) and one type of heterotrimeric complex 
of G-proteins (yeast Gα, Gβ and Gγ; Gpa1p, Ste4p and Ste18p) (Figure 2), it can offer a 
simple way to transduce the signal promoted by the agonistic ligand (Fukuda et al., 
2011). The heterotrimeric G-protein is divided into two key components from the 
perspective of structure and function. Gα (Gpa1p) is associated with the intracellular 
plasma membrane through the dual lipid modifications of myristoylation and 
palmitoylation in the N-terminus (Manahan et al., 2000), whereas the Gβγ dimer (the 
Ste4p‒Ste18p complex) is also localized to the inner leaflet of the plasma membrane 
through the farnesylation and myristoylation in the C-terminus of Ste18p that forms a 
complex with Ste4p (Hirschman and Jenness, 1999; Manahan et al., 2000). 
In the yeast haploid a-cell, the heterotrimeric G-proteins are closely associated 
with the intracellular domain of the Ste2p receptor, and the pheromone (α-factor; 
tridecapeptide)-bound receptor is conformationally changed and activates the 
G-proteins (Dosil et al., 2000). Gpa1p is thereby changed from an inactive GDP-bound 
state to an active GTP-bound state and dissociated Ste4p‒Ste18p complex. 
Subsequently, the dissociated Ste4p‒Ste18p complex binds to the following effectors 
through Ste4p, and then activates the mitogen-activated protein kinase (MAPK) cascade 
(Leberer et al., 1997: Leeuw et al., 1998). The Ste5p scaffold protein binds to the 
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kinases of the MAPK cascade composed of Ste11p, Ste7p and Fus3p, and brings them 
to the plasma membrane. The concentration of the bound kinases on the membrane 
possibly promotes amplification of the signal (Elion, 2001; Pryciak and Huntress, 1998). 
As a consequence, the activated pheromone signaling leads to the phosphorylation of 
Far1p and the transcription factor Ste12p. These phosphorylated proteins trigger cell 
cycle arrest in G1 (Chang and Herskowitz, 1990, 1992; McKinney and Cross, 1995) and 
global changes in transcription (Dolan et al., 1989; Song et al., 1991). FIG1 gene 
expression is representative of the drastic changes in transcription in response to 
pheromone signaling (Muller et al., 2003). As a principal negative regulator, the 
Gpa1-specific GTPase-activating protein Sst2p, a member of the regulator of G-protein 
signaling family, is also involved in the pathway (Apanovitch et al., 1998; Dohlman et 
al., 1996). 
 
Expression of heterologous GPCRs 
Many heterologous GPCRs containing adrenergic, muscarinic, serotonin, 
neurotensin, somatostatin, olfactory and many other receptors have been successfully 
expressed in yeast, and the feasibility of yeast-based GPCR screening systems has been 
demonstrated (Brown et al., 2000; Erlenbach et al., 2001; King et al., 1990; Ladds et al., 
2005; Leplatois et al., 2001; Li et al., 2007; Minic et al., 2005; Price et al., 1995). Yeast 
Gpa1p, which is equivalent to Gα, shares high homology, in part, with human Gαi 
classes, and a number of GPCRs of human and other species are able to interact with 
Gpa1p and activate pheromone signaling in yeast (Brown et al., 2000; Leplatois et al., 
2001; Price et al., 1995). Many other human GPCRs can also function as yeast signaling 
modulators as a result of various genetic modifications, including chimeric Gpa1p  
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Fig. 3. Schematic illustration of typical genetic modifications enabling the pheromone 
signaling pathway to be used as a biosensor to represent activation of GPCRs. Intact or 
chimeric Gpa1p can transduce the signal from yeast endogenous Ste2p or heterologous 
GPCRs that are expressed on the yeast plasma membrane. Transcription machineries 
that are closely regulated by the phosphorylated transcription factor, Ste12p, are used to 
detect activation of pheromone signaling with various reporter genes. FAR1, SST2 and 
STE2 are often disrupted (shown in light gray) to prevent growth arrest, improve ligand 
sensitivity, and avoid competitive expression of yeast endogenous receptor. 
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systems (so-called ‘transplants’), in which only five amino acids in the C-terminus of 
Gpa1p are substituted for those of human Gα subunits, such as the Gαi/o, Gαs and Gαq 
families (Figure 3) (Erlenbach et al., 2001). Indeed, these transplants have allowed 
functional coupling of serotonin, muscarinic, purinergic and many other receptors to the 
yeast pheromone pathway (Brown et al., 2000; Erlenbach et al., 2001; Li et al., 2007; 
Pausch et al., 2004). Introduction of reporter genes, such as green fluorescent protein 
(GFP) (Iguchi et al., 2010; Togawa et al., 2010), β-galactosidase (lacZ) (Brown et al., 
2000), luciferase (luc) (Fukutani et al., 2012) and growth selection marker (HIS3) 
(Manfredi et al., 1996) downstream of the pheromone signaling (G-protein signaling) 
pathway further facilitates the detection of the agonist-promoted signal. 
If the expression of human GPCR on the plasma membrane of ste2Δ yeast a-cell 
permits coupling with yeast monopolistic G-proteins, the promoted signaling by the 
cognate ligand or analog agonist can be easily monitored with reporter gene assays 
(Fukuda et al., 2011; Ishii et al., 2010). The use of an established fluorescence-based 
reporter gene assay provides the most convenient measurement procedure: the cell 
culture is simply diluted into buffers and the fluorescence is read using fluorometric 
instruments (Ishii et al., 2012). A flow cytometer is an especially powerful tool for 
comparative quantification and quantitative screening (cell sorting) (Ishii et al., 2012). 
 
Yeast two-hybrid system 
Many methodologies for elucidating protein interactions have been developed 
during the past couple of decades. To investigate interactions inside cells under 
physiological conditions, especially, yeast would be a most typical organism, and 
various in vivo approaches are now available. 
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The yeast two-hybrid (Y2H) system, which was originally designed to detect 
protein‒protein interactions in vivo by separation of a transcription factor into a 
DNA-binding domain and a transcription activation domain, is a typical representative 
of a yeast-based genetic approach (Fields and Song, 1989), and numerous improved 
Y2H systems have been developed to overcome its potential problems (Ishii et al., 
2010). Despite significant progress in development of the Y2H systems, the analysis of 
interactions between membrane proteins remained a significant challenge because of the 
hydrophobic nature of these proteins (Thaminy et al., 2003). Recently, a modified 
two-hybrid approach, the split-ubiquitin membrane Y2H system witch can specifically 
apply to membrane proteins, has emerged as a powerful tool to protein‒protein 
interaction in living cells (Stagljar et al., 1998). 
 
Constituent of this thesis 
In this study, we established the yeast-based approaches for elucidating the 
relationship between functions and structures of human GPCRs. For evaluating GPCR 
functions, we improved the system to monitor signal transmission for human GPCRs. 
For examining GPCR structures, we developed the system to monitor heterodimer 
formation among different types of human GPCRs. Finally, we combined these two 
systems into one yeast strain to simultaneously monitor the dimerization and the 
signaling. The findings of physiologically relevant GPCR dimers raise the prospect of 
developing new drugs against a wide range of diseases by focusing on the machinery of 
targeted dimers. This study is expected to provide a helpful tool for the elucidating of 
molecular biological functions of GPCR dimers and for the screening of GPCR 
dimer-specific agonistic ligands. 
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The contents in each part were described as below. 
 
Part I: Microbial yeast biosensors to monitor signal transmission for human 
G-protein-coupled receptors 
Yeast-based fluorescence reporter ligand detection system is useful for GPCR 
signaling assay since detection using a fluorescence reporter considerably simplifies the 
measurement procedure. However, the weak fluorescence generated from an 
agonist-induced cells expressing enhanced green fluorescent protein (EGFP) has limited 
the classes of GPCRs, which can be analyzed with this conventional detection system. 
In order to extend the ranges of applicable GPCRs, we constructed an improved 
fluorescence-based microbial yeast biosensor that can monitor the activation of human 
GPCR signaling responding to its agonist using tetrameric Zoanthus sp. green 
fluorescent protein (ZsGreen) as a reporter. In addition, we established a highly 
sensitive ligand detection system using yeast cell surface display technology that is 
applicable to peptide screening, and demonstrate that the display of various peptide 
analogs of neurotensin can activate signaling through the neurotensin receptor in yeast 
cells. Moreover, using the refined fluorescence biosensor, we successfully applied to 
antagonist characterization and site-directed mutagenesis analyses of human serotonin 
receptor. Furthermore we succeeded in the functional signal activation of mutated 
human angiotensin receptor in engineered yeast cells. This study showed that our 
strategy could apply to various human GPCRs by improving the sensitivity of detection 
system and modifying the human GPCRs. 
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Part II: Microbial yeast biosensors to monitor heterodimer formation for human 
G-protein-coupled receptors 
Potentially immeasurable heterodimer combinations of human GPCRs result in a 
great deal of physiological diversity and provide a new opportunity for drug discovery. 
However, due to the existence of numerous combinations, the sets of GPCR dimers are 
almost entirely unknown and thus their dominant roles are still poorly understood. This 
study shows a mitogen-activated protein kinase (MAPK) signal-independent method 
specialized to screen candidate heterodimer partners for human GPCRs based on 
split-ubiquitin two-hybrid technology. By using the constructed method, we 
successfully identified new candidates as heterodimer partners for human GPCRs. In 
addition, since our system is independent from the activation of MAPK signal, it 
permits not only the identification of heterodimer partners, but also the monitoring of 
ligand-induced conformational changes. Finally, this study shows an advanced method 
to simultaneously analyze dimerization and ligand response of GPCRs using two 
yeast-based systems for split-ubiquitin two-hybrid assay and G-protein signaling assay. 
To monitor the specific profiling for functional consequences of dimerization linked to 
ligand-mediated signaling, we successfully demonstrated that the system was capable of 
simultaneously monitoring the dimerization and the signaling by human GPCRs. 
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SYNOPSIS 
 
Part I. Microbial yeast biosensors to monitor signal transmission for human 
G-protein-coupled receptors 
 
Chapter 1 
Bright fluorescence monitoring system utilizing Zoanthus sp. green fluorescent 
protein (ZsGreen) for human G-protein-coupled receptor signaling in microbial 
yeast cells 
G-protein-coupled receptors (GPCR(s)) are currently the most important 
pharmaceutical targets for drug discovery because they regulate a wide variety of 
physiological processes. Consequently, simple and convenient detection systems for 
ligands which regulate the function of GPCR have attracted attention as powerful tools 
for new drug development. We previously developed a yeast-based fluorescence 
reporter ligand detection system using flow cytometry. However, using this 
conventional detection system, fluorescence from a cell expressing GFP and responding 
to a ligand is weak, making detection of these cells by fluorescence microscopy difficult. 
We here report improvements to the conventional yeast fluorescence reporter assay 
system resulting in the development of a new highly-sensitive fluorescence reporter 
assay system with extremely bright fluorescence and high signal-to-noise (S/N) ratio. 
This new system allowed the easy detection of GPCR signaling in yeast using 
fluorescence microscopy. Somatostatin receptor and neurotensin receptor (implicated in 
Alzheimer’s disease and Parkinson’s disease, respectively) were chosen as human 
GPCR(s). The facile detection of binding to these receptors by cognate peptide ligands 
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was demonstrated. In addition, we established a highly sensitive ligand detection system 
using yeast cell surface display technology that is applicable to peptide screening, and 
demonstrate that the display of various peptide analogs of neurotensin can activate 
signaling through the neurotensin receptor in yeast cells. Our system could be useful for 
identifying lead peptides with agonistic activity towards targeted human GPCR(s). 
 
Chapter 2 
Applications of microbial signaling biosensor using Zoanthus sp. green fluorescent 
protein for antagonist characterization and site-directed mutagenesis of human 
serotonin 1A receptor 
The neurotransmitter serotonin (5-HT) regulates a wide spectrum of human 
physiology through the 5-HT receptor family. As the signaling mediator, 5-HT1A 
receptor (HTR1A) that is the most widely studied subtype is a significant molecular 
target in medicinal and therapeutic fields. Yeast-based fluorescence reporter system is 
useful for GPCR assay since detection using a fluorescence reporter considerably 
simplifies the measurement procedure. However, previously reported systems using 
enhanced green fluorescent protein (EGFP) as the reporter gene still showed low 
signal-to-noise (S/N) ratio, making it difficult to apply to antagonist characterization 
and mutagenesis approaches. In this study, we employed a highly-potent fluorescence 
reporter (ZsGreen) and Gα-engineered yeast strain for making a refined yeast-based 
GPCR biosensor. Using the refined fluorescence biosensor, we successfully applied to 
antagonist characterization and site-directed mutagenesis analyses of human HTR1A 
receptor. The HTR1A antagonist, pindolol, was detected to specifically inhibit the 
agonist-induced activating HTR1A. In mutagenesis experiments, not only previously 
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reported mutants, but also the role of the highly conserved DRY motif in activation of 
HTR1A was investigated. Since our system provided rapid and facile assays for 
antagonist characterization and site-directed mutagenesis of HTR1A, our system has a 
potential for the effective tool towards human GPCR analyses. 
 
Chapter 3 
Yeast-based biosensing for functional Asn295-mutated human angiotensin II type 1 
receptor signal activation 
Angiotensin II (Ang II) type 1 receptor (AGTR1) is a G-protein-coupled receptor 
(GPCR). Its natural ligand, Ang II, is an important effector molecule controlling blood 
pressure and volume in the cardiovascular system, and is consequently involved in 
various diseases such as hypertension and heart failure. Thus, the signaling mediator, 
AGTR1, is a significant molecular target in medicinal and therapeutic fields. Yeast is a 
useful organism for sensing GPCR signaling because it provides a simplified version of 
the complicated machinery used by mammalian cells for signal transduction. Although 
yeast cells can successfully transmit a signal through a variety of human GPCRs 
expressed in the cell membrane, there have been no reports of the functional activation 
of AGTR1-mediated signaling in yeast cells. In the present study, we introduced a single 
mutation into human AGTR1 and used yeast-human chimeric Gα to exert the functional 
activation of AGTR1 in yeast cells. The engineered yeast cells expressing AGTR1 
mutated at Asn295 and the chimeric Gα successfully transmitted the signal inside the 
yeast cells in response to Ang II peptide added to the assay medium. Further, we 
demonstrated that the autocrined Ang II peptide and its analog (Ang III peptide), 
produced and secreted by the engineered yeast cells, could by themselves promote 
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AGTR1-mediated signaling. This means that screening for agonistic peptides with 
various sequences from a self-produced genetic library would be a viable strategy. Thus, 
the constructed yeast biosensor, integrating an Asn295-mutated AGTR1 receptor, will 
be valuable in the design of drugs to treat AGTR1-related diseases. 
 
Part II. Microbial yeast biosensors to monitor heterodimer formation for human 
G-protein-coupled receptors 
 
Chapter 1 
Rapid, facile detection of heterodimer partners for target human 
G-protein-coupled receptors using a modified split-ubiquitin membrane yeast 
two-hybrid system 
Potentially immeasurable heterodimer combinations of human G-protein-coupled 
receptors (GPCRs) result in a great deal of physiological diversity and provide a new 
opportunity for drug discovery. However, due to the existence of numerous 
combinations, the sets of GPCR dimers are almost entirely unknown and thus their 
dominant roles are still poorly understood. Thus, the identification of GPCR dimer pairs 
has been a major challenge. Here, we established a specialized method to screen 
potential heterodimer partners of human GPCRs based on the split-ubiquitin membrane 
yeast two-hybrid system. We demonstrate that the mitogen-activated protein kinase 
(MAPK) signal-independent method can detect ligand-induced conformational changes 
and rapidly identify heterodimer partners for target GPCRs. Our data present the 
abilities to apply for the intermolecular mapping of interactions among GPCRs and to 
uncover potential GPCR targets for the development of new therapeutic agents. 
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Chapter 2 
Simultaneous method for analyzing dimerization and signaling of 
G-protein-coupled receptor in yeast by dual-color reporter system 
Understanding the role of G-protein-coupled receptor (GPCR) dimerization in 
cellular function has now become a major research focus. The potentially large 
functional and physiological diversity of dimerization among GPCRs is expected to 
provide opportunities for novel drug discovery. However, there is currently a lack of 
cell-based assays capable of specific profiling for the functional consequences of 
dimerization linked to ligand-mediated signaling. Here we present an advanced method 
to simultaneously analyze the dimerization and ligand response of GPCRs using two 
yeast-based systems for split-ubiquitin two-hybrid assay and G-protein signaling assay. 
To permit simultaneous detection, we established a two-color (dual-color) fluorescence 
reporter gene assay using enhanced green fluorescent protein (EGFP) and a far-red 
derivative of the tetrameric fluorescent protein DsRed-Express2 (E2-Crimson). In the 
present study, we tested our method first by analyzing dimerization and ligand-mediated 
signaling by the yeast endogenous pheromone receptor (Ste2p). Second, we showed that 
the system facilitated mutational analysis of domains involved in dimerization and 
signaling by Ste2p. Third, we successfully demonstrated that the system could 
simultaneously monitor homo- and hetero-dimerization and somatostatin-induced 
signaling in the test case of the human SSTR5 somatostatin receptor. Our strategy is 
expected to provide a useful tool for the elucidation of molecular biological functions of 
GPCR dimers and for the screening of GPCR dimer-specific agonistic ligands. 
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Chapter 1: Bright fluorescence monitoring system utilizing Zoanthus sp. green 
fluorescent protein (ZsGreen) for human G-protein-coupled receptor 
signaling in microbial yeast cells 
 
 
Introduction 
G-protein-coupled receptors (GPCRs) represent the largest family of 
transmembrane receptors and regulate a number of signaling events (Fredriksson et al., 
2003; Rasmussen et al., 2007). In humans, these receptors are activated by a large 
variety of stimuli ranging from small molecules to larger hormones. The stimulation of 
GPCRs has been reported to engage a broad range of physiological responses, such as 
blood pressure regulation, smooth muscle contraction, neurotransmission, and cell 
proliferation (Cotton and Claing, 2009). Their key roles in cell signaling have made 
GPCRs frequent pharmaceutical and therapeutic targets for drug discovery (Gudermann 
et al., 1995). GPCRs are cell surface transmembrane receptors that transduce signals via 
heterotrimeric guanine nucleotide binding proteins (G-proteins) comprising Gα-, Gβ- 
and Gγ-subunits in all eukaryotes (Ishii et al., 2010). 
The eukaryotic unicellular yeast, Saccharomyces cerevisiae, is a typical host cell 
used to study heterologous GPCRs at the molecular level (Iguchi et al., 2010; Togawa et 
al., 2010). Compared with mammalian cell lines, S. cerevisiae provides a simple and 
predictive way for studying GPCR signaling because it expresses only one kind of 
G-protein (Li et al., 2007). A variety of human GPCRs are known to transduce signals 
in yeast cells through the endogenous yeast Gα-subunit (Gpa1p) or a yeast–human 
chimeric G-protein (Fukuda et al., 2011; Ishii et al., 2012a). Furthermore, S. cerevisiae 
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is used for not only fundamental studies of signaling, but also for research into ligand 
screening and receptor mutagenesis due to its rapid cell growth and amenability to 
genetic manipulation compared with other eukaryotes (Evans et al., 2009; Klein et al., 
1998; Ladds et al., 2005; Li et al., 2007). 
Yeast cell-surface display technology is a powerful platform that enables proteins 
expressed in yeast to be tethered onto the cell surface (Gai and Wittrup, 2007; Kondo 
and Ueda, 2004; Pepper et al., 2008; Shibasaki et al., 2009; Ueda and Tanaka, 2000). 
This is accomplished by the use of “anchor” proteins that naturally localize on the cell 
surface in yeast cells. Typically, the gene encoding the target protein is fused to the 
anchor protein together with a secretion signal sequence at the N-terminus. This enables 
both the secretion of the fusion protein and tethers the protein firmly to the cell surface. 
Two typical anchor proteins are the C-terminal domains of truncated α-agglutinin 
(Sag1p; a manno-protein involved in sexual adhesion), and truncated Flo1p (a 
lectin-like cell-wall protein involved in flocculation) containing the 
glycosyl-phosphatidylinositol (GPI) anchor attachment signal sequence. Both proteins 
are used to fuse the target protein at their N-terminus (Murai et al., 1997; Sato et al., 
2002). To date, yeast cell-surface display technology has been adopted for a broad range 
of applications including enzymatic catalysis, immune adsorption, and protein 
engineering (Feldhaus et al., 2003; Murai et al., 1997; Nakamura et al., 2001; Sato et al., 
2002). 
Yeast cell-surface display of low molecular peptides on the cell surface forms the 
basis of several ligand assay systems (Hara et al., 2012; Ishii et al., 2012b). Expressing 
a peptide ligand fused to an anchor protein together with a cognate GPCR in a single 
yeast cell can lead to a series of biological processes within the cell that include 
29 
 
expression of peptide ligands, binding to a receptor, signal transmission, and trapping of 
peptides on the cell wall (Ishii et al., 2012b). In principle, because the tethered peptides 
are unable to diffuse out of the expression cell, they do not interfere or interact with 
neighboring cells. This technique forms the basis of the Cell Wall Trapping of Autocrine 
Peptides (CWTrAP) system. In CWTrAP, transformation of a plasmid library allows the 
display of various peptides in the engineered yeast with a signal-responsive reporter 
gene. This allows the facile production of a yeast cell library expressing different 
candidate peptides and the concurrent screening of target peptides. 
Three reporter genes, HIS3 (auxotrophy), lacZ (colorimetry), and luc 
(luminometry), are often used to detect the activation of GPCR signaling in yeast cells 
(Fukutani et al., 2012; Klein et al., 1998; Li et al., 2007). These reporter genes offer 
comprehensive screening, comparative quantification, and extremely high detection 
sensitivity, respectively. In contrast, the green fluorescent protein (GFP) reporter gene 
provides the most simple procedure for the preparation of measurement samples, by 
merely washing the cells (Fukuda et al., 2011; Iguchi et al., 2010; Ishii et al., 2012a, 
2012b; Togawa et al., 2010). The most common detection methods for GFP are 
fluorescence microscopy and flow cytometry (FCM). The detection sensitivity and 
throughput of FCM are high, enabling comparative quantification (Boder and Wittrup, 
1997; Fukuda et al., 2007), population analysis (Medico et al., 2001), and quantitative 
cell sorting (Aharoni et al., 2006; Stoeckius et al., 2009). However, not all researchers 
have access to expensive FCM equipment. 
On the other hand, fluorescence microscopes are comparatively common and 
inexpensive, are simple to operate, and allow cell visualization. However, unlike other 
reporter gene assay systems, fluorescence microscopy cannot amplify the fluorescence 
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signal by prolonging the reaction time between the enzyme and the substrate (Ishii et al., 
2014). This make it difficult to capture fluorescence images of cells responding to the 
ligand using conventional yeast GPCR assay systems, even when enhanced green 
fluorescent protein (EGFP) reporter gene is expressed. There is therefore need to 
improve the fluorescence reporter system in yeast GPCR assays. 
We here report a highly-sensitive fluorescence reporter system applicable to both 
the yeast-based GPCR assay and CWTrAP technology. By using the tetrameric 
Zoanthus sp. green fluorescent protein (ZsGreen), extremely high sensitivity (high 
signal-to-noise (S/N) ratio) and bright fluorescence were attained, allowing easy 
observation using fluorescence microscopy. First, we employed human somatostatin 
receptor subtype-5 (hSSTR5), used previously, to demonstrate the dramatic 
improvement in the sensitivity and brightness by comparing with a conventional 
yeast-based fluorescence reporter system. The usefulness of this approach was exhibited 
with yeast cell-surface display technology. Second, we validated the applicability of this 
methodology using human somatostatin receptor subtype-2 (hSSTR2) and human 
neurotensin receptor subtype-1 (hNTSR1) and demonstrated sufficient brightness to 
permit verification of trapped peptide ligands on the yeast cell wall. Third, we 
demonstrated that the display of various peptidic neurotensin analogs can activate 
hNTSR1-mediated signaling in yeast cells. 
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Materials and Methods 
Media. Synthetic dextrose (SD) medium contained 6.7 g/L yeast nitrogen base without 
amino acids (YNB) (BD-Diagnostic Systems, Sparks, MD, USA) and 20 g/L glucose. 
For SDM71 media, SD medium was adjusted to pH 7.1 with 200 mM MOPSO buffer 
(Nacalai Tesque, Kyoto, Japan). YPD medium contained 10 g/L yeast extract (Nacalai 
Tesque), 20 g/L peptone (BD-Diagnostic Systems) and 20 g/L glucose. As appropriate, 
SD medium was supplemented with amino acids or nucleotides (20 mg/L histidine, 60 
mg/L leucine, 20 mg/L methionine, or 20 mg/L uracil). For solid medium, agar was 
added at 20 g/L. 
 
Plasmids. All plasmids used in this study are summarized in Table 1. All 
oligonucleotides used for the plasmid constructions are listed in Table 2. Plasmid maps 
are presented in Figure 1. 
The plasmid used for expression of Zoanthus sp. green fluorescent protein 
(ZsGreen) was constructed as follows. A DNA fragment encoding the ZsGreen gene was 
PCR-amplified from pZsGreen (Takara Bio, Shiga, Japan) using the oligonucleotides o1 
and o2, digested with NheI+EcoRI, and inserted into the same sites between the PGK1 
promoter (PPGK1) and the PGK1 terminator (TPGK1) on pGK416 (Ishii et al., 2009), 
yielding the plasmid pGK416-ZsGreen. 
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Table 1. Yeast strains and plasmids used in this study. 
Strain or plasmid Description Reference 
Strain   
BY4741 MATa his31 leu20 met150 ura30 Brachmann et al. 
(1998) 
IMFD-70 BY4741 sst2::AUR1-C ste2::LEU2 fig1::EGFP his3::PFIG1-EGFP far1 Togawa et al. (2010) 
IMFD-72 IMFD-70 gpa1::Gi3tp Ishii et al. (2012a) 
IMFD-70Zs BY4741 sst2::AUR1-C ste2::LEU2 fig1::EGFP his3::PFIG1-ZsGreen far1 This study 
IMFD-72Zs IMFD-70Zs gpa1::Gi3tp This study 
IMFD-70ZsD BY4741 sst2::AUR1-C ste2::LEU2 fig1::ZsGreen his3::PFIG1-ZsGreen far1 This study 
IMFD-72ZsD IMFD-70ZsD gpa1::Gi3tp This study 
Plasmid   
pGK416 Yeast expression vector containing PGK1 promoter, CEN/ARS origin and URA3 marker Ishii et al. (2009) 
pGK416-ZsGreen ZsGreen in pGK416 This study 
pGK416-EGFP EGFP in pGK416 Ishii et al. (2009) 
pBlueScript II KS(+) Cloning vector Agilent 
Technologies 
pBlue-FIG1p-URA3 PFIG1(300 bp)-URA3 in pBlueScript II KS(+) This study 
pBlue-FIG1pt-ZsGreen PFIG1(300 bp)-URA3-ZsGreen-TFIG1(200 bp) in pBlue-FIG1p-URA3 This study 
pBlue-HIS3t-URA3 THIS3(300 bp)-URA3 in pBlueScript II KS(+) This study 
pBlue-HIS3t-FIG1p-ZsGreen THIS3(300 bp)-URA3-PFIG1(450 bp)-ZsGreen in pBlue-HIS3t-URA3 This study 
pBlue-HIS3pt-FIG1pt-ZsGreen THIS3(300 bp)-URA3-PFIG1(450 bp)-ZsGreen-TFIG1(300 bp)-PHIS3(200 bp) in 
pBlue-HIS3t-FIG1p-ZsGreen 
This study 
pGK421 Yeast expression vector containing PGK1 promoter, 2 origin and MET15 marker Togawa et al. (2010) 
pGK421-SSTR5 hSSTR5 in pGK421 Ishii et al. (2012a) 
pGK421-SSTR2 hSSTR2 in pGK421 Ishii et al. (2014) 
pGK421-NTSR1 hNTSR1 in pGK421 Ishii et al. (2014) 
pGK426-S1442 SST–Flag–Flo42 in pGK426 Ishii et al. (2012b) 
pGK426-alpha42 α-factor–Flag–Flo42 in pGK426 Ishii et al. (2012b) 
pGK426-NTS42 NTS–Flag–Flo42 in pGK426 This study 
pGK426-NTS(8-13)42 NTS8-13–Flag–Flo42 in pGK426 This study 
pGK426-NMN42 NMN–Flag–Flo42 in pGK426 This study 
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Table 2. List of oligonucleotides. 
o# Name Sequence 
o1 NheI_ZsGreen_fw 5’-TTTTGCTAGCATGGCTCAGTCAAAGCACGG 
o2 EcoRI_ZsGreen_rv 5’-TTTTGAATTCTCAGGGCAATGCAGATCCGG 
o3 SacII_dFIG1up_fw 5’-GGGGCCGCGGTACAAAAATTATAACATTTT 
o4 XbaI_dFIG1up_rv 5’-CCCCTCTAGATTTTTTTTTTTTTTTTTTGT 
o5 XbaI_URA3_fw 5’-CCCCTCTAGATTTTTTGTTCTTTTTTTTGA 
o6 EcoRI_hr40-URA3_rv 
5’-CCCCGAATTCTTTTTTTTTTTTTTTTTTGTTTGTTTGTTTGTTTGTTTACGGGTAA
TAACTGATATAATT 
o7 EcoRI_ZsGreen_fw 5’-TTTTGAATTCATGGCTCAGTCAAAGCACGG 
o8 XhoI_ZsGreen_rv 5’-TTTTCTCGAGTCAGGGCAATGCAGATCCGG 
o9 XhoI_dFIG1dn_fw 5’-GGGGCTCGAGTTTTATCCTCAAATAAACAT 
o10 KpnI_dFIG1dn_rv 5’-CCCCGGTACCAACAGACGGTAATGATTAGA 
o11 SacII_dHIS3dn_fw 5’-AAAACCGCGGTATGAAATGCTTTTCTTGTT 
o12 XbaI_dHIS3dn_rv 5’-GGGGTCTAGATGACACCGATTATTTAAAGC 
o13 BamHI_hr40-URA3_rv 
5’-CCCCGGATCCTGACACCGATTATTTAAAGCTGCAGCATACGATATATATAGGGT
AATAACTGATATAATT 
o14 BamHI_PFIG1_fw 5’-AAAAGGATCCATCACCCTGCATTGCCTCTT 
o15 EcoRI_PFIG1_rv 5’-CCCCGAATTCTTTTTTTTTTTTTTTTTTGTTTGTTTGTTT 
o16 ClaI_ZsGreen_rv 5’-TTTTATCGATTCAGGGCAATGCAGATCCGG 
o17 ClaI_TFIG1_fw 5’-GGGGATCGATTTTTATCCTCAAATAAACAT 
o18 SalI_TFIG1_rv 5’-CCCCGTCGACATAACATTAGTATTTATAAA 
o19 SalI_dHIS3up_fw 5’-AAAAGTCGACCTTTGCCTTCGTTTATCTTG 
o20 KpnI_dHIS3up_rv 5’-AAAAGGTACCTCTTGGCCTCCTCTAGTACA 
o21 NheI_SSTR2_fw 5’-TTTTGCTAGCATGGACATGGCGGATGAGCC 
o22 BglII_SSTR2_rv 5’-CCCCAGATCTTCAGATACTGGTTTGGAGGT 
o23 NheI_NTSR1_fw 5’-AAAAGCTAGCATGCGCCTCAACAGCTCCGC 
o24 BglII_NTSR1_rv 5’-CCCCAGATCTCTAGTACAGCGTCTCGCGGG 
o25 NheI_SS_fw 5’-GGGGGCTAGCATGAGATTTCCTTCAATTTT 
o26 NTS_SS_rv 5’-ATTCTCATACAGCTGTCTTTTATCCAAAGA 
o27 SalI_NTS_rv 5’-AAAAGTCGACGAGTATGTAGGGTCTTCTGGGTTTATTCTCATACAGCTG 
o28 SalI_NTS(8-13)_rv 5’-GGGGGTCGACGAGTATGTAGGGTCTTCTTCTTTTATCCAAAGATACCC 
o29 SalI_NMN_rv 5’-GGGGGTCGACCAGAATATAAGGAATTTTTCTTTTATCCAAAGATACCC 
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Fig. 1. Plasmids used in this study. (A) Single-copy plasmid pGK416-ZsGreen (B) 
Multi-copy plasmid pGK426-NTS42 (C) Integration plasmid pBlue-FIG1pt-ZsGreen 
(D) Integration plasmid pBlue-HIS3pt-FIG1pt-ZsGreen. 
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To express the ZsGreen gene under the control of the pheromone-responsive FIG1 
promoter (Iguchi et al., 2010; Nakamura et al., 2014; Togawa et al., 2010), the ZsGreen 
gene was inserted into a plasmid that integrated into the yeast chromosome at a position 
upstream of the FIG1 gene. Plasmid construction was as follows. A DNA fragment 
containing the homologous sequence at the FIG1 promoter (upstream of FIG1 gene; 
300 bp) was PCR-amplified from BY4741 (Brachmann et al., 1998) genomic DNA 
using oligonucleotides o3 and o4. A DNA fragment containing the URA3 selectable 
marker (along with 40 nucleotides from the 3’ side of the FIG1 promoter at the 3’ end) 
was PCR-amplified from pRS426 (American Type Culture Collection, Manassas, VA) 
using oligonucleotides o5 and o6. The amplified fragments were digested with 
SacII+XbaI and XbaI+EcoRI (respectively) and ligated together into SacII, 
EcoRI-cleaved pBlueScript II KS(+) vector (Agilent Technologies, Santa Clara, CA, 
USA). The resultant plasmid was named pBlue-FIG1p-URA3. A DNA fragment 
containing the ZsGreen gene was PCR-amplified from pZsGreen using oligonucleotides 
o7 and o8. A DNA fragment containing the homologous sequence of the FIG1 
terminator (downstream of FIG1 gene; 200 bp) was PCR-amplified from BY4741 
genomic DNA using oligonucleotides o9 and o10. The amplified fragments were 
digested with EcoRI+XhoI and XhoI+KpnI (respectively) and ligated together into 
EcoRI, KpnI-cleaved pBlue-FIG1p-URA3. The resultant plasmid was named 
pBlue-FIG1pt-ZsGreen. 
The plasmid used for substituting PFIG1-ZsGreen-TFIG1 for PFIG1-EGFP-TFIG1 at the 
HIS3 gene locus on the yeast chromosome was constructed as follows. A DNA fragment 
containing the homologous sequence of the HIS3 terminator (downstream of HIS3 gene; 
300 bp) was PCR-amplified from BY4741 genomic DNA using oligonucleotides o11 
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and o12. A DNA fragment containing the URA3 selectable marker (with 40 nucleotides 
from the 5’ side of the HIS3 terminator at the 3’ end) was PCR-amplified from pRS426 
(American Type Culture Collection, Manassas, VA) using oligonucleotides o5 and o13. 
The amplified fragments were digested with SacII+XbaI and XbaI+BamHI 
(respectively) and ligated together into SacII, BamHI-cleaved pBlueScript II KS(+) 
vector (Agilent Technologies, Santa Clara, CA, USA). The resultant plasmid was named 
pBlue-HIS3t-URA3. A DNA fragment containing the FIG1 promoter (upstream of FIG1 
gene; 450 bp) was PCR-amplified from BY4741 genomic DNA using oligonucleotides 
o14 and o15. A DNA fragment containing the ZsGreen gene was PCR-amplified from 
pZsGreen using oligonucleotides o7 and o16. The amplified fragments were digested 
with BamHI+EcoRI and EcoRI+ClaI (respectively) and ligated together into BamHI, 
ClaI-cleaved pBlue-HIS3t-URA3. The resultant plasmid was named 
pBlue-HIS3t-FIG1p-ZsGreen. A DNA fragment containing the FIG1 terminator 
(downstream of FIG1 gene; 300 bp) was PCR-amplified from BY4741 genomic DNA 
using oligonucleotides o17 and o18. A DNA fragment containing the homologous 
sequence of the HIS3 promoter (upstream of HIS3 gene; 200 bp) was PCR-amplified 
from BY4741 genomic DNA using oligonucleotides o19 and o20. The amplified 
fragments were digested with ClaI+SalI and SalI+KpnI (respectively) and ligated 
together into ClaI, SalI-cleaved pBlue-HIS3t-FIG1p-ZsGreen. The resultant plasmid 
was named pBlue-HIS3pt-FIG1pt-ZsGreen. 
The plasmids used for expression of membrane-tethered peptides, in which the pre, 
pro α-factor leader region gene (containing secretion signal sequence, s.s.), peptide gene 
and FLO42 anchor gene with FLAG at the N-terminus are encoded, were constructed as 
follows. A DNA fragment containing s.s. of α-factor with a partial NTS sequence for 
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overlapping PCR was PCR-amplified from pGK426-S1442 (Ishii et al., 2012b) using 
oligonucleotides o25 and o26. The amplified fragment was then used as the template for 
overlapping PCR with the oligonucleotides o25 and o27. The s.s.-NTS was digested 
with NheI+SalI and ligated into similarly digested pGK426-tgFLO42 (Ishii et al., 
2012b), resulting in the plasmid pGK426-NTS42. A DNA fragment containing s.s. of 
α-factor and the C-terminal portion of NTS (NTS8–13) was PCR-amplified from 
pGK426-NTS42 using oligonucleotides o25 and o28. The s.s.-NTS8–13 was digested 
with NheI+SalI and ligated into similarly digested pGK426-tgFLO42 (Ishii et al., 
2012b), resulting in the plasmid pGK426-NTS(8-13)42. A DNA fragment containing s.s. 
of α-factor and neuromedin N (NMN) was PCR-amplified from pGK426-NTS42 using 
oligonucleotides o25 and o29. The s.s.-NMN was digested with NheI+SalI and ligated 
into similarly digested pGK426-tgFLO42 (Ishii et al., 2012b), resulting in the plasmid 
pGK426-NMN42. 
 
Yeast Strains. Yeast strains used in this study were generated from BY4741 
(Brachmann et al., 1998) as a parental backbone strain and are listed in Table 1. 
Transformation with linear DNA fragments was performed using the lithium acetate 
method (Gietz et al., 1992). To eliminate the URA3 selectable marker in each 
transformation step, we followed previous procedures (Iguchi et al., 2010; Togawa et al., 
2010) modified to incorporate the marker recycling method (Akada et al., 2006). 
The strains expressing Zoanthus sp. green fluorescence protein (ZsGreen) were 
generated as follows. The DNA fragment obtained by digesting 
pBlue-HIS3pt-FIG1pt-ZsGreen with SacII and KpnI was transformed into IMFD-70 
(Togawa et al., 2010) and IMFD-72 (Ishii et al., 2012a). After confirming the correct 
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integration, the URA3 marker was “popped-out” by homologous recombination using 
counter-selection with 5-fluoroorotic acid (5-FOA, Fluorochem, Derbyshire, UK). The 
resultant strains were designated as IMFD-70Zs and IMFD-72Zs, respectively. The 
DNA fragment obtained by digesting pBlue-FIG1pt-ZsGreen with SacII and KpnI was 
transformed into IMFD-70Zs and IMFD-72Zs. After confirming correct integration, the 
URA3 marker was “popped-out” by counter-selection with 5-FOA. The constructed 
strains were designated as IMFD-70ZsD and IMFD-72ZsD, respectively. 
 
Fluorescence Microscopy Imaging. The cultured cells were washed and suspended in 
distilled water. The cell suspensions were observed using a BZ-9000 fluorescence 
microscope (Keyence, Osaka, Japan). Green fluorescence images were acquired with a 
470/40 band-pass filter for excitation and a 535/50 band-pass filter for emission. Digital 
image intensities of green fluorescence were carried out, from four experiments each, 
with the ImageJ software (freely downloadable from the ImageJ website, 
http://rsbweb.nih.gov/ij/) and expressed as Integrated Density (IntDen) or its percent. 
 
Flow Cytometry Analysis. Flow cytometry measurements of green fluorescence 
followed previous procedures (Iguchi et al., 2010; Togawa et al., 2010). In brief, GFP 
was detected using a BD FACSCanto II flow cytometer equipped with a 488-nm blue 
laser (Becton, Dickinson and Company, Franklin Lakes, NJ, USA); the data were 
analyzed using BD FACSDiva software (v5.0; Becton, Dickinson and Company). The 
GFP fluorescence signal was collected through a 530/30 nm band-pass filter and the 
GFP-A mean of 10,000 cells was defined as ‘green fluorescence intensity’. 
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Comparison Assay of Constitutively-expressed Two Green Fluorescence Proteins 
(ZsGreen and EGFP). Yeast transformants were grown in SD medium (supplemented 
as needed) at 30 °C overnight, and the cells then were inoculated into 5 mL of the 
respective fresh SD medium to give an initial optical density of 0.03 at 600 nm (OD600 = 
0.03). The cells were incubated at 30 °C on a rotary shaker at 150 rpm for up to 18 h. 
After incubation, the yeast cells were observed using a fluorescence microscope, and 
then were diluted with 1 mL of sheath fluid and fluorescence was analyzed by flow 
cytometry. 
 
GPCR Signaling Assay with Exogenously Added Ligands. GPCR signaling assays 
with exogenously added ligands basically followed previous procedures (Iguchi et al., 
2010; Togawa et al., 2010). In brief, to assay signal activation from human GPCRs, 
yeast strains harboring the pGK421-based plasmids were grown in SD medium 
(supplemented as needed) at 30 °C overnight, then the cells then were inoculated into 5 
mL of the respective fresh SD medium to give an initial OD600 = 0.03. The cells were 
incubated at 30 °C on a rotary shaker at 150 rpm for up to 18 h and harvested, washed, 
and resuspended in water to give an OD600 = 10. The suspensions were added (at 10 
L/well; to give an OD600 = 1) to the wells of 96-well cluster dishes containing fresh 
SDM71 medium (80 L/well) supplemented (10 L/well) with 10 M of either 
somatostatin (SST) or neurotensin (NTS) (Calbiochem, Darmstadt, Germany) or 
distilled water (no SST (NTS), control). The plates were incubated at 30 °C with 
shaking (150 rpm) for 4 h, then the yeast cells were observed using a fluorescence 
microscope, diluted with 1 mL of sheath fluid, and fluorescence was analyzed by flow 
cytometry. 
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GPCR Signaling Assay using Membrane-tethered Peptide Ligands. GPCR signaling 
assays using membrane-tethered peptide ligands basically followed a previous 
procedure (Ishii et al., 2012b) with some modifications. In brief, to assay signal 
activation from human GPCRs, yeast strains harboring the pGK421-based GPCR 
expression plasmids and pGK426-based peptide display plasmids were grown in SD 
medium (supplemented as needed) at 30 °C overnight, then the cells then were 
inoculated into 5 mL of the respective fresh SDM71 medium to give an initial OD600 = 
0.1. The cells were incubated at 30 °C on a rotary shaker at 150 rpm, then the yeast cells 
were observed using a fluorescence microscope, diluted with 1 ml of sheath fluid, and 
fluorescence was analyzed by flow cytometry. 
 
Data Analysis. Data were analyzed using KaleidaGraph4.0. Statistical significance of 
the differences between more than two groups was calculated by one-way ANOVA, 
followed by Tukey’s post test. Z’ factor, a commonly used parameter reflecting the 
robustness and the quality of assays, was determined as follows: Z’ factor = 1 ‒ 
3(SDpositive control + SDnegative control)/ (meanpositive control ‒ meannegative control), where “SD” 
represents standard deviation of multiple replicates of an assay (Zhang et al., 1999). 
 
 
 
  
41 
 
Fig. 2. Schematic illustration of signal activation of human GPCRs by 
membrane-tethered peptide ligands. (A) Overview of this study. The 
membrane-tethered peptide activates human GPCR, which is heterologously produced 
in yeast, thereby activating the chimeric Gα proteins. This promotes the 
mitogen-activated protein kinase (MAPK) cascade and transcription factor Ste12p. 
Phosphorylated Ste12p induces transcription of the GFP reporter gene by binding to a 
pheromone response element in the FIG1 promoter. (B) Functional domains encoded by 
the membrane-tethered peptide plasmids. After processing by the secretory pathway, the 
signal sequence and glycosyl-phosphatidylinositol (GPI) targeting sequence are cleaved 
and the peptide sequence, which contains a free N-terminus, is tethered on the plasma 
membrane by GPI covalently linked to the C-terminus. 
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Results and Discussion 
General strategy 
The aim of this study was to establish a detection method for signals from human 
GPCRs induced by peptide ligands displayed on the yeast cell surface, thereby 
permitting observation by fluorescence microscopy. To tether agonistic peptides on the 
yeast cell membrane, a secretion signal sequence was fused to the N-terminus of the 
peptide, and a fusion of Flag tag and the C-terminal 42 amino acids of Flo1p (Flo42; 
anchor protein with GPI anchor attachment signal sequence) was fused to the 
C-terminus of the peptide (Ishii et al., 2012b). An outline of this strategy is shown in 
Figure 2A and B. Briefly, the yeast cells synthesize the candidate peptides fused with a 
secretion signal sequence and an anchoring motif. The membrane-anchored cognate 
agonistic peptides are capable of binding to the cell surface-expressed GPCRs and of 
transducing the signal into the cell. The GPI-anchored peptides are then cleaved from 
the plasma membrane by phosphatidylinositol-specific phospholipase C (PI-PLC) and 
tethered on the cell wall (Kondo and Ueda, 2004; Shibasaki et al., 2009). 
To detect the activation of human GPCRs in yeast, the following gene 
modifications were implemented. The sst2 allele is deficient in the yeast principal 
negative regulator of G-protein signaling (RGS). This deletion therefore results in 
hypersensitivity for the agonistic stimulus (Ishii et al., 2006, 2010) and improves 
sensitivity towards low concentrations of ligand. The far1 allele is deficient in yeast 
G1-cyclin-dependent kinase inhibitor; this inhibitor induces G1 cell cycle arrest in 
response to signaling (Elion et al., 1993; Ishii et al., 2010). The FAR1-deficient strain 
can therefore grow and plasmid recovery occurs even in signal-activated states (Ishii et 
al., 2008). The ste2 allele is deficient in the yeast single GPCR, thereby allowing 
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expression of human GPCRs in STE2-disrupted strains without competitive receptor 
expression (Iguchi et al., 2010; Ishii et al., 2010; Nakamura et al., 2013; Togawa et al., 
2010). 
To detect signal activation, green fluorescence protein (GFP) reporter was 
integrated into the yeast genome. The expression of GFP is controlled by the signal 
responsive FIG1 promoter. Therefore, stimulation by agonistic peptides results in the 
generation of a green fluorescence signal (Iguchi et al., 2010; Nakamura et al., 2014; 
Togawa et al., 2010). However, since the signal provided by the conventional detection 
system integrating an EGFP gene as the reporter is too weak to use for fluorescence 
microscopy, we explored a brighter fluorescent protein. 
 
Comparison of two green fluorescence proteins (ZsGreen and EGFP) as reporter 
genes 
To obtain the bright fluorescence required for easy observation by microscopy, we 
explored a recently described tetrameric Zoanthus sp. green fluorescent protein 
(ZsGreen) (brightness, 39,130 (quantum yield, 0.91; molar extinction coefficient, 
43,000); excitation maximum, 493 nm; emission maximum, 505 nm) (Matz et al., 1999) 
as an alternative to EGFP (brightness, 16,100 (quantum yield, 0.70; molar extinction 
coefficient, 23,000); excitation maximum, 484 nm; emission maximum, 510 nm). 
The performance (transcription, translation, folding and stability) of ZsGreen as a 
reporter gene in yeast was tested by comparing the fluorescence of yeast cells 
expressing either ZsGreen or EGFP using fluorescence microscopy and flow cytometry. 
Single-copy autonomous replicating plasmids, pGK416-ZsGreen and pGK416-EGFP, 
were constructed to express each green fluorescent protein constitutively under the 
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control of the PGK1 promoter. Yeast BY4741 wild-type strains harboring these 
plasmids or mock vector were generated and their green fluorescence was evaluated. 
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Fig. 3. Comparison of green fluorescence proteins (ZsGreen and EGFP). Yeast 
strain BY4741 was transformed with pGK416-ZsGreen, pGK416-EGFP or pGK416 
(empty vector). All transformants were grown in SD selective medium for 18 h. (A) 
Visualization of the green fluorescence (ZsGreen and EGFP). Cells were examined 
using the 40 objective lens of a fluorescence microscope. Exposure time was 1 s. The 
left photographs are fluorescence micrographs, and the right photographs are 
bright-field micrographs. (B) The mean GFP fluorescence of 10,000 cells was measured 
by flow cytometry. Error bars represent the standard deviation from three separate runs 
(n = 3); ***, p < 0.001, by one-way ANOVA, Tukey’s post test. 
  
46 
 
Using fluorescence microscopy, the cells expressing ZsGreen showed clearly 
brighter fluorescence than those expressing EGFP (Figure 3A). To compare the 
fluorescence intensity of these cells quantitatively, the average green fluorescence 
intensity per cell was measured by flow cytometry. The cells expressing ZsGreen 
exhibited a greater than 8.6-fold increase in fluorescence intensity compared with those 
expressing EGFP (Figure 3B). This is likely due to better protein features of ZsGreen 
than EGFP, including expression, translation and fluorescence property. In other cells 
(medaka melanoma cells, Chinese hamster ovary (CHO) cell line), the cells expressing 
ZsGreen also emitted brighter green fluorescence than those expressing EGFP, although 
there was a difference in GFP expression vector (promoter) (Hasegawa et al., 2009; Wan 
et al., 2012). Taken together, these results indicated that ZsGreen performs better than 
EGFP as a reporter in yeast. 
 
Demonstration of improved signal activation detection using human somatostatin 
receptor subtype-5 (hSSTR5) 
Somatostatin (SST), a cyclic neuropeptide which is a growth hormone 
release-inhibiting factor, is a natural ligand of somatostatin receptors. Five subtypes of 
somatostatin receptors have been identified (SSTR1–SSTR5) (Raynor et al., 1993a, b). 
These receptors are important therapeutic targets for acromegaly, Cushing’s disease and 
Alzheimer’s disease (Ben-Shlomo and Melmed, 2008; Lamberts et al., 1994; Saito et al., 
2005). 
The human SSTR5 receptor is known to transduce signals in yeast cells through 
the endogenous yeast Gα-subunit (Gpa1p). A yeast–human chimeric G-protein, in which 
the carboxyl-terminal 5 amino acid residues of Gpa1p (KIGII) are replaced with the 
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equivalent residues from human Gαi3 (ECGLY) (Gpa1/Gαi3 transplant, Gi3tp), has been 
shown to improve signal transmission via Gαi-specific SSTR5 in yeast (Brown et al., 
2000; Iguchi et al., 2010; Ishii et al., 2014). 
The IMFD-70 (Gpa1p) and IMFD-72 (Gi3tp) strains were selected as the parental 
yeast strains as they contain two sets of PFIG1-EGFP-TFIG1 cassettes (PFIG1, FIG1 
promoter; TFIG1, FIG1 terminator) integrated into the genome (Table 1). One or both 
sets of PFIG1-EGFP-TFIG1 cassettes were replaced with PFIG1-ZsGreen-TFIG1 cassettes to 
generate IMFD-70Zs and IMFD-72Zs (single substitutions), and IMFD-70ZsD and 
IMFD-72ZsD (double substitutions) (Table 1). To evaluate the activity of ZsGreen as a 
reporter gene for detecting the signal from human GPCRs, we quantified the induction 
of green fluorescence responding to exogenously-added SST binding in 
hSSTR5-expressing yeast cells. Yeast IMFD-70, IMFD-72, IMFD-70Zs, IMFD-72Zs, 
IMFD-70ZsD and IMFD-72ZsD strains harboring pGK421-SSTR5 or mock vector 
were generated and examined using a signaling assay. As shown in Figure 4A, all yeast 
cells harboring the mock vector showed no fluorescence. In the case of yeast cells 
harboring pGK421-SSTR5, the addition of agonist to yeast strains IMFD-70 and 
IMFD-72 induced 3.9- and 5.6-fold higher fluorescence; however, the fluorescence was 
too weak to allow observation with a fluorescence microscope (Figure 4A and B). In 
contrast, strains IMFD-70Zs and IMFD-72Zs displayed a 33- and 65-fold increase, and 
strains IMFD-70ZsD and IMFD-72ZsD displayed a 83- and 104-fold increase in 
fluorescence intensity in response to agonist stimulation (Figure 4A). Using 
fluorescence microscopy, both the hSSTR5-expressing IMFD-70ZsD and IMFD-72ZsD 
exhibited changes in green fluorescence and morphology (Yu et al., 2008) in response to 
the SST-induced signal (Figure 4B and C).  
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Fig. 4. Activation of human somatostatin receptor subtype-5 (hSSTR5) produced in 
yeast by exogenously-added somatostatin. Yeast strains IMFD-70 (a, b); IMFD-72 (c, 
d); IMFD-70Zs (e, f); IMFD-72Zs (g, h); IMFD-70ZsD (i, j) and IMFD-72ZsD (k, l) 
were transformed with either pGK421 (empty vector) (a, c, e, g, i, k) or 
pGK421-SSTR5 (b, d, f, h, j, l). All transformants were grown in SD selective medium 
for 18 h. The cells then were incubated for another 4 h in pH-adjusted SD selective 
medium with or without 10 M somatostatin (SST, 14 aa peptide). (A) The GFP 
fluorescence of 10,000 cells was measured by flow cytometry. Mean values of the green 
fluorescence signal of 10,000 cells. Error bars represent the standard deviation from 
three separate runs (n = 3); ***, p < 0.001, by one-way ANOVA, Tukey’s post test. (B, 
C) Visualization of the green fluorescence. (B) Cells were examined using the 40 
objective lens of a fluorescence microscope. Exposure time was 1 s. The left 
photographs are fluorescence micrographs, and the right photographs are bright-field 
micrographs. (C) Cells were examined using the 100 objective lens of a fluorescence 
microscope. Exposure time was 0.2 s. 
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Next, we examined whether this system is applicable to yeast cell-surface display 
technology in addition to observation by fluorescence microscopy. The hSSTR5 
expression plasmid (pGK421-SSTR5) and peptide expression plasmids (pGK426-S1442 
or pGK426-alpha42) were co-expressed in IMFD-72 and IMFD-72ZsD strains (Table 
1). As shown in Figure 5A, the control strains harboring hSSTR5 and the yeast Ste2p 
receptor agonist, α-factor (α-factor–Flag–Flo42) as the control peptide, did not induce 
GFP reporter gene expression. In contrast, the yeast strains concomitantly expressing 
hSSTR5 and SST–Flag–Flo42 induced both EGFP and ZsGreen reporter gene 
expression. However, since EGFP fluorescence in IMFD-72 was weak, fluorescence 
microscopy could not distinctly differentiate between the strains displaying control 
(α-factor) and target (SST) peptides (Figure 5B), whereas IMFD-72ZsD strain using 
ZsGreen as a reporter clearly showed brighter green fluorescence and morphology 
change in response to the SST-induced signal (Figure 5B and C). These results 
indicated that our system provides dramatically improved sensitivity and brightness 
compared with a conventional yeast-based fluorescence reporter system. 
 
Activation of human somatostatin receptor subtype-2 (hSSTR2) 
To validate the applicability of this system for human somatostatin receptor 
subtype-2 (hSSTR2), the activation of hSSTR2 by exogenously-added SST was 
quantified. Yeast IMFD-70, IMFD-72, IMFD-70ZsD and IMFD-72ZsD strains 
harboring pGK421-SSTR2 were generated and studied using the signaling assay. As 
shown in Figure 6A, whereas the addition of agonist to yeast strains IMFD-70 and 
IMFD-72 induced a 3.0- and 4.6-fold higher fluorescence, agonist stimulation of strains 
IMFD-70ZsD and IMFD-72ZsD induced a 36- and 81-fold drastic increase in the 
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fluorescence intensity. Using fluorescence microscopy, the hSSTR2-expressing 
IMFD-72ZsD clearly exhibited changes in green fluorescence and morphology in 
response to the SST-induced signal (Figure 6B and C). 
Next, to investigate the activation of hSSTR2 by membrane-tethered somatostatin, 
an hSSTR2 expression plasmid (pGK421-SSTR2) and peptide expression plasmids 
(pGK426-S1442 or pGK426-alpha42) were co-expressed in the IMFD-72ZsD strain 
(Table 1). As expected, the average fluorescence of the yeast strain concomitantly 
expressing hSSTR2 and SST–Flag–Flo42 increased with increasing incubation time, 
exhibiting a greater than 169-fold increase in fluorescence intensity compared with the 
yeast strain possessing hSSTR2 and α-factor–Flag–Flo42 after 12 h cultivation (Figure 
7A). Using a fluorescence microscope, the yeast strain concomitantly expressing 
hSSTR2 and SST–Flag–Flo42 clearly showed a brighter green fluorescence change in 
response to the SST-induced signal (Figure 7B). These results indicated that our system 
is applicable to use with yeast cell-surface display technology. 
 
Activation of human neurotensin receptor subtype-1 (hNTSR1) 
Neurotensin (NTS) is a 13-amino-acid peptide found in the nervous system and in 
peripheral tissues (Carraway and Leeman, 1973; White et al., 2012). NTS shows a wide 
range of biological activities and has important roles in Parkinson’s disease and the 
pathogenesis of schizophrenia, the modulation of dopamine neurotransmission, 
hypothermia, antinociception, and in promoting the growth of cancer cells (Bissette et 
al., 1976; Carraway and Plona, 2006; Griebel and Holsboer, 2012; Kitabgi, 2002; 
Schimpff et al., 2001). Three neurotensin receptors have been identified. NTSR1 
(Tanaka et al., 1990) and NTSR2 (Chalon et al., 1996) belong to the class A GPCR 
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Fig. 5. Activation of human somatostatin receptor subtype-5 (hSSTR5) by 
membrane-tethered somatostatin. Yeast strains IMFD-72 and IMFD-72ZsD, which 
coexpress pGK421-SSTR5 and either pGK426-S1442 (SST) or pGK426-alpha42 
(α-factor), were incubated in pH-adjusted SD selective medium. (A) The GFP 
fluorescence of 10,000 cells was measured by flow cytometry. Mean values of the green 
fluorescence signal of 10,000 cells. Error bars represent the standard deviations (n = 3); 
***, p < 0.001, by one-way ANOVA, Tukey’s post test. (B, C) Fluorescence microscopy 
analysis of cells incubated for 9 h. (B) Cells were examined using the 40 objective lens 
of a fluorescence microscope. Exposure time was 0.67 s. The left photographs are 
fluorescence micrographs, and the right photographs are bright-field micrographs. (C) 
Cells were examined using the 100 objective lens of a fluorescence microscope. 
Exposure time was 0.14 s. 
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Fig. 6. Activation of human somatostatin receptor subtype-2 (hSSTR2) by 
exogenously-added somatostatin. Yeast strains IMFD-70, IMFD-72, IMFD-70ZsD 
and IMFD-72ZsD were transformed with pGK421-SSTR2. All transformants were 
grown in SD selective medium for 18 h. The cells then were incubated for another 4 h in 
pH-adjusted SD selective medium with or without 10 M somatostatin (SST, 14 aa 
peptide). (A) The GFP fluorescence of 10,000 cells was measured by flow cytometry. 
Mean values of the green fluorescence signal of 10,000 cells. Error bars represent the 
standard deviations (n = 3); ***, p < 0.001, by one-way ANOVA, Tukey’s post test. (B, 
C) Visualization of the green fluorescence. (B) Cells were examined using the 40 
objective lens of a fluorescence microscope. Exposure time was 1 s. The left 
photographs are fluorescence micrographs, and the right photographs are bright-field 
micrographs. (C) Cells were examined using the 100 objective lens of a fluorescence 
microscope. Exposure time was 0.33 s. 
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Fig. 7. Activation of human somatostatin receptor subtype-2 (hSSTR2) by 
membrane-tethered somatostatin. Yeast strain IMFD-72ZsD which coexpresses 
pGK421-SSTR2 and either pGK426-S1442 (SST) or pGK426-alpha42 (α-factor) was 
incubated in pH-adjusted SD selective medium. (A) The GFP fluorescence of 10,000 
cells was measured by flow cytometry. Mean values of the green fluorescence signal of 
10,000 cells. Error bars represent the standard deviations (n = 3); ***, p < 0.001, by 
one-way ANOVA, Tukey’s post test. (B) Fluorescence microscopy analysis of the cells 
incubated for 9 h. Cells were examined using the 40 objective lens of a fluorescence 
microscope. Exposure time was 0.25 s. The left photographs are fluorescence 
micrographs, and the right photographs are bright-field micrographs.  
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family, whereas NTSR3 (also called SORT1) is a member of the sortilin family and 
contains a single transmembrane domain (Mazella, 2001). The crystal structure of the 
complex of NTSR1 and a partial NTS peptide was recently solved (White et al., 2012). 
Although many structures of the complex of GPCR and agonist or antagonist had been 
reported, this was the first report of the structure of NTSR1 bound with peptide 
hormone (White et al., 2012). Thus, attention was attracted to the study of 
NTSR1-mediated signaling in order to understand the GPCR-ligand binding modes. 
Yeast IMFD-70, IMFD-72, IMFD-70ZsD and IMFD-72ZsD strains harboring 
pGK421-NTSR1 were generated for study using the signaling assay. As shown in 
Figure 8A, addition of agonist to yeast strains IMFD-70 and IMFD-72 resulted in only 
1.3- and 2.3-fold higher fluorescence than in the absence of agonist, whereas strains 
IMFD-70ZsD and IMFD-72ZsD displayed a 7.9- and 45-fold increase in fluorescence 
intensity in response to agonist stimulation. Using fluorescence microscopy, the 
hNTSR1-expressing IMFD-72ZsD clearly exhibited changes in green fluorescence and 
morphology in response to the NTS-induced signal (Figure 8B and C). Similar to the 
results with hSSTR2, the IMFD-72ZsD strain harboring pGK421-NTSR1 exhibited a 
much higher average GFP intensity (S/N ratio) following stimulation by NTS compared 
with the IMFD-70ZsD strain harboring pGK421-NTSR1 (Figure 8A). These results 
indicated that the yeast–human chimeric G-protein subunit (Gi3tp) significantly 
improved hNTSR1-mediated signal transmission in yeast cells (Ishii et al., 2014). 
To test whether the fluorescence microscopy approach is applicable for 
quantitative analysis, the yeast strain IMFD-72ZsD harboring pGK421-NTSR1 was 
used for observing green fluorescence images responding to several NTS concentrations. 
As shown in Figure 9A, the cells displayed the several distinct orders of brightness in 
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ZsGreen fluorescence. Then, using the green fluorescence images, digital image 
analysis with ImageJ was conducted. The digital intensities of green fluorescence varied 
in a NTS-dependent manner, indicating that the digital image analysis with fluorescence 
microscopy is available for the quantitative comparison of the signaling levels (Figure 
9B). 
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Fig. 8. Activation of human neurotensin receptor subtype-1 (hNTSR1) produced in 
yeast following exogenously-added neurotensin. Yeast strains IMFD-70, IMFD-72, 
IMFD-70ZsD and IMFD-72ZsD were transformed with pGK421-NTSR1. All 
transformants were grown in SD selective medium for 18 h. The cells then were 
incubated for another 4 h in pH-adjusted SD selective medium with or without 10 M 
neurotensin (NTS, 13 aa peptide). (A) The GFP fluorescence of 10,000 cells was 
measured by flow cytometry. Mean values of the green fluorescence signal of 10,000 
cells. Error bars represent the standard deviation from three separate runs (n = 3); ***, p 
< 0.001, by one-way ANOVA, Tukey’s post test. (B, C) Visualization of the green 
fluorescence. (B) Cells were examined using the 40 objective lens of a fluorescence 
microscope. Exposure time was 1 s. The left photographs are fluorescence micrographs, 
and the right photographs are bright-field micrographs. (C) Cells were examined using 
the 100 objective lens of a fluorescence microscope. Exposure time was 0.5 s. 
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Fig. 9. Quantitative digital image analysis of ZsGreen fluorescence using 
fluorescence microscopy and ImageJ software. Yeast strain IMFD-72ZsD was 
transformed with pGK421-NTSR1. The transformant was grown in SD selective 
medium for 18 h. The cells then were incubated for another 4 h in pH-adjusted SD 
selective medium with neurotensin (NTS, 13 aa peptide) at several concentrations. (A) 
Visualization of the green fluorescence. Cells were examined using the 40 objective 
lens of a fluorescence microscope. Exposure time was 1 s. The upper photographs are 
fluorescence micrographs, and the lower photographs are bright-field micrographs. (B) 
The GFP fluorescence of 100 cells was measured as integrated density (IntDen, ImageJ 
software). Mean values of the green fluorescence signal of 100 cells. IntDen % was 
represented by relative IntDen normalized with the values of maximal effects of 
NTS-specific dose-responses. Error bars represent the standard deviation from four 
separate runs (n = 4); ***, p < 0.001, by one-way ANOVA, Tukey’s post test. 
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Fig. 10. Activation of human neurotensin receptor subtype-1 (hNTSR1) by 
membrane-tethered neurotensin. (A) Amino acid sequences of membrane-tethered 
peptides. (B, C) Yeast strain IMFD-72ZsD, which coexpresses pGK421-NTSR1 and 
either pGK426-NTS42 (NTS), pGK426-NTS(8-13)42 (NTS(8-13)), pGK426-NMN42 
(NMN) or pGK426-alpha42 (α-factor), was incubated in pH-adjusted SD selective 
medium. (B) The GFP fluorescence of 10,000 cells was measured by flow cytometry. 
Mean values of the green fluorescence signal of 10,000 cells. Error bars represent the 
standard deviations (n = 3); *, p < 0.05, and ***, p < 0.001, by one-way ANOVA, 
Tukey’s post test. (C) Fluorescence microscopy analysis of the cells incubated for 24 h. 
Cells were examined using the 40 objective lens of a fluorescence microscope. 
Exposure time was 0.67 s. The left photographs are fluorescence micrographs, and the 
right photographs are bright-field micrographs. 
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Activation of hNTSR1 by displaying neurotensin analogue peptides on the yeast 
cell surface 
Finally, several neurotensin sequence analogues were employed to demonstrate 
that the display of various peptidic neurotensin analogs could also activate 
hNTSR1-mediated signaling in yeast cells (Figure 10A). Neurotensin-(8-13) (NTS8–13), 
a pharmacophore of neurotensin, has higher potency and efficacy than full-length NTS 
(Barroso et al., 2000; White et al., 2012). Studies on the structure-activity relationship 
of neurotensin verified that positive charges at positions 8 and 9 are important but not 
prerequisite for its bioactivity (Granier et al., 1982). There is charge complementarity 
between NTS8–13 and its binding pocket: the positively-charged arginine side chains of 
NTS8–13 are adjacent to the electronegative rim of the binding site, and the C terminus 
of NTS8–13 is predicted to form a salt bridge with R327 (White et al., 2012). A 
neurotensin-like peptide, neuromedin N (NMN), has high homology with the 
C-terminal sequence of neurotensin and is encoded by the same gene as neurotensin 
(Kislauskis et al., 1988; Minamino et al., 1984). Although the amino acid sequence of 
NMN (KIPYIL) is similar to that of NTS8–13 (RRPYIL) (Figure 10A), NMN shows 
very weak biological activity (Minamino et al., 1984). 
An hNTSR1 expression plasmid (pGK421-NTSR1) and peptide expression 
plasmids (pGK426-NTS42, pGK426-NTS(8-13)42, pGK426-NMN42 or 
pGK426-alpha42) were co-expressed in IMFD-72ZsD strain (Table 1). As shown in 
Figure 10B, the average fluorescence of the yeast strain concomitantly expressing 
hNTSR1 and NTS–Flag–Flo42 increased with increasing incubation time, exhibiting a 
greater than 11-fold increase in fluorescence intensity compared with the strain 
possessing hNTSR1 and α-factor–Flag–Flo42 after 24 h cultivation. The 
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membrane-tethered NTS8–13 and NMN also induced ZsGreen fluorescence, exhibiting a 
greater than 35- and 1.5-fold increase in fluorescence intensity compared with α-factor 
after 24 h cultivation (NTS8–13 > NTS > NMN > α-factor) (Figure 10B). Fluorescence 
microscopy demonstrated that the observed differences in fluorescence brightness arose 
from differences in the membrane-tethered neurotensin sequence (Figure 10C) and 
showed that the display of various peptidic neurotensin analogs can activate 
hNTSR1-mediated signaling in yeast cells. To confirm the value of this assay, a small 
scale screening was carried out with membrane-tethered NTS as a positive control and 
membrane-tethered α-factor as a negative control, respectively (Figure 11). The Z’ 
factor that reflects both the assay signal dynamic range and the data variation associated 
with the measured signal (Zhang et al., 1999) was calculated to assess the assay quality. 
The value yielded upward of 0.5 (Z’ factor = 0.57), showing the robustness and 
suitability for screening of the assay. It is expected that this technology will be 
applicable to the identification of peptide ligand pharmacophores, and for screening 
random or combinatorial peptide libraries for functional activation of GPCRs. The 
methodology presented in this study could be useful for the discovery of novel peptide 
ligands of human GPCRs. 
 
In conclusion, we have established a fluorescence microscopy-based microbial 
yeast biosensor to detect human GPCR signaling that is applicable to CWTrAP 
technology and exhibits extremely bright fluorescence and high signal-to-noise (S/N) 
ratio. The biosensor employs a new highly-potent fluorescence reporter (ZsGreen) and 
Gα-engineered yeast strain. This system permitted the quick and easy visual distinction 
of cells responding to the agonist using fluorescence microscopy, thereby allowing 
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facile detection of agonistic ligands of human GPCRs. Since our system is applicable to 
not only hSSTR5 but also hSSTR2 and hNTSR1, this system can likely be extended to 
other human GPCRs, which comprise one of the most important types of drug targets 
being pursued today. Application of this method will allow the identification of lead 
peptides from combinatorial peptide libraries to provide starting points for drug 
screening. 
 
Fig. 11. Determination of the Z’ factor. Yeast strain IMFD-72ZsD, which coexpresses 
pGK421-NTSR1 and either pGK426-NTS42 (NTS, positive control) or 
pGK426-alpha42 (α-factor, negative control), was incubated in pH-adjusted SD 
selective medium for 24 h. The GFP fluorescence of 10,000 cells was measured by flow 
cytometry. Mean values of the green fluorescence signal of 10,000 cells. The solid lines 
represent the mean value for the positive control and the negative control (996 and 160 
respectively). The dashed lines marks the 3 standard deviation cut off for both the 
positive and negative control (standard deviation of 112 and 5.6 respectively). Z’ factor 
> 0.5 indicates assays robust and suitable for screening. 
  
65 
 
References 
Akada R, Kitagawa T, Kaneko S, Toyonaga D, Ito S, et al. (2006) PCR-mediated 
seamless gene deletion and marker recycling in Saccharomyces cerevisiae. Yeast 
23: 399–405. 
Aharoni A, Thieme K, Chiu CP, Buchini S, Lairson LL, et al. (2006) High-throughput 
screening methodology for the directed evolution of glycosyltransferases. Nat 
Methods 3: 609–614. 
Barroso S, Richard F, Nicolas-Ethève D, Reversat JL, Bernassau JM, et al. (2000) 
Identification of residues involved in neurotensin binding and modeling of the 
agonist binding site in neurotensin receptor 1. J Biol Chem 275: 328–336. 
Ben-Shlomo A, Melmed S (2008) Somatostatin agonists for treatment of acromegaly. 
Mol Cell Endocrinol 286: 192–198. 
Bissette G, Nemeroff CB, Loosen PT, Prange AJ Jr, Lipton MA (1976) Hypothermia 
and intolerance to cold induced by intracisternal administration of the hypothalamic 
peptide neurotensin. Nature 262: 607–609. 
Boder ET, Wittrup KD (1997) Yeast surface display for screening combinatorial 
polypeptide libraries. Nat Biotechnol 15: 553–557. 
Brachmann CB, Davies A, Cost GJ, Caputo E, Li J, et al. (1998) Designer deletion 
strains derived from Saccharomyces cerevisiae S288C: a useful set of strains and 
plasmids for PCR-mediated gene disruption and other applications. Yeast 14: 115–
132. 
Brown AJ, Dyos SL, Whiteway MS, White JH, Watson MA, et al. (2000) Functional 
coupling of mammalian receptors to the yeast mating pathway using novel 
yeast/mammalian G protein alpha-subunit chimeras. Yeast 16: 11–22. 
66 
 
Carraway R, Leeman SE (1973) The isolation of a new hypotensive peptide, 
neurotensin, from bovine hypothalami. J Biol Chem 248: 6854–6861. 
Carraway RE, Plona AM (2006) Involvement of neurotensin in cancer growth: evidence, 
mechanisms and development of diagnostic tools. Peptides 27: 2445–2460. 
Chalon P, Vita N, Kaghad M, Guillemot M, Bonnin J, et al. (1996) Molecular cloning of 
a levocabastine-sensitive neurotensin binding site. FEBS Lett 386: 91–94. 
Cotton M, Claing A (2009) G protein-coupled receptors stimulation and the control of 
cell migration. Cell Signal 21: 1045–1053. 
Elion EA, Satterberg B, Kranz JE (1993) FUS3 phosphorylates multiple components of 
the mating signal transduction cascade: evidence for STE12 and FAR1. Mol Biol 
Cell 4: 495–510. 
Evans BJ, Wang Z, Broach JR, Oishi S, Fujii N, et al. (2009) Expression of CXCR4, a 
G-protein-coupled receptor for CXCL12 in yeast identification of new-generation 
inverse agonists. Methods Enzymol 460: 399–412. 
Feldhaus MJ, Siegel RW, Opresko LK, Coleman JR, Feldhaus JM, et al. (2003) 
Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces 
cerevisiae surface display library. Nat Biotechnol 21: 163–170. 
Fredriksson R, Lagerström MC, Lundin LG, Schiöth HB (2003) The G-protein-coupled 
receptors in the human genome form five main families. Phylogenetic analysis, 
paralogon groups, and fingerprints. Mol Pharmacol 63: 1256–1272. 
Fukuda N, Ishii J, Shibasaki S, Ueda M, Fukuda H, et al. (2007) High-efficiency 
recovery of target cells using improved yeast display system for detection of 
protein–protein interactions. Appl Microbiol Biotechnol 76: 151–158. 
Fukuda N, Ishii J, Kaishima M, Kondo A (2011) Amplification of agonist stimulation of 
67 
 
human G-protein-coupled receptor signaling in yeast. Anal Biochem 417: 182–187. 
Fukutani Y, Nakamura T, Yorozu M, Ishii J, Kondo A, et al. (2012) The N-terminal 
replacement of an olfactory receptor for the development of a yeast-based 
biomimetic odor sensor. Biotechnol Bioeng 109: 205–212. 
Gai SA, Wittrup KD (2007) Yeast surface display for protein engineering and 
characterization. Curr Opin Struct Biol 17: 467–473. 
Gietz D, St Jean A, Woods RA, Schiestl RH (1992) Improved method for high 
efficiency transformation of intact yeast cells. Nucleic Acids Res 20: 1425. 
Granier C, van Rietschoten J, Kitabgi P, Poustis C, Freychet P (1982) Synthesis and 
characterization of neurotensin analogues for structure/activity relationship studies. 
Acetyl-neurotensin-(8--13) is the shortest analogue with full binding and 
pharmacological activities. Eur J Biochem 124: 117–124. 
Griebel G, Holsboer F (2012) Neuropeptide receptor ligands as drugs for psychiatric 
diseases: the end of the beginning? Nat Rev Drug Discov 11: 462–478. 
Gudermann T, Nürnberg B, Schultz G. (1995) Receptors and G proteins as primary 
components of transmembrane signal transduction. Part 1. G-protein-coupled 
receptors: structure and function. J Mol Med 73: 51–63. 
Hara K, Ono T, Kuroda K, Ueda M (2012) Membrane-displayed peptide ligand 
activates the pheromone response pathway in Saccharomyces cerevisiae. J Biochem 
151: 551–557. 
Hasegawa S, Maruyama K, Takenaka H, Furukawa T, Saga T (2009) A medaka model 
of cancer allowing direct observation of transplanted tumor cells in vivo at a 
cellular-level resolution. Proc Natl Acad Sci USA 106: 13832–13837. 
Iguchi Y, Ishii J, Nakayama H, Ishikura A, Izawa K, et al. (2010) Control of signalling 
68 
 
properties of human somatostatin receptor subtype-5 by additional signal sequences 
on its amino-terminus in yeast. J Biochem 147: 875–884. 
Ishii J, Matsumura S, Kimura S, Tatematsu K, Kuroda S, et al. (2006) Quantitative and 
dynamic analyses of G protein-coupled receptor signaling in yeast using Fus1, 
enhanced green fluorescence protein (EGFP), and His3 fusion protein. Biotechnol 
Prog 22: 954–960. 
Ishii J, Tanaka T, Matsumura S, Tatematsu K, Kuroda S, et al. (2008) Yeast-based 
fluorescence reporter assay of G protein-coupled receptor signalling for flow 
cytometric screening: FAR1-disruption recovers loss of episomal plasmid caused 
by signalling in yeast. J Biochem 143: 667–674. 
Ishii J, Izawa K, Matsumura S, Wakamura K, Tanino T, et al. (2009) A simple and 
immediate method for simultaneously evaluating expression level and plasmid 
maintenance in yeast. J Biochem 145: 701–708. 
Ishii J, Fukuda N, Tanaka T, Ogino C, Kondo A (2010) Protein–protein interactions and 
selection: yeast-based approaches that exploit guanine nucleotide-binding protein 
signaling. FEBS J 277: 1982–1995. 
Ishii J, Moriguchi M, Hara KY, Shibasaki S, Fukuda H, et al. (2012a) Improved 
identification of agonist-mediated Gα(i)-specific human G-protein-coupled receptor 
signaling in yeast cells by flow cytometry. Anal Biochem 426: 129–133. 
Ishii J, Yoshimoto N, Tatematsu K, Kuroda S, Ogino C, et al. (2012b) Cell wall trapping 
of autocrine peptides for human G-protein-coupled receptors on the yeast cell 
surface. PLoS One 7: e37136. 
Ishii J, Oda A, Togawa S, Fukao A, Fujiwara T, et al. (2014) Microbial fluorescence 
sensing for human neurotensin receptor type 1 using Gα-engineered yeast cells. 
69 
 
Anal Biochem. 446: 37–43. 
Kislauskis E, Bullock B, McNeil S, Dobner PR (1988) The rat gene encoding 
neurotensin and neuromedin N. Structure, tissue-specific expression, and evolution 
of exon sequences. J Biol Chem 263: 4963–4968. 
Kitabgi P (2002) Targeting neurotensin receptors with agonists and antagonists for 
therapeutic purposes. Curr Opin Drug Discov Devel 5: 764–776. 
Klein C, Paul JI, Sauvé K, Schmidt MM, Arcangeli L, et al. (1998) Identification of 
surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeast. 
Nat Biotechnol 16: 1334–1337. 
Kondo A, Ueda M (2004) Yeast cell-surface display-applications of molecular display. 
Appl Microbiol Biotechnol 64: 28–40. 
Ladds G, Goddard A, Davey J (2005) Functional analysis of heterologous GPCR 
signaling pathways in yeast. Trends Biotechnol 23: 367–373. 
Lamberts SW, de Herder WW, Krenning EP, Reubi JC (1994) A role of (labeled) 
somatostatin analogs in the differential diagnosis and treatment of Cushing’s 
syndrome. J Clin Endocrinol Metab 78: 17–19. 
Li B, Scarselli M, Knudsen CD, Kim SK, Jacobson KA, et al. (2007) Rapid 
identification of functionally critical amino acids in a G protein-coupled receptor. 
Nat Methods 4: 169–174. 
Matz MV, Fradkov AF, Labas YA, Savitsky AP, Zaraisky AG, et al. (1999) Fluorescent 
proteins from nonbioluminescent Anthozoa species. Nat Biotechnol 17: 969–973. 
Mazella J (2001) Sortilin/neurotensin receptor-3: a new tool to investigate neurotensin 
signaling and cellular trafficking? Cell Signal 13: 1–6. 
Medico E, Gambarotta G, Gentile A, Comoglio PM, Soriano P (2001) A gene trap 
70 
 
vector system for identifying transcriptionally responsive genes. Nat Biotechnol 19: 
579–582. 
Minamino N, Kangawa K, Matsuo H (1984) Neuromedin N: a novel neurotensin-like 
peptide identified in porcine spinal cord. Biochem Biophys Res Commun 122: 
542–549. 
Murai T, Ueda M, Atomi H, Shibasaki Y, Kamasawa N, et al. (1997) Genetic 
immobilization of cellulase on the cell surface of Saccharomyces cerevisiae. Appl 
Microbiol Biotechnol 48: 499–503. 
Nakamura Y, Shibasaki S, Ueda M, Tanaka A, Fukuda H, et al. (2001) Development of 
novel whole-cell immunoadsorbents by yeast surface display of the IgG-binding 
domain. Appl Microbiol Biotechnol 57: 500–505. 
Nakamura Y, Ishii J, Kondo A (2013) Rapid, facile detection of heterodimer partners for 
target human G-protein-coupled receptors using a modified split-ubiquitin 
membrane yeast two-hybrid system. PLoS One 8: e66793. 
Nakamura Y, Takemoto N, Ishii J, Kondo A (2014) Simultaneous method for analyzing 
dimerization and signaling of G-protein-coupled receptor in yeast by dual-color 
reporter system. Biotechnol Bioeng 111: 586–596. 
Pepper LR, Cho YK, Boder ET, Shusta EV (2008) A decade of yeast surface display 
technology: where are we now? Comb Chem High Throughput Screen 11: 127–
134. 
Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, et al. (2007) Crystal 
structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 450: 
383–387. 
Raynor K, Murphy WA, Coy DH, Taylor JE, Moreau JP, et al. (1993a) Cloned 
71 
 
somatostatin receptors: identification of subtype-selective peptides and 
demonstration of high affinity binding of linear peptides. Mol Pharmacol 43: 838–
844. 
Raynor K, O’Carroll AM, Kong H, Yasuda K, Mahan LC, et al. (1993b) 
Characterization of cloned somatostatin receptors SSTR4 and SSTR5. Mol 
Pharmacol 44: 385–392. 
Saito T, Iwata N, Tsubuki S, Takaki Y, Takano J, et al. (2005) Somatostatin regulates 
brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. 
Nat Med 11: 434–439. 
Sato N, Matsumoto T, Ueda M, Tanaka A, Fukuda H, et al. (2002) Long anchor using 
Flo1 protein enhances reactivity of cell surface-displayed glucoamylase to polymer 
substrates. Appl Microbiol Biotechnol 60: 469–474. 
Schimpff RM, Avard C, Fénelon G, Lhiaubet AM, Tennezé L, et al. (2001) Increased 
plasma neurotensin concentrations in patients with Parkinson’s disease. J Neurol 
Neurosurg Psychiatry 70: 784–786. 
Shibasaki S, Maeda H, Ueda M (2009) Molecular display technology using 
yeast-arming technology. Anal Sci 25: 41–49. 
Stoeckius M, Maaskola J, Colombo T, Rahn HP, Friedländer MR, et al. (2009) 
Large-scale sorting of C. elegans embryos reveals the dynamics of small RNA 
expression. Nat Methods 6: 745–751. 
Tanaka K, Masu M, Nakanishi S (1990) Structure and functional expression of the 
cloned rat neurotensin receptor. Neuron 4: 847–854. 
Togawa S, Ishii J, Ishikura A, Tanaka T, Ogino C, et al. (2010) Importance of asparagine 
residues at positions 13 and 26 on the amino-terminal domain of human 
72 
 
somatostatin receptor subtype-5 in signalling. J Biochem 147: 867–873. 
Ueda M, Tanaka A (2000) Genetic immobilization of proteins on the yeast cell surface. 
Biotechnol Adv 18: 121–140. 
Wan CK, Shaikh SB, Green CR, Nicholson LF (2012) Comparison of bidirectional and 
bicistronic inducible systems for coexpression of connexin genes and fluorescent 
reporters. Anal Biochem 431: 90–95. 
White JF, Noinaj N, Shibata Y, Love J, Kloss B, et al. (2012) Structure of the 
agonist-bound neurotensin receptor. Nature 490: 508–513. 
Yu L, Qi M, Sheff MA, Elion EA (2008) Counteractive control of polarized 
morphogenesis during mating by mitogen-activated protein kinase Fus3 and G1 
cyclin-dependent kinase. Mol Biol Cell 19: 1739–1752. 
Zhang JH, Chung TD, Oldenburg KR (1999) A simple statistical parameter for use in 
evaluation and validation of high throughput screening assays. J Biomol Screen 4: 
67–73. 
 
  
73 
 
Chapter 2: Applications of microbial signaling sensor using Zoanthus sp. green 
fluorescent protein for antagonist characterization and site-directed 
mutagenesis of human serotonin 1A receptor 
 
 
Introduction 
The neuromodulator serotonin [5-hydroxytryptamine (5-HT)] is essential for 
diverse functions at nearly every organ system in the human body (Berger et al., 2009; 
Roth et al., 2004; Wacker et al., 2013). The activity of 5-HT is mediated through 
activation of members of a large family of 5-HT receptor proteins that can be grouped 
into seven subfamilies (5-HT1-7) on the basis of sequence homology and signaling 
mechanisms (Kroeze et al., 2002). In all 13 members, except for the 5-HT3 receptor, 
which is a ligand-gated ion channel, the other 12 members are heterotrimeric guanine 
nucleotide binding protein (G-protein) coupled receptors (GPCRs). GPCRs belong to a 
large and diverse family of integral membrane proteins that participate in the regulation 
of many cellular processes and, therefore, represent key targets for pharmacological 
treatment. The serotonergic system is a target of many prescribed drugs, including 
atypical antipsychotics, antimigraine medications, anxiolytics, and antidepressants 
(Berger et al., 2009). 
In addition, 5-HT is known to act as a growth factor on several types of 
non-tumoral cells (Nemecek et al., 1986; Sibella-Arguelles, 2001; Takuwa et al., 1989), 
and it was also related to oncogenes (Julius et al., 1989). Depending on the tumor type, 
either 5-HT2 (Launay et al., 1996) or 5-HT1 receptor antagonist have been found to 
inhibit the 5-HT-induced increase in tumor growth (Seuwen and Pouysségur, 1990). 
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Among subtype 1 receptors, 5-HT1A receptor (HTR1A) is the most widely studied 
subtype. HTR1A is also involved in the proliferation of human tumor cells (Cattaneo et 
al., 1993, 1995; Ishizuka et al., 1992; Launay et al., 1996; Rajamannan et al., 2001). 
Previously, HTR1A antagonists and serotonin-uptake inhibitors were reported to inhibit 
the growth of tumor cell lines (Abdul et al., 1994, 1995; Dizeyi et al., 2004). Thus, 
simple and convenient detection systems for not only HTR1A agonists but also 
antagonists have a potential for the powerful tool towards new drug development. 
The eukaryotic unicellular yeast Saccharomyces cerevisiae is a useful microbial 
host organism for studying GPCRs as monomolecular models (Ishii et al., 2010; Minic 
et al., 2005). Because of their uncompetitive and monopolistic G-protein signaling 
pathway, yeast can be used to simplify the complicated signaling pathways of higher 
eukaryotic cells (Iguchi et al., 2010; Togawa et al., 2010). A variety of human GPCRs 
are known to transduce signals in yeast cells through the endogenous yeast Gα-subunit 
(Gpa1p) or a yeast-human chimeric G-protein (Fukuda et al., 2011; Ishii et al., 2014). 
The yeast cells have successfully expressed many types of human GPCRs and have 
been adeptly used for various applications such as ligand screening and receptor 
mutagenesis using enzymatic and growth reporter genes (Klco et al., 2006; Minic et al., 
2005; Scarselli et al., 2007). It was recently reported that the use of an established 
fluorescence-based reporter gene assay provides the most convenient measurement 
procedure: the cell culture is simply diluted into buffers and the fluorescence is read 
using fluorometric instruments (Ishii et al., 2012a, b). A flow cytometer is an especially 
powerful tool for comparative quantification and quantitative screening (cell sorting) 
(Ishii et al., 2012a, b). In addition, mutagenesis approaches can be implemented to 
obtain human GPCR structural information. Unfortunately, however, previously 
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reported systems using enhanced green fluorescent protein (EGFP) as reporter gene 
resulted in low signal-to-noise (S/N) ratio, making it difficult to apply to antagonist 
characterization and mutagenesis approaches. 
In this study, we generated an engineered yeast strain, which can transduce the 
HTR1A-specific signal in response to its agonist by using the brighter fluorescent 
reporter (ZsGreen) gene. Using the generated yeast strain, we successfully performed 
not only antagonist characterization but also site-directed mutagenesis for human 
HTR1A receptor. This biosensor specifically responded to HTR1A antagonist, pindolol, 
inhibiting the agonist-induced activating HTR1A. In mutagenesis experiments, several 
mutants were analyzed to confirm the validity of the biosensor and the role of the highly 
conserved DRY motif in activation of HTR1A was investigated. 
 
Materials and Methods 
Plasmid constructions 
All plasmids used in this study are listed in Table 1. All primers used for plasmid 
construction are listed in Table 2. 
A DNA fragment encoding the human HTR1A gene was PCR-amplified from 
pPR3-HTR1A (Nakamura et al., 2013a) using the primers #1 and #2, digested with 
NheI+BglII, and inserted into the same sites between the PGK1 promoter (PPGK1) and 
the PGK1 terminator (TPGK1) on pGK421 (Togawa et al., 2010), yielding the plasmid 
pGK421-HTR1A. 
The plasmids for expressing mutated HTR1A proteins were constructed as follows. 
To introduce point mutations, gene fragments encoding the upstream and downstream 
parts of mutated HTR1A were respectively PCR-amplified from pGK421-HTR1A using 
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primers #1 + #3 and #4 + #2 (for D82N); #1 + #5 and #6 + #2 (for D116N); #1 + #7 and 
#8 + #2 (for C109A); #1 + #9 and #10 + #2 (for C187A); #1 + #11 and #12 + #2 (for 
S199A); #1 + #13 and #14 + #2 (for T200A); #1 + #15 and #16 + #2 (for N386V); #1 + 
#17 and #18 + #2 (for D133A); #1 + #19 and #20 + #2 (for R134A); #1 + #21 and #22 
+ #2 (for Y135A). These amplified fragments then were used as the templates for 
overlap PCR with primers #1 and #2. The resulting linear mutated HTR1A fragments 
were digested with NheI+BglII and ligated into similarly digested pGK421, resulting in 
plasmids designated pGK421-HTR1A-D82N, -D116N, -C109A, -C187A, -S199A, 
-T200A, -N386V, -D133A, -R134A, or -Y135A, respectively. 
 
Yeast strains and media 
All yeast strains used in this study are listed in Table 1. Transformation with 
plasmids was performed using the lithium acetate method (Gietz et al., 1992). 
Synthetic dextrose (SD) medium contained 6.7 g/L yeast nitrogen base without 
amino acids (YNB) (BD-Diagnostic Systems, Sparks, MD, USA) and 20 g/L glucose. 
For SDM71 media, SD medium was adjusted to pH 7.1 with 200 mM 
3-(N-morpholino)-2-hydroxypropanesulfonic acid (MOPSO) (Nacalai Tesque, Kyoto, 
Japan). YPD medium contained 10 g/L yeast extract (Nacalai Tesque), 20 g/L peptone 
(BD-Diagnostic Systems) and 20 g/L glucose. Amino acids and nucleotides (20 mg/L 
histidine, 60 mg/L leucine, or 20 mg/L uracil) were supplemented into SD media to lack 
the relevant auxotrophic components. For solid medium, agar was added at 20 g/L. 
 
HTR1A signaling assay 
HTR1A signaling assays basically followed previous procedures (Nakamura et al., 
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2013b, 2014) except changes in the ligand. In brief, to assay signal activation from 
human HTR1A, the yeast strains transformed with the wild-type or mutated HTR1A 
expression plasmids were grown in SD medium (supplemented as needed) at 30 °C 
overnight, and the cells then were inoculated into 5 mL of the respective fresh SD 
medium to give an initial optical density of 0.03 at 600 nm (OD600 = 0.03). The cells 
were incubated at 30 °C on a rotary shaker at 150 rpm for up to 18 h and harvested, 
washed, and resuspended in water to yield an OD600 = 10. The resulting yeast cell 
suspensions were added (at 10 L/well; to give an OD600 = 1) to the wells of 96-well 
cluster dishes containing fresh SDM71 medium (80 L/well) supplemented with 
10-times concentrated 5-HT (Nacalai Tesque) (10 L/well) at various concentrations or 
distilled water (without 5-HT; control). The plates were incubated at 30 °C with shaking 
(150 rpm) for 4 h. After incubation, the samples containing the yeast cells were diluted 
with 1 mL of sheath fluid, and fluorescence was analyzed by flow cytometer. Half 
maximal effective concentrations (EC50) values were determined using 
KaleidaGraph4.0 Fits to a dosersplgst model. 
 
Flow cytometry analysis 
Flow cytometry measurements of green fluorescence followed previous 
procedures (Ishii et al., 2012b). In brief, fluorescent cells were detected using a BD 
FACSCanto II flow cytometer equipped with a 488-nm blue laser (Becton, Dickinson 
and Company, Franklin Lakes, NJ, USA); the data were analyzed using BD FACSDiva 
software (v5.0; Becton, Dickinson and Company). The GFP fluorescence signal was 
collected through a 530/30 nm band-pass filter and the GFP-A mean of 10,000 cells was 
defined as ‘green fluorescent intensity’. 
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Table 1. Yeast strains and plasmids used in this study. 
Strain or plasmid Specific features Source 
Strain   
BY4741 MATa his31 leu20 met150 ura30 
Brachmann 
et al. (1998) 
IMFD-70 BY4741 sst2::AUR1-C ste2::LEU2 fig1::EGFP his3::PFIG1-EGFP far1 
Togawa et 
al. (2010) 
IMFD-72 BY4741 sst2::AUR1-C ste2::LEU2 fig1::EGFP his3::PFIG1-EGFP far1 gpa1::Gi3tp 
Ishii et al. 
(2012a) 
IMFD-70ZsD BY4741 sst2::AUR1-C ste2::LEU2 fig1::ZsGreen his3::PFIG1-ZsGreen far1 
Nakamura et 
al. (2013b) 
IMFD-72ZsD BY4741 sst2::AUR1-C ste2::LEU2 fig1::ZsGreen his3::PFIG1-ZsGreen far1 gpa1::Gi3tp 
Nakamura et 
al. (2013b) 
Plasmid   
pGK421 
Yeast expression vector containing PGK1 promoter, PGK1 terminator, 2 origin and MET15 
marker 
Togawa et 
al. (2010) 
pGK421-HTR1A Human HTR1A receptor expression in pGK421 This study 
pGK421-HTR1A-D82N Human HTR1A receptor (D82N) mutant expression in pGK421 This study 
pGK421-HTR1A-D116N Human HTR1A receptor (D116N) mutant expression in pGK421 This study 
pGK421-HTR1A-C109A Human HTR1A receptor (C109A) mutant expression in pGK421 This study 
pGK421-HTR1A-C187A Human HTR1A receptor (C187A) mutant expression in pGK421 This study 
pGK421-HTR1A-S199A Human HTR1A receptor (S199A) mutant expression in pGK421 This study 
pGK421-HTR1A-T200A Human HTR1A receptor (T200A) mutant expression in pGK421 This study 
pGK421-HTR1A-N386V Human HTR1A receptor (N386V) mutant expression in pGK421 This study 
pGK421-HTR1A-D133A Human HTR1A receptor (D133A) mutant expression in pGK421 This study 
pGK421-HTR1A-R134A Human HTR1A receptor (R134A) mutant expression in pGK421 This study 
pGK421-HTR1A-Y135A Human HTR1A receptor (Y135A) mutant expression in pGK421 This study 
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Table 2. List of primers. 
 Name Sequence 
#1 NheI_HTR1A_fw 5'-AAAAGCTAGCATGGATGTGCTCAGCCCTGG 
#2 BglII_HTR1A_rv 5'-TTTTAGATCTTCACTGGCGGCAGAACTTAC 
#3 HTR1A-D82N_rv 5'-CGACACCATGAGGTTGGTGACCGCCAAAGA 
#4 HTR1A-D82N_fw 5'-TCTTTGGCGGTCACCAACCTCATGGTGTCG 
#5 HTR1A-D116N_rv 5'-GCAGCACAGCACGTTGAGGGCGATGAACAG 
#6 HTR1A-D116N_fw 5'-CTGTTCATCGCCCTCAACGTGCTGTGCTGC 
#7 HTR1A-C109A_rv 5'-GATGAACAGGTCGGCGGTTACCTGGCCCAG 
#8 HTR1A-C109A_fw 5'-CTGGGCCAGGTAACCGCCGACCTGTTCATC 
#9 HTR1A-C187A_rv 5'-CTTGCTAATGGTGGCTGCGTCGGGGTCCGA 
#10 HTR1A-C187A_fw 5'-TCGGACCCCGACGCAGCCACCATTAGCAAG 
#11 HTR1A-S199A_rv 5'-AGCTCCAAAGGTGGCATAGATAGTGTAGCC 
#12 HTR1A-S199A_fw 5'-GGCTACACTATCTATGCCACCTTTGGAGCT 
#13 HTR1A-T200A_rv 5'-GAAAGCTCCAAAGGCGGAATAGATAGTGTA 
#14 HTR1A-T200A_fw 5'-TACACTATCTATTCCGCCTTTGGAGCTTTC 
#15 HTR1A-N386V_rv 5'-GTAGCCCAGCCAAACGATTATGGCGCCCAA 
#16 HTR1A-N386V_fw 5'-TTGGGCGCCATAATCGTTTGGCTGGGCTAC 
#17 HTR1A-D133A_rv 5'-GGCCCAGTACCTGGCCAGCGCGATGGCGCA 
#18 HTR1A-D133A_fw 5'-TGCGCCATCGCGCTGGCCAGGTACTGGGCC 
#19 HTR1A-R134A_rv 5'-GATGGCCCAGTACGCGTCCAGCGCGATGGC 
#20 HTR1A-R134A_fw 5'-GCCATCGCGCTGGACGCGTACTGGGCCATC 
#21 HTR1A-Y135A_rv 5'-CGTGATGGCCCAGGCCCTGTCCAGCGCGAT 
#22 HTR1A-Y135A_fw 5'-ATCGCGCTGGACAGGGCCTGGGCCATCACG 
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Antagonist inhibition assay 
To assay antagonist inhibition of signal activation from human HTR1A, the yeast 
strains transformed with the wild-type or mutated HTR1A expression plasmids were 
grown in SD medium (supplemented as needed) at 30 °C overnight, and the cells then 
were inoculated into 5 mL of the respective fresh SD medium to give an initial optical 
density of 0.03 at 600 nm (OD600 = 0.03). The cells were incubated at 30 °C on a rotary 
shaker at 150 rpm for up to 18 h and harvested, washed, and resuspended in water to 
yield an OD600 = 10. The resulting yeast cell suspensions were added (at 10 L/well; to 
give an OD600 = 1) to the wells of 96-well cluster dishes containing fresh SDM71 
medium with 100 μM or 1 mM 5-HT (80 L/well) supplemented with 10-times 
concentrated pindolol (Tocris Bioscience, Bristol, United Kingdom) (10 L/well) at 
various concentrations or distilled water (without pindolol; control). The plates were 
incubated at 30 °C with shaking (150 rpm) for 4 h. After incubation, the samples 
containing the yeast cells were diluted with 1 mL of sheath fluid, and fluorescence was 
analyzed by flow cytometer. 
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Results and Discussion 
Comparing the reporting sensitivity between the ZsGreen and the EGFP systems 
The aim of this study was to conduct antagonist characterization and site-directed 
mutagenesis analyses of human HTR1A receptor using yeast-based biosensor. To 
monitor the signal activation of human HTR1A receptor, previously engineered yeast 
cells in which the GFP reporter genes have been integrated into the genomes were used 
as the host strains (Nakamura et al., 2013b). In the engineered strains, the tetrameric 
Zoanthus sp. green fluorescent protein (ZsGreen), whose fluorescence is brighter than 
enhanced green fluorescent protein (EGFP), is used as the GFP reporter. The expression 
of ZsGreen is controlled by the signal responsive FIG1 promoter. Therefore, the 
signaling activation by agonist stimulus results in the generation of a green fluorescence 
signal (Nakamura et al., 2013b). 
In addition, all engineered yeast strains have the ste2, sst2, and far1 alleles 
that are deficient in the yeast single GPCR, the yeast principal negative regulator of 
G-protein signaling (RGS), and the yeast G1-cyclin-dependent kinase inhibitor; this 
inhibitor induces G1 arrest in response to signaling, respectively (Fukuda et al., 2011; 
Iguchi et al., 2010; Ishii et al., 2012b; Togawa et al., 2010). These deletions respectively 
allow expression of human GPCRs without competitive receptor expression (Iguchi et 
al., 2010; Ishii et al., 2010; Togawa et al., 2010), hypersensitive agonist stimulation 
even in the low ligand concentrations (Ishii et al., 2006), and vital growth in association 
with the plasmid retention under signal-activated states (Ishii et al., 2008). 
The human HTR1A receptor is known to transduce signals in yeast cells through 
the endogenous yeast Gα-subunit (Gpa1p). A yeast-human chimeric G-protein, in which 
the carboxyl-terminal 5 amino acid residues of Gpa1p (KIGII) are replaced with the 
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equivalent residues from human Gαi3 (ECGLY) (Gpa1/Gαi3 transplant, Gi3tp), has been 
shown to improve signal transmission via Gαi-specific HTR1A in yeast (Brown et al., 
2000). Therefore, the effects of the performance of reporter gene and the yeast-human 
chimeric G-protein in engineered yeast cells were tested by comparing the fluorescence 
of yeast cells expressing either ZsGreen or EGFP as a reporter and either the 
endogenous yeast G-protein (Gpa1p) or the yeast-human chimeric G-protein (Gi3tp), 
when human HTR1A receptor was expressed in yeast cells. The human HTR1A 
receptor was expressed via a multicopy episomal plasmid under the control of 
constitutive PGK1 promoter (pGK421-HTR1A) (Table 1). Yeast IMFD-70 (EGFP, 
Gpa1p), IMFD-72 (EGFP, Gi3tp), IMFD-70ZsD (ZsGreen, Gpa1p) and IMFD-72ZsD 
(ZsGreen, Gi3tp) strains (Table 1) harboring pGK421-HTR1A were generated and the 
signaling assays were performed. As shown in Figure 1, in all yeast cells, the addition 
of 5-HT resulted in a dose-dependent increase in fluorescence intensity. The 
half-maximal effective concentration (EC50) values were 32 μM (IMFD-70), 18 μM 
(IMFD-72), 24 μM (IMFD-70ZsD) and 12 μM (IMFD-72ZsD), respectively. These 
results suggested that the affinity or sensitivity of HTR1A for 5-HT was increased by 
yeast-human chimeric Gα (Gi3tp). The addition of agonist to yeast strains IMFD-70 and 
IMFD-72 were modest response and induced only 1.2- and 1.4-fold higher maximum 
fluorescence (Figure 2). In contrast, strains IMFD-70ZsD and IMFD-72ZsD displayed 
a 2.3- and 4.0-fold increase in maximum fluorescence intensity in response to agonist 
stimulation (Figure 1). Because IMFD-72ZsD strain provided the highest fluorescence 
and signal-to-noise (S/N) ratio, further studies were conducted using the yeast strain 
IMFD-72ZsD. 
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Fig. 1. Dose‒response curves for 5-HT-specific HTR1A signaling activities of 
recombinant yeast cells. Yeast strains IMFD-70 (EGFP (Gpa1)), IMFD-72 (EGFP 
(Gi3tp)), IMFD-70ZsD (ZsGreen (Gpa1)) and IMFD-72ZsD (ZsGreen (Gi3tp)) were 
transformed with pGK421-HTR1A. All transformants were grown in SD selective 
medium for 18 h. The cells then were incubated for another 4 h in pH-adjusted SD 
selective medium with 5-HT at various concentrations. The GFP fluorescence of 10,000 
cells was measured by flow cytometry. Each data point is presented as the mean ± 
standard deviation of separate runs (n = 3 each). 
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Fig. 2. Dose‒response curves for 5-HT-specific HTR1A signaling activities of 
recombinant yeast cells. Yeast strains IMFD-70 (EGFP (Gpa1)) and IMFD-72 (EGFP 
(Gi3tp)) were transformed with pGK421-HTR1A. All transformants were grown in SD 
selective medium for 18 h. The cells then were incubated for another 4 h in pH-adjusted 
SD selective medium with 5-HT at various concentrations. The GFP fluorescence of 
10,000 cells was measured by flow cytometry. Each data point is presented as the mean 
± standard deviation of separate runs (n = 3 each). 
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Fig. 3. Inhibition of 5-HT (100 μM)-mediated functional responses of HTR1A by 
pindolol. The dose‒response relationship to pindolol was determined by recombinant 
yeast strain IMFD-72ZsD (ZsGreen (Gi3tp)) transformed with pGK421-HTR1A. The 
transformants were grown in SD selective medium for 18 h. The cells then were 
incubated for another 4 h in pH-adjusted SD selective medium with 5-HT (100 μM) and 
pindolol at various concentrations. The GFP fluorescence of 10,000 cells was measured 
by flow cytometry. Each data point is presented as the mean ± standard deviation of 
separate runs (n = 3 each). 
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Antagonist inhibition of 5-HT induced activating HTR1A 
To measure antagonist inhibition of the agonist-induced activating HTR1A, the 
fluorescence responses to various concentrations of HTR1A antagonist, pindolol were 
examined. Yeast IMFD-72ZsD strain harboring pGK421-HTR1A was generated and 
examined using an antagonist inhibition assay. The cells were incubated in media 
containing 100 μM 5-HT and various concentrations of pindolol, and the resulting 
expression levels of the ZsGreen reporter gene were measured by flow cytometry. 
Figure 3 shows that the cells exhibited suppressed fluorescence depending on the 
concentration of pindolol and reached almost basal level at a concentration of 100 μM 
pindolol. This indicated that pindolol exhibited a dose-dependent inhibition of the 
agonist-induced activating HTR1A. In addition, the cells were incubated in media 
containing 1 mM 5-HT and various concentrations of pindolol. The cells exhibited 
suppressed fluorescence depending on the concentration of pindolol and reached almost 
basal level at a concentration of 1 mM pindolol (Figure 4). These results indicated that 
our system was applicable for evaluating antagonist inhibition of the agonist-induced 
activating HTR1A. 
 
Site-directed mutagenesis analysis of HTR1A 
To evaluate the site-directed mutagenesis analysis of HTR1A, the fluorescence 
responses of yeast strains expressing several mutants of HTR1A were examined. We 
constructed 10 of plasmids for expressing mutants of HTR1A. The positions of the 
residues of HTR1A selected as targets for site-directed mutagenesis are shown in 
Figure 5. 
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Fig. 4. Inhibition of 5-HT (1 mM)-mediated functional responses of HTR1A by 
pindolol. The dose‒response relationship to pindolol was determined by recombinant 
yeast strain IMFD-72ZsD (ZsGreen (Gi3tp)) transformed with pGK421-HTR1A. The 
transformants were grown in SD selective medium for 18 h. The cells then were 
incubated for another 4 h in pH-adjusted SD selective medium with 5-HT (1 mM) and 
pindolol at various concentrations. The GFP fluorescence of 10,000 cells was measured 
by flow cytometry. Each data point is presented as the mean ± standard deviation of 
separate runs (n = 3 each). 
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Fig. 5. Schematic illustration of the human HTR1A showing the positions of the 
mutations. Each circle represents an amino acid residue. The positions of amino acids 
mutated in this study are indicated as red circles. 
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Primarily, the previously reported mutants (D82N, D116N, C109A, C187A, 
S199A, T200A and N386V) were used for the site-directed mutagenesis. Yeast 
IMFD-72ZsD strains harboring pGK421-HTR1A-D82N or -D116N were generated and 
studied using the signaling assay. As shown in Figure 6A and B, the D82N and D116N 
mutants completely and significantly lost the ability to respond to 5-HT-specific 
signaling, respectively. This result is consistent with the previous report in which the 
substitutions D82N and D116N resulted in a 60‒100 fold decreased affinity for 5-HT 
(Ho et al., 1992). Subsequently, the yeast strains IMFD-72ZsD expressing the C109A or 
C187A mutants exhibited abolish HTR1A function (Figure 6C and D). The mutation of 
C109A or C187A was crucial for the signaling stimulated from 5-HT, suggesting that 
disulfide-bridge between Cys109 and Cys187 was critical for the affinity to 5-HT or the 
activation of receptor (Pucadyil et al., 2005). Other many GPCRs also form 
disulfide-bridge within cysteine residues between the first extracellular loop and the 
second extracellular loop (Klco et al., 2006). Next, yeast IMFD-72ZsD strains harboring 
pGK421-HTR1A-S199A or -T200A were generated and studied using the signaling 
assay. As shown in Figure 7A and B, the yeast strains expressing S199A or T200A 
displayed both 2.9-fold increase in maximum fluorescence intensity in response to 
agonist stimulation and the EC50 values were 54 μM (S199A) and 257 μM (T200A), 
respectively. This result is also consistent with the previous report in which a significant 
reduction of agonist binding and the activation of receptor (Ho et al., 1992). 
Additionally, the mutant N386V which displayed a lower affinity for pindolol without 
any effect on the affinity for other ligands had been reported. Yeast IMFD-72ZsD strain 
harboring pGK421-HTR1A-N386V was generated and studied using the signaling assay. 
As shown in Figure 7C and D, although the yeast strain expressing N386V displayed 
90 
 
only 1.3-fold increase in maximum fluorescence intensity in response to agonist 
stimulation, the EC50 values was 24 μM. This result indicated that the N386V affected 
not the affinity for 5-HT but the receptor activity or signaling. In addition, the cells were 
incubated in media containing 100 μM 5-HT and various concentrations of pindolol. As 
shown in Figure 3 and 8, while the yeast strain expressing WT or S199A displayed that 
fluorescence intensity started to decrease at a concentration of 100 μM pindolol, the 
yeast strain expressing N386V displayed that fluorescence intensity started to decrease 
at a concentration of 1 mM pindolol. This result indicated that the N386V mutant 
displayed a lower affinity for pindolol according to the previous report. 
Finally, the previously no reported mutants (D133A, R134A and Y135A) were 
used for the site-directed mutagenesis. We selected the DRY motif as targets for the 
mutants. The DRY motif present in the second intracellular loop is considered to be the 
switch that activates G-proteins upon agonist binding to the receptor. This DRY motif is 
highly conserved amino acid sequence motif in many GPCRs (Rovati et al., 2007; 
Savarese and Fraser, 1992), but the role of the DRY motif in HTR1A activation is not 
known. Yeast IMFD-72ZsD strains harboring pGK421-HTR1A-D133A, -R134A or 
-Y135A were generated and studied using the signaling assay. As shown in Figure 9, 
the D133A and Y135A mutants significantly lost the ability to respond to 5-HT-specific 
signaling and the R134A mutant completely lost the ability to respond to 5-HT-specific 
signaling. These results suggested that the central arginine of the DRY motif seems to 
be more directly involved in receptor activation. 
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Fig. 6. Ligand response of wild-type (WT) and mutant HTR1A receptors (D82N, 
D116N, C109A, C187A). The dose‒response relationship to 5-HT was determined by 
recombinant yeast strain IMFD-72ZsD (ZsGreen (Gi3tp)) expressing WT HTR1A 
receptor (open diamond ◊) or its mutants (filled square ■). Dose‒response curves are 
shown for (A) D82N mutants, (B) D116N mutants, (C) C109A mutants, and (D) C187A 
mutants, respectively. The transformants were grown in SD selective medium for 18 h. 
The cells then were incubated for another 4 h in pH-adjusted SD selective medium with 
5-HT at various concentrations. The GFP fluorescence of 10,000 cells was measured by 
flow cytometry. Each data point is presented as the mean ± standard deviation of 
separate runs (n = 3 each). 
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Fig. 7. Ligand response of wild-type (WT) and mutant HTR1A receptors (S199A, 
T200A, N386V). The dose‒response relationship to 5-HT was determined by 
recombinant yeast strain IMFD-72ZsD (ZsGreen (Gi3tp)) expressing WT HTR1A 
receptor (open diamond ◊) or its mutants (filled square ■). Dose‒response curves are 
shown for (A) S199A mutants, (B) T200A mutants, and (C, D) N386V mutants, 
respectively. The transformants were grown in SD selective medium for 18 h. The cells 
then were incubated for another 4 h in pH-adjusted SD selective medium with 5-HT at 
various concentrations. The GFP fluorescence of 10,000 cells was measured by flow 
cytometry. Each data point is presented as the mean ± standard deviation of separate 
runs (n = 3 each). 
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Fig. 8. Inhibition of 5-HT (100 μM)-mediated functional responses by pindolol in 
mutant HTR1A receptors. The dose‒response relationship to pindolol was determined 
by recombinant yeast strain IMFD-72ZsD (ZsGreen (Gi3tp)) expressing HTR1A 
mutants. Dose‒response curves are shown for (A) S199A mutants, and (B) N386V 
mutants, respectively. The transformants were grown in SD selective medium for 18 h. 
The cells then were incubated for another 4 h in pH-adjusted SD selective medium with 
5-HT (100 μM) and pindolol at various concentrations. The GFP fluorescence of 10,000 
cells was measured by flow cytometry. Each data point is presented as the mean ± 
standard deviation of separate runs (n = 3 each). 
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Fig. 9. Ligand response of wild-type (WT) and mutant HTR1A receptors (D133A, 
R134A, Y135A). The dose‒response relationship to 5-HT was determined by 
recombinant yeast strain IMFD-72ZsD (ZsGreen (Gi3tp)) expressing WT HTR1A 
receptor (open diamond ◊) or its mutants (filled square ■). Dose‒response curves are 
shown for (A) D133A mutants, (B) R134A mutants, and (C) Y135A mutants, 
respectively. The transformants were grown in SD selective medium for 18 h. The cells 
then were incubated for another 4 h in pH-adjusted SD selective medium with 5-HT at 
various concentrations. The GFP fluorescence of 10,000 cells was measured by flow 
cytometry. Each data point is presented as the mean ± standard deviation of separate 
runs (n = 3 each). 
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Conclusion 
In this study, we successfully conducted antagonist characterization and 
site-directed mutagenesis analyses of human HTR1A receptor using yeast-based 
biosensor. The biosensor employs a highly-potent fluorescence reporter (ZsGreen) and 
Gα-engineered yeast strain. This biosensor specifically responded to HTR1A antagonist, 
pindolol, inhibiting the agonist-induced activating HTR1A. In mutagenesis experiments, 
several mutants were analyzed to confirm the validity of the biosensor and the role of 
the highly conserved DRY motif in activation of HTR1A was investigated. This 
yeast-based system using a fluorescent reporter gene will be available for other human 
GPCRs and be beneficial for the simplification of experimental procedures in a GPCR 
signaling study. 
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Chapter 3: Construction of a yeast-based signaling biosensor for human 
angiotensin II type 1 receptor via functional coupling between 
Asn295-mutated receptor and Gpa1/Gi3 chimeric Gα 
 
 
Introduction 
Angiotensin II (Ang II) is a naturally occurring, linear octapeptide that exhibits 
several extremely potent biological activities, including reversible blood pressure 
elevation and smooth muscle contraction (Printz et al., 1972). While Ang II binds to two 
major subtypes of Ang II receptors, Ang II type 1 receptor (AGTR1) and Ang II type 2 
receptor (AGTR2), the most noted physiological and pathophysiological actions are 
mainly invoked through AGTR1. Both AGTR1 and AGTR2 are heterotrimeric guanine 
nucleotide binding protein (G-protein) coupled receptors (GPCRs), which is a large and 
diverse family of integral membrane proteins. GPCRs participate in the regulation of 
many cellular processes and, therefore, represent key targets for pharmacological 
treatment. Ang II regulates the cardiovascular response through AGTR1 (Griendling et 
al., 1996; Mehta and Griendling, 2007) and is involved in a wide range of diseases such 
as hypertension, atherosclerosis, heart failure, and diabetes (Chien, 1999; Dzau and 
Lopez-Ilasaca, 2005; MacLellan and Schneider, 1998; McKinsey and Olson, 1999; 
Sadoshima and Izumo, 1997). Consequently, AGTR1 is a significant molecular target in 
various research fields, including medicine, therapeutics, and pharmaceutics. 
All eukaryotes conserve heterotrimer G-proteins that comprise Gα-, Gβ-, and 
Gγ-subunits on the inner leaflets of plasma membranes. Mammalian cells possess 
several types of G-proteins that enable the control of diverse physiological responses 
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mediated by interactions with a variety of transmembrane GPCRs (Hur and Kim, 2002). 
However, this diversity makes it difficult to identify which G-protein-GPCR pair is 
responsible for specific signals (Ishii et al., 2010). Because haploid Saccharomyces 
cerevisiae expresses one type of GPCR (either the a-cell specific pheromone receptor, 
Ste2p, or the α-cell specific pheromone receptor, Ste3p) and one type of heterotrimeric 
complex of G-proteins (Gpa1p, Ste4p, and Ste18p, which encode yeast Gα, Gβ, and Gγ, 
respectively), it can offer a simple way to transduce the signal promoted by the 
agonistic ligand (Fukuda et al., 2011). Moreover, S. cerevisiae provides several 
advantages, including the possession of eukaryotic secretory machinery, 
post-translational modifications, rapid cell growth, and well-established and versatile 
genetic techniques (Ishii et al., 2010). The introduction of several kinds of reporter 
genes such as green fluorescent protein (GFP) (Iguchi et al., 2010; Togawa et al., 2010), 
β-galactosidase (lacZ) (Brown et al., 2000), luciferase (luc) (Fukutani et al., 2012), and 
growth selection marker (HIS3) (Manfredi et al., 1996) downstream of the pheromone 
signaling (G-protein signaling) pathway further facilitates the detection of the 
agonist-promoted signal. Thus, the eukaryotic unicellular yeast S. cerevisiae is a useful 
microbial host organism for studying GPCRs as monomolecular models (Ishii et al., 
2010; Minic et al., 2005). 
If expression of human GPCR on the plasma membrane of ste2Δ yeast a-cells 
permits coupling with yeast monopolistic G-proteins, the promoted signal in response to 
the cognate ligand or analog agonist can be easily monitored with reporter gene assays 
(Fukuda et al., 2011; Ishii et al., 2010). The use of an established fluorescence-based 
reporter gene assay provides the most convenient measurement procedure: the cell 
culture is simply diluted into buffers and the fluorescence is read using fluorometric 
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instruments (Ishii et al., 2012a, b). A flow cytometer is an especially powerful tool for 
comparative quantification and quantitative screening (cell sorting) (Ishii et al., 2012a, 
b). Signaling assays using fluorescent reporter genes have to date been applied to 
several GPCRs, including yeast endogenous Ste2p (Ishii et al., 2006), murine olfactory 
receptor (OR226) (Fukutani et al., 2012), human somatostatin receptors (SSTR5 and 
SSTR2) (Iguchi et al., 2010; Nakamura et al., 2013b; Togawa et al., 2010), and human 
neurotensin receptor (NTSR1) (Ishii et al., 2014; Nakamura et al., 2013b). However, 
there have been no reports regarding the functional activation of AGTR1-mediated 
signaling in yeast cells. Since AGTR1 is a peptidic ligand-responsive GPCR, functional 
expression of AGTR1 in yeast cells could be applied to screening Ang II analogs or 
entirely new peptidic backbones that work as agonists or antagonists. 
In this study, we succeeded in functional signal activation of human AGTR1 in 
engineered yeast cells. AGTR1-mediated signaling in response to its agonists was easily 
monitored using a fluorescence reporter assay. To allow functional activation of AGTR1 
in yeast cells, we introduced a single Ala or Ser mutation at Asn295 in AGTR1 and used 
yeast-human chimeric Gα in place of the intrinsic yeast protein, Gpa1p. In addition, we 
demonstrated that the autocrined Ang II peptide and its analog (Ang III peptide) 
produced and secreted by the engineered yeast cells could by themselves promote 
AGTR1-mediated signaling. 
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Materials and Methods 
Plasmid construction 
All plasmids used in this study are listed in Table 1. All primers used for plasmid 
construction are listed in Table 2. Plasmid maps are presented in Figure 1. 
A DNA fragment encoding the human AGTR1 gene was PCR-amplified from 
pPR3-AGTR1 (Nakamura et al., 2013a) using the primers #1 and #2, digested with 
NheI+BglII, and inserted into the same sites between the PGK1 promoter (PPGK1) and 
the PGK1 terminator (TPGK1) on pGK421 (Togawa et al., 2010), yielding the plasmid 
pGK421-AGTR1. 
The plasmids for expressing mutated AGTR1 proteins were constructed as follows. 
To introduce point mutations, gene fragments encoding the upstream and downstream 
parts of mutated AGTR1 were respectively PCR-amplified from pGK421-AGTR1 using 
primers #1 + #3 and #4 + #2 (for N111G); #1 + #5 and #6 + #2 (for N111A); #1 + #7 
and #8 + #2 (for N111S); #1 + #9 and #10 + #2 (for N295A); #1 + #11 and #12 + #2 
(for N295S); #1 + #13 and #14 + #2 (for L305Q). These amplified fragments then were 
used as the templates for overlap PCR with primers #1 and #2. The resulting linear 
mutated AGTR1 fragments were digested with NheI+BglII and ligated into similarly 
digested pGK421, resulting in plasmids designated pGK421-AGTR1-N111G, -N111A, 
-N111S, -N295A, -N295S, or -L305Q, respectively. 
To secret the peptidic ligands, the plasmids expressing the fusions of secretion 
signal sequence (s.s.; containing pre, pro α-factor leader region) and mature regions of 
several peptidic ligands were constructed as follows. A DNA fragment encoding the 
fusion between s.s. of α-factor and angiotensin II (AGII) was PCR-amplified from 
pGK426-S1442 (Ishii et al., 2012a) using primers #15 and #16. The s.s.-AGII fragment 
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was digested with NheI+SalI and ligated into similarly digested pGK426 (Ishii et al., 
2009), resulting in the plasmid pGK426-ssAGII. A DNA fragment encoding the fusion 
between s.s. of α-factor and angiotensin III (AGIII) was PCR-amplified from 
pGK426-ssAGII using primers #15 and #17. The s.s.-AGIII fragment was digested with 
NheI+SalI and ligated into similarly digested pGK426, resulting in the plasmid 
pGK426-ssAGIII. A DNA fragment encoding the fusion between s.s. of α-factor and 
angiotensin IV (AGIV) was PCR-amplified from pGK426-ssAGII using primers #15 
and #18. The s.s.-AGIV fragment was digested with NheI+SalI and ligated into similarly 
digested pGK426, resulting in the plasmid pGK426-ssAGIV. 
 
Yeast transformation and media 
All yeast strains used in this study are listed in Table 1. Transformation with 
plasmids was performed using the lithium acetate method (Gietz et al., 1992). 
Synthetic dextrose (SD) medium contained 6.7 g/L yeast nitrogen base without 
amino acids (YNB) (BD-Diagnostic Systems, Sparks, MD, USA) and 20 g/L glucose. 
For SDM71 media, SD medium was adjusted to pH 7.1 with 200 mM 
3-(N-morpholino)-2-hydroxypropanesulfonic acid (MOPSO) (Nacalai Tesque, Kyoto, 
Japan). YPD medium contained 10 g/L yeast extract (Nacalai Tesque), 20 g/L peptone 
(BD-Diagnostic Systems) and 20 g/L glucose. Amino acids and nucleotides (20 mg/L 
histidine, 60 mg/L leucine, or 20 mg/L uracil) were supplemented into SD media to lack 
the relevant auxotrophic components. For solid medium, agar was added at 20 g/L. 
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Table 1. Yeast strains and plasmids used in this study. 
Strain or plasmid Specific features Source 
Strain   
BY4741 MATa his31 leu20 met150 ura30 
Brachmann et 
al. (1998) 
IMFD-70ZsD BY4741 sst2::AUR1-C ste2::LEU2 fig1::ZsGreen his3::PFIG1-ZsGreen far1 
Nakamura et 
al. (2013b) 
IMFD-72ZsD 
BY4741 sst2::AUR1-C ste2::LEU2 fig1::ZsGreen his3::PFIG1-ZsGreen far1 
gpa1::Gi3tp 
Nakamura et 
al. (2013b) 
Plasmid   
pGK421 
Yeast expression vector containing PGK1 promoter, PGK1 terminator, 2 origin 
and MET15 marker 
Togawa et al. 
(2010) 
pGK421-AGTR1 Human AGTR1 receptor expression in pGK421 This study 
pGK421-AGTR1-N111G Human AGTR1 receptor (N111G) mutant expression in pGK421 This study 
pGK421-AGTR1-N111A Human AGTR1 receptor (N111A) mutant expression in pGK421 This study 
pGK421-AGTR1-N111S Human AGTR1 receptor (N111S) mutant expression in pGK421 This study 
pGK421-AGTR1-N295A Human AGTR1 receptor (N295A) mutant expression in pGK421 This study 
pGK421-AGTR1-N295S Human AGTR1 receptor (N295S) mutant expression in pGK421 This study 
pGK421-AGTR1-L305Q Human AGTR1 receptor (L305Q) mutant expression in pGK421 This study 
pGK426 
Yeast expression vector containing PGK1 promoter, PGK1 terminator, 2 origin 
and URA3 marker 
Ishii et al. 
(2009) 
pGK426-ssAGII Ang II secretory expression in pGK426 This study 
pGK426-ssAGIII Ang III secretory expression in pGK426 This study 
pGK426-ssAGIV Ang IV secretory expression in pGK426 This study 
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Table 2. List of primers. 
 Name Sequence 
#1 NheI_AGTR1_fw 5'-GGGGGCTAGCATGATTCTCAACTCTTCTAC 
#2 BglII_AGTR1_rv 5'-GGGGAGATCTTCACTCAACCTCAAAACATG 
#3 AGTR1-N111G_rv 5'-ACTAGCGTACAGGCCGAAACTGACGCTGGC 
#4 AGTR1-N111G_fw 5'-GCCAGCGTCAGTTTCGGCCTGTACGCTAGT 
#5 AGTR1-N111A_rv 5'-ACTAGCGTACAGGGCGAAACTGACGCTGGC 
#6 AGTR1-N111A_fw 5'-GCCAGCGTCAGTTTCGCCCTGTACGCTAGT 
#7 AGTR1-N111S_rv 5'-ACTAGCGTACAGGGAGAAACTGACGCTGGC 
#8 AGTR1-N111S_fw 5'-GCCAGCGTCAGTTTCTCCCTGTACGCTAGT 
#9 AGTR1-N295A_rv 5'-AGGATTCAGGCAAGCGTTAAAATAAGCTAT 
#10 AGTR1-N295A_fw 5'-ATAGCTTATTTTAACGCTTGCCTGAATCCT 
#11 AGTR1-N295S_rv 5'-AGGATTCAGGCAACTGTTAAAATAAGCTAT 
#12 AGTR1-N295S_fw 5'-ATAGCTTATTTTAACAGTTGCCTGAATCCT 
#13 AGTR1-L305Q_rv 5'-AAATTTTTTCCCCTGAAAGCCATAAAAAAG 
#14 AGTR1-L305Q_fw 5'-CTTTTTTATGGCTTTCAGGGGAAAAAATTT 
#15 NheI_SS_fw 5'-GGGGGCTAGCATGAGATTTCCTTCAATTTT 
#16 SalI_AGII-SS_rv 5'-AAAAGTCGACTTAGAAGGGGTGTATGTACAC 
CCGGTCTCTTTTATCCAAAGATACCC 
#17 SalI_AGIII-SS_rv 5'-AAAAGTCGACTTAGAAGGGGTGTATGTACAC 
CCGTCTTTTATCCAAAGATACCC 
#18 SalI_AGIV-SS_rv 5'-AAAAGTCGACTTAGAAGGGGTGTATGTACAC 
TCTTTTATCCAAAGATACCC 
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Fig. 1. Plasmids used in this study. (A) Multi-copy plasmid pGK421-AGTR1 (B) 
Multi-copy plasmid pGK426-ssAII. 
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AGTR1 signaling assay 
AGTR1 signaling assays basically followed previously described procedures 
(Nakamura et al., 2013b, 2014) except for changes in the ligands. In brief, to assay 
signal activation from human AGTR1, the yeast strains transformed with the wild-type 
or mutated AGTR1 expression plasmids were grown in SD medium (supplemented as 
needed) at 30 °C overnight, then the cells were inoculated into 5 mL of the respective 
fresh SD medium to give an initial optical density of 0.03 at 600 nm (OD600 = 0.03). 
The cells were incubated at 30 °C on a rotary shaker at 150 rpm for up to 18 h, then 
harvested, washed, and resuspended in water to yield an OD600 = 10. The resulting yeast 
cell suspensions were added (at 10 L/well; OD600 = 1) to the wells of 96-well cluster 
dishes containing fresh SDM71 medium (80 L/well) supplemented with 10-times 
concentrated Ang II (Calbiochem, Darmstadt, Germany) (10 L/well) at various 
concentrations or with distilled water (without Ang II; control). The plates were 
incubated at 30 °C with shaking (150 rpm) for 4 h. After incubation, the samples 
containing the yeast cells were observed using a fluorescence microscope or diluted 
with 1 mL of sheath fluid, then fluorescence was analyzed by flow cytometry. Half 
maximal effective concentration (EC50) values were determined using KaleidaGraph4.0 
Fits to a dosersplgst model. 
 
Flow cytometry analysis 
Flow cytometry measurements of green fluorescence followed a previously 
described procedure (Iguchi et al., 2010; Togawa et al., 2010). In brief, fluorescent cells 
were detected using a BD FACSCanto II flow cytometer equipped with a 488-nm blue 
laser (Becton, Dickinson and Company, Franklin Lakes, NJ, USA); the data were 
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analyzed using BD FACSDiva software (v5.0; Becton, Dickinson and Company). The 
GFP fluorescence signal was collected through a 530/30 nm band-pass filter; a GFP-A 
mean of 10,000 cells was defined as ‘green fluorescent intensity’. 
 
Fluorescence microscopy imaging 
The cultured cells were washed and suspended in distilled water, and observed 
using a BZ-9000 fluorescence microscope (Keyence, Osaka, Japan). Green fluorescence 
images were acquired with a 470/40 band-pass filter for excitation and a 535/50 
band-pass filter for emission. 
 
AGTR1 signaling assay using secretory expression system of peptide ligands 
AGTR1 signaling assays using a secretory expression system for the peptide 
ligands basically followed a previously reported procedure (Nakamura et al., 2013b) 
with some modifications. In brief, to assay signal activation from human AGTR1, yeast 
strains harboring pGK421-AGTR1-N295A or -N295S receptor expression plasmids and 
pGK426-based peptide expression plasmids were grown in SD medium (supplemented 
as needed) at 30 °C overnight, then the cells were inoculated into 5 mL of the respective 
fresh SDM71 medium to give an initial OD600 = 0.1. The cells were incubated at 30 °C 
on a rotary shaker at 150 rpm for 9 h. The yeast cells were observed using a 
fluorescence microscope, or diluted with 1 ml of sheath fluid and fluorescence was 
analyzed by flow cytometry. 
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Results and Discussion 
Mutated AGTR1 is capable of coupling to the yeast signal transduction pathway 
To monitor the signal activation of human AGTR1 receptor, previously engineered 
yeast cells in which the GFP reporter genes have been integrated into the genome were 
used as the host strains (Nakamura et al., 2013b). In the engineered strains, the 
tetrameric Zoanthus sp. green fluorescent protein (ZsGreen), the fluorescence of which 
is brighter than enhanced green fluorescent protein (EGFP), was used as the GFP 
reporter. The expression of ZsGreen is controlled by the signal responsive FIG1 
promoter. Therefore, signaling activation by agonist stimulus results in the generation of 
a green fluorescence signal (Nakamura et al., 2013b). 
In addition, all engineered yeast strains have the ste2, sst2, and far1 alleles 
that are deficient in the yeast single GPCR, the yeast principal negative regulator of 
G-protein signaling (RGS), and the yeast G1-cyclin-dependent kinase inhibitor, an 
inhibitor that induces G1 cell cycle arrest in response to signaling (Fukuda et al., 2011; 
Iguchi et al., 2010; Ishii et al., 2012b; Togawa et al., 2010). These deletions respectively 
allow expression of human GPCRs without competitive receptor expression (Iguchi et 
al., 2010; Ishii et al., 2010; Togawa et al., 2010), hypersensitive agonist stimulation 
even at low ligand concentrations (Ishii et al., 2006), and growth in association with 
plasmid retention under signal-activated states (Ishii et al., 2008). 
Since there have been no reports of functional activation of AGTR1-mediated 
signaling in yeast cells, we constructed multicopy episomal plasmids for expressing 
wild-type and six mutants of AGTR1 receptor under the control of the constitutive 
PGK1 promoter (Figure 2, Table 1). The selected six AGTR1 mutants have increased 
affinities and potencies for Ang II, although they present the constitutive activations of 
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signaling in mammalian cells (Balmforth et al., 1997; Feng et al., 1998, 2005; 
Groblewski et al., 1997; Noda et al., 1996). Yeast IMFD-70ZsD strain, which 
specifically possesses intrinsic Gα (Gpa1p) (Table 1), was used to transform AGTR1 
and its mutant expression plasmids, and then AGTR1 signaling assays were carried out. 
As shown in Figure 3A, none of the IMFD-70ZsD yeast cells expressing wild-type 
AGTR1 or its mutants showed green fluorescence, even in the presence of 1 mM Ang II. 
This result indicated that wild-type and mutant AGTR1 cannot transduce signals in 
yeast cells through the endogenous yeast Gα-subunit (Gpa1p). 
A yeast-human chimeric Gα-subunit, in which the carboxyl-terminal 5 amino acid 
residues of Gpa1p (KIGII) are replaced with the equivalent residues from human Gαi3 
(ECGLY) (Gpa1/Gαi3 transplant, Gi3tp), has been shown to improve signal transmission 
via several GPCRs expressed in yeast cells (Brown et al., 2000; Ishii et al., 2014; 
Nakamura et al., 2013b). Therefore, yeast IMFD-72ZsD strains, which specifically 
possess the chimeric Gα (Gi3tp) (Table 1), were used to transform AGTR1 and its 
mutant expression plasmids, and then AGTR1 signaling assays were performed. As 
shown in Figure 3B, the yeast strains expressing wild-type, and Asn111 and Leu305 
mutants, of AGTR1 receptor showed no fluorescence. In contrast, the yeast strains 
expressing Asn295 mutants (N295A and N295S) displayed a 48-fold increase in 
fluorescence intensity in response to agonistic Ang II stimulation (Figure 3B). 
Microscope images of green fluorescence visually displayed clear differences in 
brightness in response to the Ang II-induced signal (Figure 4 and 5). These results 
indicated that the mutation of AGTR1 at Asn295 to either an alanine or serine residue 
permits functional coupling with yeast-human chimeric G-protein (Gi3tp) and enables 
signal transmission in the engineered yeast cells. 
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Fig. 2. Schematic illustration of the human AGTR1 showing the positions of the 
mutations. Each circle represents an amino acid residue. The positions of amino acids 
mutated in this study are indicated as red circles. 
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Fig. 3. Activation of human AGTR1 produced in yeast following 
exogenously-added angiotensin II. Yeast strains IMFD-70ZsD (Gpa1p) (A) and 
IMFD-72ZsD (Gi3tp) (B) were transformed with pGK421-AGTR1-based plasmids (WT 
AGTR1 or its mutants). All transformants were grown in SD selective medium for 18 h. 
The cells then were incubated for another 4 h in pH-adjusted SD selective medium with 
or without 1 mM angiotensin II (Ang II, 8 aa peptide). The GFP fluorescence of 10,000 
cells was measured by flow cytometry. Mean values of the green fluorescence signal of 
10,000 cells. Error bars represent the standard deviation from three separate runs (n = 
3). 
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Fig. 4. Visualization of activated human AGTR1 produced in yeast following 
exogenously-added angiotensin II. Yeast strain IMFD-72ZsD was transformed with 
pGK421-AGTR1 (WT). The transformant was grown in SD selective medium for 18 h. 
The cells then were incubated for another 4 h in pH-adjusted SD selective medium with 
or without 1 mM angiotensin II (Ang II, 8 aa peptide). Cells were examined using the 
100× objective lens of a fluorescence microscope. Exposure time was 0.5 s. The left 
photographs are fluorescence micrographs, and the right photographs are bright-field 
micrographs. 
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Fig. 5. Visualization of activated human AGTR1 produced in yeast following 
exogenously-added angiotensin II. Yeast strain IMFD-72ZsD was transformed with 
pGK421-AGTR1-N295A (A) or pGK421-AGTR1-N295S (B). All transformants were 
grown in SD selective medium for 18 h. The cells then were incubated for another 4 h in 
pH-adjusted SD selective medium with or without 1 mM angiotensin II (Ang II, 8 aa 
peptide). Cells were examined using the 100× objective lens of a fluorescence 
microscope. Exposure time was 0.5 s. The left photographs are fluorescence 
micrographs, and the right photographs are bright-field micrographs. 
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Dose-dependency of Asn295-mutated AGTR1 signaling for Ang II in 
Gα-engineered yeast cells 
To investigate the dose-dependency of AGTR1 receptors with an Asn295 mutation, 
yeast IMFD-72ZsD strains harboring pGK421-AGTR1-N295A or -N295S were used in 
signaling assays. Figure 6 shows the dose-response curve for the pharmacological 
efficacy of ligand-specific signaling of Asn295-mutated AGTR1 in yeast cells that 
express yeast-human chimeric Gi3tp (IMFD-72ZsD). Changing the Ang II concentration 
allowed confirmation of dose-dependent increases in fluorescence intensity in both cell 
types (Figure 6). The half-maximal effective concentration (EC50) values were 368 μM 
(N295A) and 402 μM (N295S). These results suggested that the affinity or sensitivity of 
the N295A mutant for Ang II was higher than that of the N295S mutant. Previous 
reports revealed that Asn295 located in the seventh transmembrane helix is in spatial 
proximity to Asn111 in the third transmembrane helix, raising the possibility of an 
interaction between these two residues (Balmforth et al., 1997). Since this interaction is 
disrupted by the mutation of Asn295 to either an alanine or serine residue, its loss is 
likely responsible for the observed changes in ligand binding or receptor activation, 
thereby allowing AGTR1 to “relax” into its active conformation (Balmforth et al., 
1997). 
 
Activation of Asn295-mutated AGTR1 by secretory expressed angiotensin peptides 
Finally, several Ang II peptidic analogs that differ in affinity or activity towards 
AGTR1 were employed to test whether the secretory expression system of various 
peptides could also permit the functional signaling activation of Asn295-mutated 
AGTR1 in yeast cells (Figure 7A). Ang III is a heptapeptide that has 40% of the pressor 
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activity of Ang II (Salhan et al., 2012). Ang IV is a hexapeptide that, like Ang III, has 
decreased activity compared to Ang II (Wright et al., 2008). Yeast cells were engineered 
to synthesize and secret these peptidic Ang II analogs by fusing with a secretion signal 
sequence. 
The human Asn295-mutated AGTR1 expression plasmids 
(pGK421-AGTR1-N295A or -N295S) and peptide expression plasmids 
(pGK426-ssAGII, -ssAGIII, -ssAGIV or pGK426 (mock)) were co-transformed into the 
IMFD-72ZsD strain (Table 1). As shown in Figure 7B, the yeast strains concomitantly 
expressing AGTR1 (N295A and N295S) and secretory Ang II exhibited a greater than 
94- and 91-fold increase in fluorescence intensity compared with the mock strain after 9 
h cultivation. The secretory expressed Ang III also induced ZsGreen fluorescence, 
exhibiting a greater than 36- and 45-fold increase in fluorescence intensity compared 
with mock after 9 h cultivation (N295A and N295S, respectively) (Figure 7B). 
Although the strain secreting Ang IV showed no green fluorescence after 9 h cultivation 
(Figure 7B), it exhibited a greater than 1.5- and 2.4-fold increase in fluorescence 
intensity compared with mock after 18 h cultivation (N295A and N295S, respectively) 
(Figure 8). Microscope images of green fluorescence visually displayed clear 
differences in brightness arising from the distinct sequences of the secretory expressed 
angiotensin peptides (Figure 9 and 10). These results demonstrated that the secretory 
expression system could screen the peptidic angiotensin analogs, which can activate 
AGTR1-mediated signaling in yeast cells. Furthermore, the fluorescence intensity was 
clearly correlated with the agonistic activity of the ligands. Thus, it is expected that this 
yeast biosensor, integrating an Asn295-mutated AGTR1 receptor, will be useful for 
screening angiotensin agonists from peptidic libraries and for identifying their 
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pharmacophores. The methodology presented in this study could also be useful for other 
human GPCRs. 
 
 
 
Fig. 6. Dose‒response curves for angiotensin II-specific AGTR1 signaling activities 
of recombinant yeast cells. Yeast strain IMFD-72ZsD was transformed with 
pGK421-AGTR1-N295A or pGK421-AGTR1-N295S. All transformants were grown in 
SD selective medium for 18 h. The cells then were incubated for another 4 h in 
pH-adjusted SD selective medium with Ang II at various concentrations. The GFP 
fluorescence of 10,000 cells was measured by flow cytometry. Each data point is 
presented as the mean ± standard deviation of separate runs (n = 3 each). 
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Fig. 7. Activation of human AGTR1 by secretory expressed angiotensin II. (A) Amino 
acid sequences of secretory expressed peptides. (B) Yeast strain IMFD-72ZsD, which 
coexpresses either pGK421-AGTR1-N295A or -N295S, and either pGK426-ssAGII 
(Ang II), pGK426-ssAGIII (Ang III), pGK426-ssAGIV (Ang IV) or pGK426 (mock), 
was incubated in pH-adjusted SD selective medium for 9 h. The GFP fluorescence of 
10,000 cells was measured by flow cytometry. Mean values of the green fluorescence 
signal of 10,000 cells. Error bars represent the standard deviations (n = 3). 
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Fig. 8. Activation of human AGTR1 by secretory expressed angiotensin IV. Yeast strain 
IMFD-72ZsD, which coexpresses either pGK421-AGTR1-N295A or -N295S, and 
either pGK426-ssAGIV (Ang IV) or pGK426 (mock), was incubated in pH-adjusted SD 
selective medium for 18 h. The GFP fluorescence of 10,000 cells was measured by flow 
cytometry. Mean values of the green fluorescence signal of 10,000 cells. Error bars 
represent the standard deviations (n = 3). Statistical significance was assessed by the 
t-test (***, p < 0.001). 
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Fig. 9. Visualization of activated human AGTR1 (N295A) by secretory expressed 
angiotensin II. Yeast strain IMFD-72ZsD, which coexpresses pGK421-AGTR1-N295A 
and either pGK426-ssAGII (Ang II), pGK426-ssAGIII (Ang III), pGK426-ssAGIV 
(Ang IV) or pGK426 (mock), was incubated in pH-adjusted SD selective medium for 9 
h. Cells were examined using the 100× objective lens of a fluorescence microscope. 
Exposure time was 0.33 s. The upper photographs are fluorescence micrographs, and 
the lower photographs are bright-field micrographs. 
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Fig. 10. Visualization of activated human AGTR1 (N295S) by secretory expressed 
angiotensin II. Yeast strain IMFD-72ZsD, which coexpresses pGK421-AGTR1-N295S 
and either pGK426-ssAGII (Ang II), pGK426-ssAGIII (Ang III), pGK426-ssAGIV 
(Ang IV) or pGK426 (mock), was incubated in pH-adjusted SD selective medium for 9 
h. Cells were examined using the 100× objective lens of a fluorescence microscope. 
Exposure time was 0.33 s. The upper photographs are fluorescence micrographs, and 
the lower photographs are bright-field micrographs. 
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Conclusion 
In this study, we established a fluorescence-based yeast biosensor based on an 
Asn295-mutated AGTR1 receptor. To exert the functional activation of AGTR1 in yeast 
cells, we introduced a single Ala or Ser mutation at Asn295 in AGTR1 and used 
yeast-human chimeric Gα. In addition, we demonstrated that the autocrined Ang II 
peptide and its analog (Ang III peptide) produced and secreted by the engineered yeast 
cells by themselves also could promote AGTR1-mediated signaling. Since our system is 
applicable to AGTR1, this system can likely be extended to other human GPCRs, which 
comprise one of the most important families of drug targets being pursued today. 
Consequently, the proposed system has the potential to be an effective tool for screening 
angiotensin agonists from peptidic libraries and to identify their pharmacophores. This 
work thus opens up a way for generating new devices in various pharmaceutical 
research areas. 
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Chapter 1: Rapid, facile detection of heterodimer partners for target human 
G-protein-coupled receptors using a modified split-ubiquitin 
membrane yeast two-hybrid system 
 
 
Introduction 
The potentially large functional and physiological diversity of dimerization among 
G-protein-coupled receptors (GPCRs) has generated a great deal of excitement due to 
the opportunity for novel drug discovery (George et al., 2002; Panetta and Greenwood, 
2008). The findings of physiologically relevant GPCR dimers raise the prospect of 
developing new drugs against a wide range of diseases by focusing on the machinery of 
targeted dimers because ligand-induced conformational changes in GPCR dimers could 
affect ligand affinity and signaling function (Ayoub et al., 2004; Percherancier et al., 
2005). Since the human genome encodes more than 800 GPCR genes (Fredriksson et al., 
2003), the possible combinations of physiologically significant GPCR heterodimers 
would be immeasurable. However, due to the existence of numerous combinations, the 
sets of GPCR dimers are almost entirely unknown and thus their dominant roles are still 
poorly understood. 
Techniques to observe the dimerization of GPCRs include atomic force 
microscopy, electrophoresis, co-immunoprecipitation, cross-linkage, and fluorescence 
and bioluminescence resonance energy transfer (FRET and BRET) (Ayoub et al., 2004; 
Percherancier et al., 2005; Pfleger and Eidne, 2005). The FRET and BRET approaches 
are especially helpful for in vivo analysis and therefore are widely used for the studies 
of dimerized GPCRs. However, although the FRET and BRET techniques permit the 
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direct monitoring of GPCR dimerization, it might be difficult to use these techniques to 
achieve rapid and facile identification of dimerizable candidates among numerous 
GPCR combinations. 
To overcome this limitation, here we established a specialized method to screen 
candidate heterodimer partners for target GPCRs based on the split-ubiquitin membrane 
yeast two-hybrid method. In addition, since our system is independent from the 
activation of mitogen-activated protein kinase (MAPK) signal, it permits not only the 
identification of heterodimer partners, but also the monitoring of ligand-induced 
conformational changes. 
 
Materials and Methods 
Media. Synthetic dextrose (SD) media contained 6.7 g/l yeast nitrogen base without 
amino acids (YNB) (BD Diagnostic Systems, Sparks, MD, USA) and 20 g/l glucose. 
YPDA media contained 10 g/l yeast extract, 20 g/l peptone, 20 g/l glucose and 55 mg/l 
adenine. Amino acids and nucleotides (60 mg/l leucine, 40 mg/l tryptophan, 40 mg/l 
adenine, 20 mg/l histidine or 20 mg/l uracil) were supplemented into SD media to 
provide the relevant auxotrophic components. For solid plates, 2% agar was added to 
the media. 
 
Yeast strains. All yeast strains were generated from NMY51 (Dualsystems Biotech AG, 
Schlieren, Switzerland) as a parental backbone strain and are listed in Table 1. 
Transformation with linear DNA fragments was performed by using the lithium acetate 
method (Gietz et al., 1992). To eliminate the URA3 selectable marker in each 
transformation step, we basically followed previous procedures (Iguchi et al., 2010; 
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Togawa et al., 2010) with the marker recycling method (Akada et al., 2006). All 
oligonucleotides used for the strain constructions are listed in Table 2. To disrupt the 
target genes (STE20, STE11 and STE2), the first half of DNA fragments containing 
upstream regions of target genes and URA3 selectable marker were PCR-amplified from 
pGK406 (Ishii et al., 2009) by using gene-specific oligonucleotides. The last half of 
DNA fragments containing downstream regions of target genes and homologous 
sequences to eliminate URA3 marker were PCR-amplified from NMY51 genomic DNA 
by using gene-specific oligonucleotides. These amplified fragments were then used as 
the templates for overlap PCR. The combined linear fragments were introduced into 
appropriate parental yeast strains, and the transformants were selected on SD solid 
media lacking uracil. After confirming integration of the fragments at the correct 
positions, the cells were maintained on SC media containing 1 mg/ml 5-fluoroorotic 
acid (5-FOA, Fluorochem, Derbyshire, UK) to eliminate URA3 marker. 
 
Plasmids. All plasmids used for the assays are listed in Table 3. The transformation 
procedure followed the lithium acetate method (Gietz et al., 1992). 
All oligonucleotides are listed in Table 2. The bait proteins (X) were fused with a 
C-terminal ubiquitin moiety linked to an artificial transcription factor (X-Cub) in 
pBT3-C (Dualsystems Biotech AG, Schlieren, Switzerland). The prey proteins (Y) were 
fused with an N-terminal moiety of split-ubiquitin with I13G mutation (Y-NubG) in 
pPR3-C (Dualsystems Biotech AG). 
Bait vectors: For bait vectors, several promoters exhibiting distinctive expression 
strength were substituted for the original weak CYC1 promoter of pBT3-C as follows. 
PHO5 promoter (stronger than CYC1 promoter) was PCR-amplified with 
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oligonucleotides o1 and o2. The SacII-XbaI PHO5 promoter was inserted at the 
SacII-XbaI site on pBT3-C, resulting in the plasmid pBPH3-C. 
TPI1 promoter (stronger than PHO5 promoter) was PCR-amplified with 
oligonucleotides o3 and o4. The SacII-XbaI TPI1 promoter was inserted at the 
SacII-XbaI site on pBT3-C, resulting in the plasmid pBTP3-C. 
TDH3 promoter (stronger than TPI1 promoter) was PCR-amplified with 
oligonucleotides o5 and o6. The SacII-XbaI TDH3 promoter was inserted at the 
SacII-XbaI site on pBT3-C, resulting in the plasmid pBTD3-C. 
GPCR expression plasmids: The bait and prey plasmids used for the expression of 
GPCRs were constructed as follows. Full length STE2 genes encoding yeast pheromone 
receptor were PCR-amplified with oligonucleotide pairs: o7 and o8; o9 and o10. The 
XbaI-HindIII STE2 gene fragments were inserted at the XbaI-HindIII site on pBT3-C, 
pBPH3-C, pBTP3-C and pBTD3-C, resulting in the plasmids pBT3-STE2, 
pBPH3-STE2, pBTP3-STE2 and pBTD3-STE2, respectively. The SpeI-EcoRI STE2 
gene fragment was inserted at the SpeI-EcoRI site on pPR3-C, resulting in the plasmid 
pPR3-STE2. 
Truncated STE2 genes that lack the C-terminal domain (Ste2ΔC) were PCR-amplified 
with oligonucleotide pairs: o7 and o11; o9 and o12. The XbaI-HindIII STE2ΔC gene 
fragments were inserted at the XbaI-HindIII site on pBT3-C and pBTP3-C, resulting in 
the plasmid pBT3-STE2ΔC and pBTP3-STE2ΔC, respectively. The SpeI-EcoRI 
STE2ΔC gene fragment was inserted at the SpeI-EcoRI site on pPR3-C, resulting in the 
plasmid pPR3-STE2ΔC. 
Deletional STE2 genes that lack the domains from TM6 until C-terminal tail (TM1-5) 
were PCR-amplified with oligonucleotide pairs: o7 and o13; o9 and o14. The 
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XbaI-HindIII TM1-5 gene fragment was inserted at the XbaI-HindIII site on pBT3-C, 
resulting in the plasmid pBT3-STE2TM1-5. The SpeI-EcoRI TM1-5 gene fragment was 
inserted at the SpeI-EcoRI site on pPR3-C, resulting in the plasmid pPR3-STE2TM1-5. 
Deletional STE2 genes that lack the domains from the N-terminal tail to TM5 and 
C-terminal domain (TM6-7) were PCR-amplified with oligonucleotide pairs: o15 and 
o11; o16 and o12. The XbaI-HindIII TM6-7 gene fragment was inserted at the 
XbaI-HindIII site on pBT3-C, resulting in the plasmid pBT3-STE2TM6-7. The 
SpeI-EcoRI TM6-7 gene fragment was inserted at the SpeI-EcoRI site on pPR3-C, 
resulting in the plasmid pPR3-STE2TM6-7. 
The HXT1 gene encoding glucose transporter was PCR-amplified with oligonucleotides 
o17 and o18. The SpeI-EcoRI HXT1 gene fragment was inserted at the SpeI-EcoRI site 
on pPR3-C, resulting in the plasmid pPR3-HXT1. 
GABBR1a genes encoding GABAB1a receptor were PCR-amplified with oligonucleotide 
pairs: o19 and o20; o21 and o22. The XbaI-HindIII GABBR1a gene fragment was 
inserted at the XbaI-HindIII site on pBTP3-C, resulting in the plasmid 
pBTP3-GABBR1a. The SpeI-EcoRI GABBR1a gene fragment was inserted at the 
SpeI-EcoRI site on pPR3-C, resulting in the plasmid pPR3-GABBR1a. 
GABBR2 genes encoding GABAB2 receptor were PCR-amplified with oligonucleotide 
pairs: o23 and o24; o25 and o26. The XbaI-HindIII GABBR2 gene fragments were 
inserted at the XbaI-HindIII site on pBTP3-C and pBTD3-C, resulting in the plasmid 
pBTP3-GABBR2 and pBTD3-GABBR2, respectively. The SpeI-EcoRI GABBR2 gene 
fragment was inserted at the SpeI-EcoRI site on pPR3-C, resulting in the plasmid 
pPR3-GABBR2. 
AGTR1 genes encoding AT1 (angiotensin type 1) receptor were PCR-amplified with 
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oligonucleotide pairs: o27 and o28; o29 and o30. The XbaI-HindIII AGTR1 gene 
fragments were inserted at the XbaI-HindIII site on pBT3-C and pBTP3-C, resulting in 
the plasmid pBT3-AGTR1 and pBTP3-AGTR1, respectively. The SpeI-EcoRI AGTR1 
gene fragment was inserted at the SpeI-EcoRI site on pPR3-C, resulting in the plasmid 
pPR3-AGTR1. 
AGTR2 gene encoding AT2 (angiotensin type 2) receptor was PCR-amplified with 
oligonucleotides o31 and o32. The SpeI-EcoRI AGTR2 gene fragment was inserted at 
the SpeI-EcoRI site on pPR3-C, resulting in the plasmid pPR3-AGTR2. 
MTNR1A genes encoding MT1 (melatonin 1A) receptor were PCR-amplified with 
oligonucleotide pairs: o33 and o34; o35 and o36. The XbaI-HindIII MTNR1A gene 
fragments were inserted at the XbaI-HindIII site on pBT3-C, resulting in the plasmid 
pBT3-MTNR1A and pBPH3-MTNR1A, respectively. The SpeI-EcoRI MTNR1A gene 
fragment was inserted at the SpeI-EcoRI site on pPR3-C, resulting in the plasmid 
pPR3-MTNR1A. 
MTNR1B gene encoding MT2 (melatonin 1B) receptor was PCR-amplified with 
oligonucleotides o37 and o38. The SpeI-EcoRI MTNR1B gene fragment was inserted at 
the SpeI-EcoRI site on pPR3-C, resulting in the plasmid pPR3-MTNR1B. 
SSTR2 genes encoding somatostatin receptor 2 were PCR-amplified with 
oligonucleotide pairs: o39 and o40; o41 and o42. The XbaI-HindIII SSTR2 gene 
fragments were inserted at the XbaI-HindIII site on pBT3-C, pBPH3-C, pBTP3-C and 
pBTD3-C, resulting in the plasmid pBT3-SSTR2, pBPH3-SSTR2, pBTP3-SSTR2 and 
pBTD3-SSTR2, respectively. The SpeI-EcoRI SSTR2 gene fragment was inserted at the 
SpeI-EcoRI site on pPR3-C, resulting in the plasmid pPR3-SSTR2. 
SSTR5 genes encoding somatostatin receptor 5 were PCR-amplified with 
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oligonucleotide pairs: o43 and o44; o45 and o46. The XbaI-HindIII SSTR5 gene 
fragment was inserted at the XbaI-HindIII site on pBTD3-C, resulting in the plasmid 
pBTD3-SSTR5. The SpeI-EcoRI SSTR5 gene fragment was inserted at the SpeI-EcoRI 
site on pPR3-C, resulting in the plasmid pPR3-SSTR5. 
ADRB2 genes encoding β2-adrenergic receptor were PCR-amplified with 
oligonucleotide pairs: o47 and o48; o49 and o50. The XbaI-HindIII ADRB2 gene 
fragments were inserted at the XbaI-HindIII site on pBT3-C, pBTP3-C and pBTD3-C, 
resulting in the plasmid pBT3-ADRB2, pBTP3-ADRB2 and pBTD3-ADRB2, 
respectively. The SpeI-EcoRI ADRB2 gene fragment was inserted at the SpeI-EcoRI site 
on pPR3-C, resulting in the plasmid pPR3-ADRB2. 
HTR1A genes encoding 5-hydroxytryptamine (serotonin) receptor 1A were 
PCR-amplified with oligonucleotide pairs: o51 and o52; o53 and o54. The XbaI-HindIII 
HTR1A gene fragments were inserted at the XbaI-HindIII site on pBPH3-C and 
pBTP3-C, resulting in the plasmid pBPH3-HTR1A and pBTP3-HTR1A, respectively. 
The SpeI-EcoRI HTR1A gene fragment was inserted at the SpeI-EcoRI site on pPR3-C, 
resulting in the plasmid pPR3-HTR1A. 
EDNRB gene encoding endothelin receptor type B was PCR-amplified with 
oligonucleotides o55 and o56. The SpeI-ClaI EDNRB gene fragment was inserted at the 
SpeI-ClaI site on pPR3-C, resulting in the plasmid pPR3-EDNRB. 
NTSR1 gene encoding neurotensin receptor 1 was PCR-amplified with oligonucleotides 
o57 and o58. The SpeI-EcoRI NTSR1 gene fragment was inserted at the SpeI-EcoRI site 
on pPR3-C, resulting in the plasmid pPR3-NTSR1. 
NTSR2 gene encoding neurotensin receptor 2 was PCR-amplified with oligonucleotides 
o59 and o60. The SpeI-EcoRI NTSR2 gene fragment was inserted at the SpeI-EcoRI site 
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on pPR3-C, resulting in the plasmid pPR3-NTSR2. 
 
 
Table 1. Yeast strains used in this study 
Strain Genotype Source 
NMY51 MATa his3200 trp1-901 leu2-3, 112 ade2 LYS2::(lexAop)4-HIS3 
ura3::(lexAop)8-lacZ ade2::(lexAop)8-ADE2 GAL4 
Dualsystems Biotech 
AG 
NMY61 NMY51 ste20 This study 
NMY62 NMY51 ste11 This study 
NMY63 NMY51 ste11 ste2 This study 
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Table 2. List of oligonucleotides. 
Yeast strain construction 
 Name Sequence 
 
dSTE20up-URA3_fw 
5’-GCAAGCAACCCAAACTTCTTCCCTTCACTGCCTCACACCCCATCCTAAATATC
CCACAAGATCCTCGACTAATACAAGAATTTTTTGTTCTTTTTTTTGA 
 dSTE20up-URA3_rv 5’-CTTGTGGGATATTTAGGATGGGGTAATAACTGATATAATT 
 
dSTE20dn_fw 
5’-AATTATATCAGTTATTACCCCATCCTAAATATCCCACAAGATCCTCGACTAATAC
AAGAAACGTAGCAAGCAGGGTACAC 
 dSTE20dn_rv 5’-CTCCTTCGTTACATAGAACGCAGACAGATG 
 
dSTE11up-URA3_fw 
5’-TATTCATATTTACACACATGCATAAAGAGAGACCACTTAATAAAGCTAGTATGAT
AAGATCACCGGTAGACGAAATATACTTTTTTGTTCTTTTTTTTGA 
 dSTE11up-URA3_rv 5’-ATCTTATCATACTAGCTTTAGGGTAATAACTGATATAATT 
 
dSTE11dn_fw 
5’-AATTATATCAGTTATTACCCTAAAGCTAGTATGATAAGATCACCGGTAGACGAAA
TATACAAAAGGGCTACTTATTAATT 
 dSTE11dn_rv 5’-TCACCTCGCAAAGAAAGGCCTGTTTCTTCG 
 
dSTE2up-URA3_fw 
5’-TTTCTTTTCACCTGCTCTGGCTATAATTATAATTGGTTACTTAAAAATGCACCGT
TAAGAACCATATCCAAGAATCAAAATTTTTTGTTCTTTTTTTTGA 
 dSTE2up-URA3_rv 5’-TCTTAACGGTGCATTTTTAAGGGTAATAACTGATATAATT 
 
dSTE2dn_fw 
5’-AATTATATCAGTTATTACCCTTAAAAATGCACCGTTAAGAACCATATCCAAGAAT
CAAAATCAAAATTTACGGCTTTGAAAAAGTAATTTCGTGACCTTC 
 dSTE2dn_rv 5’-AAGATTAACTGTATATATTGCCTGAGAGTTCTAGATCATG 
Plasmid construction 
 Name Sequence 
o1 SacII_PHO5p_fw 5’-AAAACCGCGGTTTTCTTTGTCTGCACAAAG 
o2 XbaI_PHO5p_rv 5’-AAAATCTAGATGGTAATCTCGAATTTGCTT 
o3 SacII_TPI1p_fw 5’-AAAACCGCGGCTACTTATTCCCTTCGAGAT 
o4 XbaI_TPI1p_rv 5’-AAAATCTAGATTTTAGTTTATGTATGTGTT 
o5 SacII_TDH3p_fw 5’-GGGGCCGCGGGAATAAAAAACACGCTTTTT 
o6 XbaI_TDH3p_rv 5’-CCCCTCTAGATTTGTTTGTTTATGTGTGTT 
o7 XbaI_STE2_fw 5’-AAAATCTAGAATGTCTGATGCGGCTCCTTC 
o8 HindIII_lin_STE2_rv 5’-GGGGAAGCTTGAACCTCCGCCACCTGATAAATTATTATTATCTTCAG 
o9 SpeI_STE2_fw 5’-GGGGACTAGTATGTCTGATGCGGCTCCTTC 
o10 EcoRI_lin_STE2_rv 5’-GGGGGAATTCGGAACCTCCGCCACCTGATAAATTATTATTATCTTCAG 
o11 HindIII_lin_STE2-304_rv 5’-GGGGAAGCTTGAACCTCCGCCACCTGATTTGGATGCATTATTAGCAG 
o12 EcoRI_lin_STE2-304_rv 5’-GGGGGAATTCGGAACCTCCGCCACCTGATTTGGATGCATTATTAGCAG 
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o13 HindIII_lin_STE2-236_rv 5’-GGGGAAGCTTGAACCTCCGCCACCTGAAAGGAATCTTCTTGATCTAA 
o14 EcoRI_lin_STE2-236_rv 5’-GGGGGAATTCGGAACCTCCGCCACCTGAAAGGAATCTTCTTGATCTAA 
o15 XbaI_STE2-237_fw 5’-GGGGTCTAGAATGGGTCTCAAGCAGTTCGA 
o16 SpeI_STE2-237_fw 5’-GGGGACTAGTATGGGTCTCAAGCAGTTCGA 
o17 SpeI_HXT1sm_fw 5’-GGGGACTAGTATGAACTCAACTCCCGATCTAATATCTCCT 
o18 EcoRI_lin_HXT1_rv 5’-GGGGGAATTCGGAACCTCCGCCACCTGATTTCCTGCTAAACAAACTCTTG 
o19 XbaI_GABBR1a_fw 5’-AAAATCTAGAATGTTGCTGCTGCTGCTACT 
o20 HindIII_lin_GABBR1a_rv 5’-GGGGAAGCTTGAACCTCCGCCACCTGACTTATAAAGCAAATGCACTC 
o21 SpeI_GABBR1a_fw 5’-AAAAACTAGTATGTTGCTGCTGCTGCTACT 
o22 EcoRI_lin_GABBR1a_rv 5’-GGGGGAATTCGGAACCTCCGCCACCTGACTTATAAAGCAAATGCACTC 
o23 XbaI_GABBR2_fw 5’-AAAATCTAGAATGGCTTCCCCGCGGAGCTC 
o24 HindIII_lin_GABBR2_rv 5’-TTTTAAGCTTGAACCTCCGCCACCTGACAGGCCCGAGACCATGACTC 
o25 SpeI_GABBR2_fw 5’-AAAAACTAGTATGGCTTCCCCGCGGAGCTC 
o26 EcoRI_lin_GABBR2_rv 5’-TTTTGAATTCGGAACCTCCGCCACCTGACAGGCCCGAGACCATGACTC 
o27 XbaI_AGTR1_fw 5’-AAAATCTAGAATGATTCTCAACTCTTCTAC 
o28 HindIII_lin_AGTR1_rv 5’-GGGGAAGCTTGAACCTCCGCCACCTGACTCAACCTCAAAACATGGTG 
o29 SpeI_AGTR1_fw 5’-GGGGACTAGTATGATTCTCAACTCTTCTAC 
o30 EcoRI_lin_AGTR1_rv 5’-GGGGGAATTCGGAACCTCCGCCACCTGACTCAACCTCAAAACATGGTG 
o31 SpeI_AGTR2_fw 5’-TTTTACTAGTATGAAGGGCAACTCCACCCT 
o32 EcoRI_lin_AGTR2_rv 5’-TTTTGAATTCGGAACCTCCGCCACCTGAAGACACAAAGGTCTCCATTT 
o33 XbaI_MTNR1A_fw 5’-TTTTTCTAGAATGCAGGGCAACGGCAGCGC 
o34 HindIII_lin_MTNR1A_rv 5’-GGGGAAGCTTGAACCTCCGCCACCTGAAACGGAGTCCACCTTTACTA 
o35 SpeI_MTNR1A_fw 5’-TTTTACTAGTATGCAGGGCAACGGCAGCGC 
o36 EcoRI_lin_MTNR1A_rv 5’-GGGGGAATTCGGAACCTCCGCCACCTGAAACGGAGTCCACCTTTACTA 
o37 SpeI_MTNR1B_fw 5’-GGGGACTAGTATGTCAGAGAACGGCTCCTT 
o38 EcoRI_lin_MTNR1B_rv 5’-AAAAGAATTCGGAACCTCCGCCACCTGAGAGAGCATCTGCCTGGTGCT 
o39 XbaI_SSTR2_fw 5’-AAAATCTAGAATGGACATGGCGGATGAGCC 
o40 HindIII_lin_SSTR2_rv 5’-AAAAAAGCTTGAACCTCCGCCACCTGAGATACTGGTTTGGAGGTCTC 
o41 SpeI_SSTR2_fw 5’-CCCCACTAGTATGGACATGGCGGATGAGCC 
o42 EcoRI_lin_SSTR2_rv 5’-AAAAGAATTCGGAACCTCCGCCACCTGAGATACTGGTTTGGAGGTCTC 
o43 XbaI_SSTR5_fw 5’-AAAATCTAGAATGGAGCCCCTGTTCCCAGC 
o44 HindIII_lin_SSTR5_rv 5’-TTTTAAGCTTGAACCTCCGCCACCTGACAGCTTGCTGGTCTGCATAA 
o45 SpeI_SSTR5_fw 5’-AAAAACTAGTATGGAGCCCCTGTTCCCAGC 
o46 EcoRI_lin_SSTR5_rv 5’-AAAAGAATTCGGAACCTCCGCCACCTGACAGCTTGCTGGTCTGCATAA 
o47 XbaI_ADRB2_fw 5’-TTTTTCTAGAATGGGGCAACCCGGGAACGG 
o48 HindIII_lin_ADRB2_rv 5’-TTTTAAGCTTGAACCTCCGCCACCTGACAGCAGTGAGTCATTTGTAC 
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o49 SpeI_ADRB2_fw 5’-AAAAACTAGTATGGGGCAACCCGGGAACGG 
o50 EcoRI_lin_ADRB2_rv 5’-AAAAGAATTCGGAACCTCCGCCACCTGACAGCAGTGAGTCATTTGTAC 
o51 XbaI_HTR1A_fw 5’-AAAATCTAGAATGGATGTGCTCAGCCCTGG 
o52 HindIII_lin_HTR1A_rv 5’-TTTTAAGCTTGAACCTCCGCCACCTGACTGGCGGCAGAACTTACACT 
o53 SpeI_HTR1A_fw 5’-GGGGACTAGTATGGATGTGCTCAGCCCTGG 
o54 EcoRI_lin_HTR1A_rv 5’-GGGGGAATTCGGAACCTCCGCCACCTGACTGGCGGCAGAACTTACACT 
o55 SpeI_EDNRB_fw 5’-GGGGACTAGTATGCAGCCGCCTCCAAGTCT 
o56 ClaI_lin_EDNRB_rv 5’-GGGGATCGATGGAACCTCCGCCACCTGAAGATGAGCTGTATTTATTAC 
o57 SpeI_NTSR1_fw 5’-GGGGACTAGTATGCGCCTCAACAGCTCCGC 
o58 EcoRI_lin_NTSR1_rv 5’-AAAAGAATTCGGAACCTCCGCCACCTGAGTACAGCGTCTCGCGGGTGG 
o59 SpeI_NTSR2_fw 5’-TTTTACTAGTATGGAAACCAGCAGCCCGCG 
o60 EcoRI_lin_NTSR2_rv 5’-AAAAGAATTCGGAACCTCCGCCACCTGAGGTCCGGGTTTCTGGGGGAT 
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Table 3. List of plasmids 
Plasmid name Expressed protein
a,b
 Vector backbone Promoter Source 
Bait     
pCCW-Alg5 Alg5-Cub – CYC1 Dualsystems Biotech AG 
pBT3-C Cub – CYC1 Dualsystems Biotech AG 
pBPH3-C Cub pBT3-C PHO5 This study 
pBTP3-C Cub pBT3-C TPI1 This study 
pBTD3-C Cub pBT3-C TDH3 This study 
pBT3-STE2 Ste2(full length)-Cub pBT3-C CYC1 This study 
pBPH3-STE2 Ste2(full length)-Cub pBPH3-C PHO5 This study 
pBTP3-STE2 Ste2(full length)-Cub pBTP3-C TPI1 This study 
pBTD3-STE2 Ste2(full length)-Cub pBTD3-C TDH3 This study 
pBT3-STE2C Ste2(aa 1-304)-Cub pBT3-C CYC1 This study 
pBTP3-STE2C Ste2(aa 1-304)-Cub pBTP3-C TPI1 This study 
pBT3-STE2TM1-5 Ste2(aa 1-236)-Cub pBT3-C CYC1 This study 
pBT3-STE2TM6-7 Ste2(aa 237-304)-Cub pBT3-C CYC1 This study 
pBTP3-GABBR1a GABBR1a-Cub pBTP3-C TPI1 This study 
pBTP3-GABBR2 GABBR2-Cub pBTP3-C TPI1 This study 
pBTD3-GABBR2 GABBR2-Cub pBTD3-C TDH3 This study 
pBT3-AGTR1 AGTR1-Cub pBT3-C CYC1 This study 
pBTP3-AGTR1 AGTR1-Cub pBTP3-C TPI1 This study 
pBT3-MTNR1A MTNR1A-Cub pBT3-C CYC1 This study 
pBPH3-MTNR1A MTNR1A-Cub pBPH3-C PHO5 This study 
pBT3-SSTR2 SSTR2-Cub pBT3-C CYC1 This study 
pBPH3-SSTR2 SSTR2-Cub pBPH3-C PHO5 This study 
pBTP3-SSTR2 SSTR2-Cub pBTP3-C TPI1 This study 
pBTD3-SSTR2 SSTR2-Cub pBTD3-C TDH3 This study 
pBTD3-SSTR5 SSTR5-Cub pBTD3-C TDH3 This study 
pBT3-ADRB2 ADRB2-Cub pBT3-C CYC1 This study 
pBTP3-ADRB2 ADRB2-Cub pBTP3-C TPI1 This study 
pBTD3-ADRB2 ADRB2-Cub pBTD3-C TDH3 This study 
pBPH3-HTR1A HTR1A-Cub pBPH3-C PHO5 This study 
pBTP3-HTR1A HTR1A-Cub pBTP3-C TPI1 This study 
Prey     
pAI-Alg5 Alg5-NubI – ADH1 Dualsystems Biotech AG 
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pPR3-C NubG – ADH1 Dualsystems Biotech AG 
pPR3-STE2 Ste2(full length)-NubG pPR3-C ADH1 This study 
pPR3-STE2C Ste2(aa 1-304)-NubG pPR3-C ADH1 This study 
pPR3-STE2TM1-5 Ste2(aa 1-236)-NubG pPR3-C ADH1 This study 
pPR3-STE2TM6-7 Ste2(aa 237-304)-NubG pPR3-C ADH1 This study 
pPR3-HXT1 Hxt1(full length)-NubG pPR3-C ADH1 This study 
pPR3-GABBR1a GABBR1a-NubG pPR3-C ADH1 This study 
pPR3-GABBR2 GABBR2-NubG pPR3-C ADH1 This study 
pPR3-AGTR1 AGTR1-NubG pPR3-C ADH1 This study 
pPR3-AGTR2 AGTR2-NubG pPR3-C ADH1 This study 
pPR3-MTNR1A MTNR1A-NubG pPR3-C ADH1 This study 
pPR3-MTNR1B MTNR1B-NubG pPR3-C ADH1 This study 
pPR3-SSTR2 SSTR2-NubG pPR3-C ADH1 This study 
pPR3-SSTR5 SSTR5-NubG pPR3-C ADH1 This study 
pPR3-ADRB2 ADRB2-NubG pPR3-C ADH1 This study 
pPR3-HTR1A HTR1A-NubG pPR3-C ADH1 This study 
pPR3-EDNRB EDNRB-NubG pPR3-C ADH1 This study 
pPR3-NTSR1 NTSR1-NubG pPR3-C ADH1 This study 
pPR3-NTSR2 NTSR2-NubG pPR3-C ADH1 This study 
a) Cub indicates the Cub-LexA-VP16 fusion protein 
b) NubG indicates Nub with I13G mutation 
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Agar diffusion bioassay. An agar diffusion bioassay (halo assay) was performed to 
measure growth inhibition in response to signal-induced cell-cycle arrest (Ishii et al., 
2006). Cells were grown in YPDA media overnight at 30°C. Sterilized paper filter disks 
(6 mm in diameter) were placed on a square Petri dish, and various amounts of α-factor 
pheromone (Zymo Research, Orange, CA, USA) were spotted onto the disks. YPDA 
medium containing 20 g/l agar (maintained at 50°C) was inoculated with the grown 
cells to give an initial optical density of 5 × 10
-4
 at 600 nm (OD600 = 5 × 10
-4
), and the 
suspension was immediately poured into the dish. The plates were incubated at 30°C for 
1 to 2 days. 
 
Evaluation of receptor dimerization. Cub and NubG fusion constructs (Table 3) were 
co-transformed into yeast strains. Cells were grown in SD media lacking leucine and 
tryptophan overnight at 30°C on a rotatory shaker set at 150 rpm and then harvested to 
evaluate receptor dimerization by growth assay and β-galactosidase assay. 
 
Growth assay. Harvested cells were washed with distilled water, and cell suspensions 
were prepared to give an OD600 of 10. Seven microliters of serial dilutions of cell 
suspensions (1:10) were spotted on SD agar plates lacking leucine, tryptophan, adenine 
and histidine. The plates were incubated at 30°C. 
 
β-D-galactosidase activity assay. β-D-galactosidase activity was determined by using 
chlorophenol red β-D-galactopyranoside (CPRG) (Roche Applied Science, Indianapolis, 
IN, USA) as the chromogenic substrate. The procedure basically followed the method 
described in the Yeast Protocols Handbook (Clontech Laboratories, Inc./Takara Bio 
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Company). Harvested cells were washed once with buffer 1 [100 mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 150 mM NaCl, 4 mM 
L-aspartic acid hemimagnesium salt hydrate, 10 g/l bovine serum albumin (BSA) and 
0.05% polyoxyethylene sorbitan monolaurate (Tween 20); pH 7.25-7.30] and 
resuspended in buffer 1 to give an OD600 of 10. Four microliters of chloroform and 7 l 
of 0.1% SDS were added to 100 l of cell suspension, the mixtures were agitated with a 
vortex, and then buffer 1 (700 l) containing 2.23 mM CPRG was added to the mixtures. 
After incubation for 10 min at room temperature, 500 l of 3 mM ZnCl2 was added to 
stop the enzyme reaction. After centrifugation, the OD578 of supernatants were measured 
with a spectrophotometer. β-Gal units were calculated as 1,000 × OD578 / (10 min × 0.1 
ml × OD600). 
 
Ligand assay. Harvested cells were inoculated into 5 mL of fresh SD media containing 
ligand to give an initial OD600 of 0.03. They were incubated at 30ºC with shaking at 150 
rpm for up to 18 h. Afterwards, the β-D-galactosidase activity was performed. 
 
Model screening. A small-sized prey GPCR library (Table 4) was transformed into 
yeast strain NMY63 harboring pBT3-AGTR1 by using the lithium acetate method 
(Gietz et al., 1992). Transformants were selected on SD medium lacking leucine, 
tryptophan, adenine and histidine for bait-prey interaction. Prey plasmids were isolated 
from 30 positive clones, amplified in Escherichia coli, and analyzed by sequencing 
analysis. 
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Table 4. List of prey GPCR library. 
Prey plasmid name 
pPR3-AGTR1 
pPR3-ADRB2 
pPR3-HTR1A 
pPR3-SSTR2 
pPR3-SSTR5 
pPR3-EDNRB 
pPR3-NTSR1 
pPR3-NTSR2 
pPR3-C(Control) 
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Results and Discussion 
 While the original split-ubiquitin system enables comprehensive screening of 
protein-protein interactions (Stagljar et al., 1998), it is intrinsically possible that the 
addition of ligand triggers activation of pheromone signaling via endogenous yeast 
heterotrimeric G-protein (Ishii et al., 2010). The activation of pheromone signaling in 
yeast induces cell cycle arrest in G1 phase and triggers global changes in transcription 
of mating-related genes (Elion et al., 1993). The ligand-induced G1 arrest that is 
exposed as robust growth inhibition in yeast cells (Ishii et al., 2008) might lead to an 
inadequate assessment of reporter gene activity. Therefore, we constructed a yeast 
deletion mutant lacking the STE20 or STE11 gene involved in the activation of the 
MAPK cascade by using NMY51 as the parental strain with an aim to enable screening 
of GPCR dimers with and without ligand (Figure 1 and Table 1). Halo bioassays 
responding to α-factor pheromone showed the formations of a thin halo and no halos 
with 100 μg of α-factor in NMY61 (ste20Δ) and NMY62 (ste11Δ) yeast strains, 
respectively, revealing that ste11Δ allele provides more strict avoidance of 
signal-promoted growth arrest in the presence of ligand (Figure 2A). For checking the 
expressions of reporter genes, the growth assays in the presence of ligand were carried 
out (Figure 2B). While the strains harboring mock vectors pBT3-C and pPR3-C were 
used as negative controls, those harboring pCCW-Alg5 and pAI-Alg5 to express 
Alg5-NubI and Alg5-Cub-LexA-VP16 were used as positive controls. Alg5-NubI is a 
yeast membrane protein fused with a WT Nub tag. The NubI tag interacts spontaneously 
with any Cub tag-containing constructs (Iyer et al., 2005; Kittanakom et al., 2009). The 
deletion mutants (ste20Δ and ste11Δ) avoided the robust growth inhibition and therefore 
could allow the growth assays with ADE2 and HIS3 reporter genes even in the presence 
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of ligand (Figure 2B). We used the MAPK-defective NMY62 yeast strain for the 
following experiments. 
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Fig. 1. Schematic illustration of yeast pheromone signaling pathway and principle 
for GPCR dimerization assay based on split-ubiquitin system in yeast. Agonistic 
ligand binding to the GPCR leads to the activation of heterotrimeric G-proteins, the 
mitogen-activated protein kinase (MAPK) cascade and a cyclin-dependent kinase 
inhibitor Far1p. Phosphorylated Far1p induces G1 cell-cycle arrest. The STE20 or 
STE11 gene located upstream of the MAPK cascade was disrupted in the NMY51 strain. 
In the split-ubiquitin yeast two-hybrid system, NubG will only efficiently interact with 
Cub when the proteins to which the two split tags are attached interact with each other, 
resulting in the formation of a NubG/Cub complex. This complex is recognized by 
ubiquitin-specific proteases (UBPs), which release the artificial transcription factor 
(LexA-VP16) from the Cub-containing construct. LexA-VP16 then enters the nucleus 
via diffusion and binds to the LexA-binding sites upstream of the reporter genes. In this 
study, the GPCRs are fused to the split-ubiquitin and are expressed in MAPK-defective 
mutant yeast strain of NMY51 to allow the monitoring of GPCR dimerizations and 
conformational changes responding to binding of ligand. 
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Fig. 2. ste11Δ allele allowed more strict avoidance of signal-promoted growth arrest 
in the presence of ligand. (A) Halo-bioassay (agonist-induced growth arrest assay) for 
STE20-, STE11- and STE2-gene-disrupted strains: NMY51 (WT); NMY61 (ste20Δ); 
NMY62 (ste11Δ); and NMY63 (ste11Δ ste2Δ). Each paper filter disk was spotted with 
the indicated amount of α-factor. (B) Growth assay of NMY51 (WT; a,b), NMY61 
(ste20Δ; c,d) and NMY62 (ste11Δ; e,f) strains on SD –Leu, Trp, Ade and His dropout 
plates. Yeast strains harboring pBT3-C/pPR3-C or pCCW-Alg5/pAI-Alg5 respectively 
expressed Cub/NubG (negative control; a,c,e) or Alg5-Cub/Alg5-NubI (positive 
control; b,d,f). Each cell was spotted in serial 10-fold dilutions on selective agar plates 
with or without 5 μM of -factor. NubI is a WT Nub tag and interacts spontaneously 
with Cub.  
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To test the viability of split-ubiquitin–based reporter gene assays for detecting 
GPCR dimers, we first analyzed the homodimerization of endogenous yeast pheromone 
receptor (Ste2p) in the NMY62 yeast strain. The N-terminal moiety of split-ubiquitin 
with an I13G mutation (NubG) and the C-terminal ubiquitin moiety linked to an 
artificial transcription factor (Cub-LexA-VP16) (Stagljar et al., 1998) were respectively 
designed to genetically fuse to the C-termini of Ste2p receptors by using original 
pPR3-C (prey) and pBT3-C (bait) split-ubiquitin vectors (Table 3). Upon in vivo 
protein-protein interaction, the reconstituted ubiquitin leads to cleavage and release of 
LexA-VP16 by ubiquitin-specific proteases (UBPs) (Stagljar et al., 1998); therefore, the 
dimerization of Ste2p should be detected via the transcription activation of the reporter 
genes (ADE2, HIS3, and lacZ) (Figure 1 and Table 1). However, the cells coexpressing 
Ste2p-NubG and Ste2p-Cub-LexA-VP16 never grew on the adenine/histidine-deficient 
selectable media (Figure 3A). Therefore, we replaced the weak CYC1 promoter of the 
original pBT3-C bait vector by comparatively strong PHO5, TPI1 and TDH3 promoters 
(PCYC1 < PPHO5 < PTPI1 < PTDH3). As a result, the expression of Ste2p-Cub-LexA-VP16 
by the TPI1 and TDH3 promoters prompted cell growth on the selection media when 
combined with the expression of Ste2p-NubG (Figure 3B and C). Even though 
previous report expressed the Ste2p in relatively low expression manner (Gehret et al., 
2006), our result did not show evidence of dimerization for the Ste2p expressed under 
the control of the CYC1 promoter in the split-ubiquitin system. This is assumed that 
attached transcription factor might be not present at levels adequate to activate the 
response. 
Then, we replaced the full-length Ste2p receptors with a truncated version that 
lacks the C-terminal tails (Ste2ΔC; amino acids 1–304) to adjust the distance between 
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the C-termini of the receptors (Gehret et al., 2006), providing an increased 
signal-to-noise (S/N) ratio (under the control of the TPI1 promoter; Figure 4A and B). 
Furthermore, we replaced the TPI1 promoter with the CYC1 promoter of the bait vector 
again, which resulted in much lower background cell growth and a drastically improved 
S/N ratio (Figure 5A and B). Since the truncation of the C-termini of Ste2p receptors 
had been reported to increase in the number of receptor sites (Konopka et al., 1988), the 
greatly enriched receptors at the plasma membrane might have provided the drastic 
improvement of S/N ratio. These results indicate that the bait receptor is predominant 
for successful detection of the dimerized receptors. Thus, the consideration of the 
receptor’s expression manner is important to screen the GPCR dimer partners, because 
the leaky background cell growth often brings unanticipated candidates. 
In the optimized system, Hxt1p never presented background cell growth in the 
dimerization assay with the Ste2ΔC receptor (Figure 5A). Previously, Overton et al. had 
used the Hxt1p as the negative control for FRET analysis of Ste2p dimerization and 
confirmed the subcellular localization of it at the plasma membrane (Overton and 
Blumer, 2000). The β-galactosidase assay that reflects lacZ reporter enzyme activity 
also displayed similar trends (Figure 5B). The addition of ligand had no effect on the 
dimerization events of Ste2ΔC, since the MAPK-defective NMY62 yeast strain 
displayed unchanged growth in the presence of α-factor (Figure 5A). We additionally 
constructed two types of deletion mutants in which the TM6–7 domains and the TM1–5 
domains were removed, respectively (TM1–5 (amino acids 1–236) and TM6–7 (amino 
acids 237–304)) (Figure 6A). Overton et al. also indicated that self-association of 
TM6–7 had not been detected, and plasma membrane localization of the YFP-tagged 
TM1–5 and TM6–7 was observed (Overton and Blumer, 2002). As previously indicated 
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(Overton and Blumer, 2002), only TM1–5 formed the homodimer (Figure 6B and C), 
showing that our system is applicable to examine critical domains involved in the 
dimerization of 7TM receptors. 
 
 
Fig. 3. Effect of promoter on detection of dimerization of yeast Ste2p receptor in 
NMY62 strain. NMY62 yeast strain was transformed with the plasmids expressing 
indicated protein pairs and grown on SD –Leu, Trp, Ade and His dropout plate at 30ºC. 
(A) CYC1 promoter. (B) PHO5 promoter and TPI1 promoter. (C) TDH3 promoter. 
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Fig. 4. Effect of removal of C-terminal tail on detection of dimerization of yeast 
Ste2p receptor in NMY62 strain. NMY62 yeast strain was transformed with plasmids 
expressing indicated protein pairs. Quantitative β-galactosidase assays for full-length 
Ste2p receptor under the control of TPI1 promoter (A) and Ste2p receptor that lacks the 
C-terminal tail (Ste2ΔC) under the control of TPI1 promoter (B). 
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Fig. 5. Detection for dimerization of yeast truncated Ste2p lacking the 
carboxy-terminal tail (Ste2ΔC) receptor in NMY62 strain. Growth and quantitative 
-galactosidase activity of yeast cells expressing various combinations of Cub and 
NubG fusions. The control bait plasmid was pBT3-C mock vector (empty vector). The 
control prey plasmids were pPR3-C mock vector (empty vector) and pPR3-HXT1. (A) 
Growth assay without α-factor (left panels) and with 5 μM -factor (right panels). Each 
cell was spotted in serial 10-fold dilutions on SD –Leu, Trp, Ade and His dropout plate. 
(B) Quantitative -galactosidase assay. Error bars represent the standard deviations (n = 
3). 
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Fig. 6. Detection for dimerization of yeast Ste2p deletion mutants (TM1–5 and 
TM6–7) in NMY62 strain. (A) Schematic of Ste2ΔC and the deletion mutants. 
Transmembrane (TM) domains are indicated with pillar-type boxes, and the Cub 
(Cub-LexA-VP16) or NubG (Nub with I13G mutation) is depicted as a rounded 
rectangle. (B) Growth assay without α-factor (left panels) and with 5 μM α-factor (right 
panels). Each cell was spotted in serial 10-fold dilutions on SD –Leu, Trp, Ade and His 
dropout plate. (C) Quantitative β-galactosidase activity in yeast cells containing various 
combinations of plasmids. Error bars represent the standard deviations (n = 3). The 
control prey plasmids were pPR3-C mock vector (empty vector) and pPR3-HXT1. 
  
158 
 
Subsequently, we validated the capability of our system to detect human GPCR 
heterodimer pairs. To avoid competitive dimerization with the endogenous yeast Ste2p 
receptor, we constructed an NMY63 mutant strain in which the STE2 gene was 
additionally deleted (Table 1 and Figure 7). Since clear evidence for the functional role 
of GPCR homodimer and heterodimer pairs was first obtained for class C receptors, 
such as GABAB receptors (Kaupmann et al., 1998), we tested the dimerization of 
GABAB2 receptor (GABBR2) with GABAB1a receptor (GABBR1a). The 
β-galactosidase assay clearly showed the specific activities both for GABAB2/GABAB2 
and GABAB2/GABAB1a couples (Figure 8A and 9A). This result was coincident with 
the fact that GABAB2 receptor could form not only heterodimer with GABAB1a receptor 
but also homodimer (Maurel et al., 2004, 2008), indicating that the split-ubiquitin-based 
approach could detect the homodimerization and heterodimerization of GABAB2 
receptors. Additionally, the β-galactosidase assay for dimerization of GABAB1a receptor 
also showed similar results (Figure 10). 
In contrast to the widely accepted concept of class C GPCR dimerization, the 
significance of in vivo dimerization of class A GPCRs remains controversial (Prezeau et 
al., 2010). Since a growing amount of evidence indicates that class A GPCRs are able to 
form dimers or higher-ordered oligomers in vivo (Albizu et al., 2010; Rivero-Müller et 
al., 2010), we next evaluated class A GPCR heterodimer pairs. As class A GPCRs, AT1 
and AT2 angiotensin receptors (AGTR1 and AGTR2) were selected. Consistent with 
previous reports (Lyngsø et al., 2009; Porrello et al., 2011), the β-galactosidase assay 
also illustrated the formation of heterodimers between AGTR1 and AGTR2 (Figure 8B 
and 9B). 
Next, we aimed to apply our system to screen new candidate heterodimer partners 
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of AGTR1 receptor within the class A GPCRs, except for AGTR2. The CYC1 promoter 
was selected for expressing AGTR1 as a bait protein (Figure 9B). As a model candidate 
library, we constructed the prey vectors to express AGTR1 (as a positive control), 
β2-adrenergic receptor (ADRB2), 5-hydroxytryptamine (serotonin) receptor 1A 
(HTR1A), somatostatin receptor 2 (SSTR2), somatostatin receptor 5 (SSTR5), 
endothelin receptor type B (EDNRB), neurotensin receptor 1 (NTSR1) and neurotensin 
receptor 2 (NTSR2) (Table 3 and 4) and then mixed equal amounts of these 9 prey 
vectors (containing pPR3-C mock vector). After introduction of the constructed library 
into the NMY63 yeast strains harboring AGTR1 bait vector, the selection with 
ADE2/HIS3 growth reporter genes was performed (Figure 11A). A total of 30 colonies 
was generated on the adenine/histidine-deficient selection media (Figure 11A). 
Following isolation of prey plasmids from each colony, the obtained GPCR clones were 
determined by sequencing analysis. Ten clones of AGTR1 were dominantly identified as 
the homodimer (33.3%), whereas 5 clones of SSTR2 (16.7%), 3 clones of ADRB2 
(10.0%) and 3 clones of HTR1A (10.0%) were successfully screened as the candidate 
heterodimer partners for AGTR1. 
To validate the success or failure of the screening, we measured the 
β-galactosidase activities of the yeast cells separately co-transformed with the AGTR1 
bait vector and 9 other prey vectors including the previously reported AGTR1/ADRB2 
heterodimer pairs (Barki-Harrington et al., 2003), yeast Ste2p control receptor and 
mock control. The results likely reflected the occupancies of identified clones, 
indicating that our system succeeded in screening heterodimer candidates (Figure 11B). 
Additionally, β-galactosidase activities measured with other GPCRs as bait proteins 
were fairly consistent with the results of the screening and also revealed new candidates 
160 
 
for heterodimer pairs including SSTR2/HTR1A, SSTR2/ADRB2, and HTR1A/EDNRB 
(Figure 12A–C and 9C–E). Our experiments indicated that Ste2p could not 
co-oligomerize with the human GPCRs (Figure 11B and 12A–C). 
 
 
 
Fig. 7. Detection of homodimerization of human SSTR5 receptor in NMY62 or 
NMY63 strains. NMY63 yeast strain was transformed with plasmids expressing 
indicated protein pairs. Quantitative β-galactosidase assays for the NMY62 strain (A) 
and NMY63 strain (B). 
  
161 
 
 
Fig. 8. Dimerization assays of human GPCRs. Quantitative -galactosidase assay. 
(A) Detection of GABAB1a/GABAB2 (GABBR1a/GABBR2) heterodimers. (B) 
Detection of AT1/AT2 (AGTR1/AGTR2) heterodimers. Error bars represent the 
standard deviations (n = 3). The control prey plasmid was pPR3-C mock vector. 
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Fig. 9. Optimization of promoter to detect homodimerization of human GPCRs in 
NMY63 strain. NMY63 yeast strain was transformed with plasmids expressing the 
indicated protein pairs. (A) Quantitative β-galactosidase assays. (B–F) Growth assays 
on SD –Leu, Trp, Ade and His dropout plate at 30ºC. (A) GABAB2 receptor (GABBR2) 
(B) AT1 angiotensin receptor (AGTR1) (C) MT1 melatonin receptor (MTNR1A) (D) 
somatostatin receptor 2 (SSTR2) (E) β2-adrenergic receptor (ADRB2) (F) 
5-hydroxytryptamine (serotonin) receptor 1A (HTR1A). The control prey plasmid was 
pPR3-C mock vector. 
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Fig. 10. Detection of homo- and hetero-dimerization of human GABAB1a receptor 
with GABAB2 receptor in NMY63 strain. Quantitative β-galactosidase assay. NMY63 
yeast strain was transformed with plasmids expressing indicated protein pairs. Error 
bars represent the standard deviations (n = 3). The control prey plasmid was pPR3-C 
mock vector. 
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Fig. 11. Screening of candidate heterodimer partners of AT1 angiotensin receptor 
(AGTR1). (A) Workflow of a yeast two-hybrid screen. Prey library was transformed 
into the NMY63 yeast strains harboring AGTR1 bait vector, and the selection with 
growth reporter genes was performed. Following isolation of prey plasmids from each 
colony, the obtained GPCR clones were determined by sequencing analysis. (B) 
Quantitative -galactosidase assays for homo- and hetero-dimerization of AGTR1 in 
NMY63 strain. NMY63 yeast strain was transformed with GPCR-NubG indicated at the 
left and AGTR1-Cub-LexA-VP16. The control prey plasmid was pPR3-C mock vector. 
Error bars represent the standard deviations (n = 3). 
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Fig. 12. Quantitative -galactosidase assays for homo- and hetero-dimerization 
between human-GPCRs in NMY63 strain. NMY63 yeast strain was transformed with 
GPCR-NubG indicated at the left and SSTR2-Cub-LexA-VP16 (A), 
ADRB2-Cub-LexA-VP16 (B), or HTR1A-Cub-LexA-VP16 (C). The control prey 
plasmid was pPR3-C mock vector. Error bars represent the standard deviations (n = 3). 
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Additionally, we measured the β-galactosidase activities of the yeast cells 
separately co-transformed with the AGTR1 bait vector and GABBR1a, GABBR2, MT1 
and MT2 melatonin receptor (MTNR1A and MTNR1B) prey vectors. The results 
indicated new candidates for heterodimer pairs including AGTR1/GABBR1a and 
AGTR1/MTNR1B (Figure 13A). Thus, the obtained results from all heterodimerization 
assays with the split-ubiquitin system might have implicated a general statement about 
the ability of various human GPCRs to heterooligomerize with each other. 
Finally, we performed detection of not only the dimer formation of target human 
GPCRs but also the ligand-mediated conformational changes in living yeast cells. In the 
case of AGTR1 the addition of 10 μM of native ligand, angiotensin II, did not affect the 
states of the homodimerized and heterodimerized receptors with AGTR2 (Figure 13B). 
MT1 and MT2 melatonin receptors (MTNR1A and MTNR1B) not only form 
heterodimers, but also induce a conformational change within the heterodimers (Ayoub 
et al., 2004). In addition, it has been reported that expressions of MTNR1A and 
MTNR1B in yeast activated the pheromone signaling pathway via the endogenous yeast 
G-proteins in response to the native ligand melatonin (Brown et al., 2000; Kokkola et al., 
1998). β-galactosidase assays based on the split-ubiquitin technique in the 
MAPK-defective NMY63 yeast strain allowed successful detection of the 
conformational change of MTNR1A/MTNR1B heterodimers in the presence of 
melatonin (Figure 13C and 9F), suggesting that our system can detect ligand-mediated 
conformational changes as well as the heterodimer formations. Moreover, we also tested 
the detection of the conformational change of GABAB2/GABAB1a heterodimers in the 
presence of GABA (Figure 13D). While the addition of 100 μM of GABA did not affect 
the states of the GABAB2 homodimers, the β-galactosidase assay exposed the 
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conformational change of GABAB2/GABAB1a heterodimers in consistency with 
previous reports (Matsushita et al., 2010) (Figure 13D). 
Because a positive result in the assay potentially could come about through 
indirect association of receptors via a third protein or close co-localization, it is 
important to re-evaluate the irrefragability with other methods or in human cells. 
Additionally, there is no guarantee that association is actually physiologically relevant. 
However, it is also true that this system could narrow down the new candidates of 
GPCR heterodimers with a bit of effort. If one accepts these uncertainties, the assay 
provides a nice way of monitoring changes that does not depend on effective 
downstream signaling through the GPCR pathway. 
In summary, we have developed a specialized method to screen candidate 
heterodimer partners for target GPCRs based on the split-ubiquitin membrane yeast 
two-hybrid method. This modified system permitted the rapid and facile detection of not 
only the heterodimer formation of target human GPCRs, but also the ligand-mediated 
conformational changes in living yeast cells. Since budding yeast Saccharomyces 
cerevisiae can functionally express human GPCRs (Ishii et al., 2012; Li et al., 2007), 
construction of a large prey library would be beneficial for the identification of 
heterodimer candidates as the partners of target human GPCRs. Our system will be a 
useful tool to assist in the intermolecular mapping of interactions among GPCRs and 
uncover potential targets for the development of new therapeutic agents. 
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Fig. 13. Detection for dimerization and ligand-induced conformational changes of 
human GPCRs. (A) Quantitative -galactosidase assays for heterodimerization of 
AGTR1 in NMY63 strain. NMY63 yeast strain was transformed with GPCR-NubG 
indicated at the bottom and AGTR1-Cub-LexA-VP16. (B–D) Ligand assays for 
detection of conformational changes in GPCR dimerizations. (B) AT1/AT2 
(AGTR1/AGTR2) heterodimers. Incubation time, 18 h. Angiotensin II conc., 0 or 10 
M. (C) MT1/MT2 (MTNR1A/MTNR1B) heterodimers. Incubation time, 18 h. 
Melatonin conc., 0 or 10 M. (D) GABAB1a/GABAB2 (GABBR1a/GABBR2) 
heterodimers. Incubation time, 18 h. GABA conc., 0 or 100 M. The control prey 
plasmid was pPR3-C mock vector. Error bars represent the standard deviations (n = 3). 
(*P < 0.05). 
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Chapter 2: Simultaneous method for analyzing dimerization and signaling of 
G-protein-coupled receptor in yeast by dual-color reporter system 
 
 
Introduction 
Seven-transmembrane G-protein-coupled receptors (GPCRs) represent the largest 
and the most ubiquitous of protein families, regulating a number of signaling events 
within the membrane receptors (Fredriksson et al., 2003; Rasmussen et al., 2007). In 
response to a remarkable range of stimuli, such as neurotransmitters, hormones, ions, 
and sensory substances, these receptors regulate the metabolism, secretory properties, 
electrical activity, shape, and motility of virtually all mammalian cells (Lefkowitz and 
Shenoy, 2005). Their key roles in cell signaling have made GPCRs frequent 
pharmaceutical and therapeutic targets for drug discovery (Gudermann et al., 1995). 
It is now clear that GPCRs interact with a range of proteins, including other 
GPCRs (Bockaert et al., 2010; Ferré and Franco, 2010; Ritter and Hall, 2009). 
Identifying and elucidating the function of such interactions will significantly enhance 
our understanding of cellular function, with the promise of new and improved 
pharmaceuticals. Evidence suggests that oligomerization (dimerization, including 
homo-dimerization and hetero-dimerization) of GPCRs is important for their trafficking 
to and from the plasma membrane (Benkirane et al., 1997; Grosse et al., 1997; Jordan et 
al., 2001; Margeta-Mitrovic et al., 2000), for agonist binding activity (Jordan and Devi, 
1999; Mijares et al., 2000; Potter et al., 1991), for signal transduction (AbdAlla et al., 
2000; Hebert et al., 1996), and for down-regulation of receptor expression (Cvejic and 
Devi, 1997; Yesilaltay and Jenness, 2000). 
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Currently, the ascendancy of GPCRs as molecular targets has gradually decreased 
among newly developed Food and Drug Administration (FDA)-approved drugs (Drews, 
2000; Overington et al., 2006), in part because conventional screening trials have been 
exhausted. Therefore, new screening trials, such as heterodimer-targeted ligand 
screening, are required for further drug discovery. Notably, dimerization can increase 
the diversity of the regulation and modulation of GPCR signaling, and thus the specific 
evaluation of signaling properties among variously dimerized receptors will have 
important implications not only for the development of new drugs but also for the 
understanding of signaling networks (Jordan and Devi, 1999). 
The budding yeast Saccharomyces cerevisiae is an attractive host cell system for 
the study of GPCR signaling, because this fungus can simplify analyses of complicated 
mammalian GPCR signaling systems. Haploid yeast cells encode a single endogenous 
GPCR (Ste2p) and harbor a monopolistic G-protein (pheromone) signaling pathway; 
thus, the use of yeast as a host precludes the signaling cross-talk and unexpected 
activation of intrinsic GPCRs or G-proteins that is observed when using mammalian 
host cells (Dowell and Brown, 2002; Fukutani et al., 2012; Iguchi et al., 2010; Stewart 
et al., 2009; Togawa et al., 2010). Therefore, heterologous expression in yeast often has 
been used for analysis of ligand-mediated signaling properties, mutational analysis of 
critical amino acid residues, and identification of agonistic ligands for human and other 
mammalian GPCRs (Ishii et al., 2010). In previous work, we reported the use of a 
split-ubiquitin yeast two-hybrid method (a genetic screening approach that detects 
protein-protein interactions) to identify hetero-dimerization by human GPCRs 
(Nakamura et al., 2013). 
In the present work, we describe a unique system to simultaneously detect 
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dimerization and signaling of GPCRs, using a combination of the split-ubiquitin yeast 
two-hybrid assay and a G-protein signaling assay. To enable this strategy, we 
established a dual-color fluorescent reporter detection method using flow cytometry. As 
we report here, we used the yeast endogenous GPCR (Ste2p) and its natural ligand 
(α-factor) to demonstrate our concept. In addition, by using mutant Ste2p receptors and 
the human SSTR5 somatostatin receptor, we validated the applicability of our system 
for the simultaneous detection of dimerization and signaling by these receptors. 
 
Materials and Methods 
Media 
Synthetic dextrose (SD) medium was formulated as 6.7 g/L yeast nitrogen base 
without amino acids (YNB) (BD-Diagnostic Systems, Sparks, MD, USA) and 20 g/L 
glucose. To generate SDM71 medium, SD medium was adjusted to pH 7.1 with 200 
mM MOPSO buffer (Nacalai Tesque, Kyoto, Japan). YPD medium was formulated as 
10 g/L yeast extract (Nacalai Tesque), 20 g/L peptone (BD-Diagnostic Systems), and 20 
g/L glucose. As appropriate, SD medium was supplemented with amino acids or 
nucleotides (20 mg/L histidine, 60 mg/L leucine, 20 mg/L methionine, 20 mg/L uracil, 
or 40 mg/L tryptophan). For solid medium, agar was added at 20 g/L. 
 
Construction of plasmids 
All plasmids used in this study are summarized in Table 1. All oligonucleotides used for 
the plasmid constructions are listed in Table 2. 
The plasmid used for expression of the far-red variant of tetrameric fluorescent 
protein DsRed-Express2 (E2-Crimson) was constructed as follows. A DNA fragment 
177 
 
encoding the E2-Crimson gene was PCR-amplified from pE2-Crimson (Takara Bio, 
Shiga, Japan) using the oligonucleotides o1 and o2, digested with NheI+EcoRI, and 
inserted into the same sites between the PGK1 promoter (PPGK1) and the PGK1 
terminator (TPGK1) on pGK426 (Ishii et al., 2009), yielding the plasmid 
pGK426-E2-Crimson. 
To integrate the artificial transcription factor (LexA-VP16)-responsive 
E2-Crimson reporter gene at the yeast TRP1 chromosomal locus, a plasmid containing 
the following cassette was constructed. The cassette fused a chimeric GAL1 promoter 
(including eight LexA operators) with the E2-Crimson gene, all flanked by TRP1 
homologous sequences. Upon transformation of yeast cells, the resulting cassette was 
expected to disrupt the TRP1 gene. The resulting trp1 auxotroph then could be used as a 
recipient for transformation (via selection for TRP1 prototrophy) with the split-ubiquitin 
prey plasmids, which contained the TRP1 selectable marker. A DNA fragment 
containing the fusion of eight LexA operators (390 bp) and the partial GAL1 promoter 
was PCR-amplified from NMY51 (Dualsystems Biotech AG, Schlieren, Switzerland) 
genomic DNA using oligonucleotides o3 and o4. A fragment harboring the E2-Crimson 
gene was PCR-amplified from pE2-Crimson with oligonucleotides o5 and o6. The 
amplified fragments were digested with BamHI+EcoRI and EcoRI+ClaI (respectively) 
and ligated together into BamHI, ClaI-cleaved pBlueScript II KS(+) vector (Agilent 
Technologies, Santa Clara, CA, USA). The resultant plasmid was named 
pBlue-(lexAop)8-E2-Crimson. A DNA fragment containing a sequence (300 bp) internal 
to the TRP1 locus was PCR-amplified from BY4741 genomic DNA using 
oligonucleotides o7 and o8. A DNA fragment containing the URA3 selectable marker 
(along with 40 nucleotides of the internal portion of TRP1 at the downstream end) was 
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PCR-amplified from pRS426 (American Type Culture Collection, Manassas, VA) using 
oligonucleotides o9 and o10. The amplified fragments were digested with SacII+XbaI 
and XbaI+BamHI (respectively) and ligated together into SacII, BamHI-cleaved 
pBlue-(lexAop)8-E2-Crimson. The resultant plasmid was named 
pBlue-URA3-(lexAop)8-E2-Crimson. A DNA fragment containing the homologous 
sequence at the TRP1 promoter (upstream of TRP1 gene; 250 bp) was PCR-amplified 
from BY4741 genomic DNA using oligonucleotides o11 and o12. The amplified 
fragment was digested with ClaI+XhoI and ligated into 
pBlue-URA3-(lexAop)8-E2-Crimson digested with the same enzymes. The resultant 
plasmid was named pBlue-URA3-(lexAop)8-E2-Crimson-TRP1. 
For expressing Ste2p and mutant proteins, the constructs were designed to encode 
protein lacking the C-terminal cytoplasmic tail, which contributes to receptor 
internalization and desensitization but is dispensable for agonist binding and signaling 
(Reneke et al., 1988). The plasmids for expressing Ste2p proteins were constructed as 
follows. To introduce point mutations for bait plasmids, gene fragments encoding the 
upstream (amino acids 1–62) and downstream (amino acids 53–304) ends of mutated 
Ste2p were PCR-amplified from pBT3-STE2ΔC (Nakamura et al., 2013) using 
oligonucleotides o13 + o14 and o15 + o16 for G56A; o13 + o17 and o18 + o16 for 
G60A; o13 + o19 and o20 + o16 for G56A/G60A; o13 + o21 and o22 + o16 for G56L; 
o13 + o23 and o24 + o16 for G60L; o13 + o25 and o26 + o16 for G56L/G60L. These 
amplified fragments then were used as the templates for overlap PCR with 
oligonucleotides o13 and o16. For prey plasmids, an equivalent PCR process was 
performed, except that oligonucleotides o13 and o16 were replaced with 
oligonucleotides o27 and o28, respectively. For bait plasmids, the resulting linear STE2 
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(or ste2) fragments were digested with XbaI+HindIII and ligated into similarly digested 
pBT3-C (Dualsystems Biotech AG, Schlieren, Switzerland), resulting in plasmids 
designated pBT3-STE2ΔC-G56A, -G60A, -G56AG60A, -G56L, -G60L, or -G56LG60L, 
respectively. For prey plasmids, the resulting linear STE2 (or ste2) fragments were 
digested with SpeI+EcoRI and ligated into similarly digested pPR3-C (Dualsystems 
Biotech AG, Schlieren, Switzerland), resulting in plasmids designated 
pPR3-STE2ΔC-G56A, -G60A, -G56AG60A, -G56L, -G60L, or -G56LG60L, 
respectively. 
 
Construction of yeast strains 
Yeast strains used in this study are listed in Table 1. Transformation with linear DNA 
fragments was performed using the lithium acetate method (Gietz et al., 1992). To 
eliminate the URA3 selectable marker at each transformation step, we followed previous 
procedures (Iguchi et al., 2010; Togawa et al., 2010) modified to incorporate the marker 
recycling method (Akada et al., 2006). All oligonucleotides used for the strain 
constructions are listed in Table 2. 
The strain expressing enhanced green fluorescent protein (EGFP) was generated as 
follows. First, using previously described methods (Iguchi et al., 2010), a sst2Δ allele 
was inserted into a ste2Δ single mutant strain derived from BY4741 (Brachmann et al., 
1998) (obtained from the Saccharomyces Genome Deletion Project (Winzeler et al., 
1995)). The resulting sst2Δ ste2Δ double mutant was designated MI-50. Next, the 
pheromone-responsive FIG1 gene of MI-50 was replaced with a reporter gene (EGFP) 
encoding EGFP. Gene replacement was performed as follows. A DNA fragment 
containing the FIG1 promoter, EGFP gene, 40 nucleotides (of FIG1 terminator), URA3  
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Table 1. Yeast strains and plasmids used in this study. 
Strain or plasmid Description Reference or source 
Strain   
NMY51 MATa his3200 trp1-901 leu2-3, 112 ade2 LYS2::(lexAop)4-HIS3 
ura3::(lexAop)8-lacZ ade2::(lexAop)8-ADE2 GAL4 
Dualsystems Biotech AG 
BY4741 MATa his31 leu20 met150 ura30 Brachmann et al. (1998) 
MI-10 BY4741 ste2::kanMX4 Winzeler et al. (1999) 
purchased from Invitrogen, 
Carlsbad, CA, USA 
MI-50 MI-10 sst2 This study 
MIF-50 MI-50 fig1::EGFP This study 
MIFLE-50 MIF-50 trp1::(lexAop)8-E2-Crimson This study 
IMFD-50 BY4741 sst2::AUR1-C ste2::LEU2 fig1::EGFP his3::PFIG1-EGFP Togawa et al. (2010) 
IMFD-250 BY4741 sst2::AUR1-C ste2 fig1::EGFP his3::PFIG1-EGFP This study 
IMFDLE-250 IMFD-250 trp1::(lexAop)8-E2-Crimson This study 
Plasmid   
pGK426 Yeast expression vector containing PGK1 promoter, 2 origin, and URA3 marker Ishii et al. (2009) 
pGK426-E2-Crimson E2-Crimson in pGK426 This study 
pGK425 Yeast expression vector containing PGK1 promoter, 2 origin, and LEU2 marker Ishii et al. (2009) 
pGK425-EGFP EGFP in pGK425 Ishii et al. (2009) 
pBlueScript II KS(+) Cloning vector Agilent Technologies 
pBlue-(lexAop)8-E2- 
Crimson 
(lexAop)8-E2-Crimson in pBlueScript II KS(+) This study 
pBlue-URA3-(lexAop)8- 
E2-Crimson 
TRP1(300 bp)-URA3-(lexAop)8-E2-Crimson in pBlue-(lexAop)8-E2-Crimson This study 
pBlue-URA3-(lexAop)8- 
E2-Crimson-TRP1 
TRP1(300 bp)-URA3-(lexAop)8-E2-Crimson-PTRP1(250 bp) in pBlue-URA3- 
(lexAop)8-E2-Crimson 
This study 
pBT3-C Cub-LexA-VP16 expression vector containing CYC1 promoter, CEN/ARS origin, 
and LEU2 marker 
Dualsystems Biotech AG 
pPR3-C NubG expression vector containing ADH1 promoter, 2 origin, and TRP1 
marker 
Dualsystems Biotech AG 
pCCW-Alg5 Alg5-Cub-LexA-VP16 expression, CYC1 promoter, CEN/ARS origin, and LEU2 
marker 
Dualsystems Biotech AG 
pAI-Alg5 Alg5-NubI expression, ADH1 promoter, 2 origin, and TRP1 marker Dualsystems Biotech AG 
pBT3-STE2C STE2C in pBT3-C Nakamura et al. (2013) 
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pPR3-STE2C STE2C in pPR3-C Nakamura et al. (2013) 
pBT3-STE2C-G56A STE2C (G56A) mutant in pBT3-C This study 
pBT3-STE2C-G60A STE2C (G60A) mutant in pBT3-C This study 
pBT3-STE2C-G56AG60A STE2C (G56A/G60A) mutant in pBT3-C This study 
pBT3-STE2C-G56L STE2C (G56L) mutant in pBT3-C This study 
pBT3-STE2C-G60L STE2C (G60L) mutant in pBT3-C This study 
pBT3-STE2C-G56LG60L STE2C (G56L/G60L) mutant in pBT3-C This study 
pPR3-STE2C-G56A STE2C (G56A) mutant in pPR3-C This study 
pPR3-STE2C-G60A STE2C (G60A) mutant in pPR3-C This study 
pPR3-STE2C-G56AG60A STE2C (G56A/G60A) mutant in pPR3-C This study 
pPR3-STE2C-G56L STE2C (G56L) mutant in pPR3-C This study 
pPR3-STE2C-G60L STE2C (G60L) mutant in pPR3-C This study 
pPR3-STE2C-G56LG60L STE2C (G56L/G60L) mutant in pPR3-C This study 
pBTD3-SSTR5 SSTR5-Cub-LexA-VP16 expression, TDH3 promoter, CEN/ARS origin, and 
LEU2 marker 
Nakamura et al. (2013) 
pPR3-SSTR5 SSTR5 in pPR3-C Nakamura et al. (2013) 
pPR3-SSTR2 SSTR2 in pPR3-C Nakamura et al. (2013) 
pPR3-ADRB2 ADRB2 in pPR3-C Nakamura et al. (2013) 
pPR3-STE2 STE2 in pPR3-C Nakamura et al. (2013) 
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Table 2. List of oligonucleotides. 
 Name Sequence 
o1 NheI_E2-Crimson_fw 5'-TTTTGCTAGCATGGATAGCACTGAGAACGT 
o2 EcoRI_E2-Crimson_rv 5'-AAAAGAATTCCTACTGGAACAGGTGGTGGC 
o3 BamHI_lexAop_fw 5'-CCCCGGATCCTCGACTGCTGTATATAAAAC 
o4 EcoRI_PGAL1_rv 5'-GGGGGAATTCTATAGTTTTTTCTCCTTGAC 
o5 EcoRI_E2-Crimson_fw 5'-CCCCGAATTCATGGATAGCACTGAGAACGT 
o6 ClaI_E2-Crimson_rv 5'-TTTTATCGATCTACTGGAACAGGTGGTGGC 
o7 SacII_dTRP1_fw 5'-TTTTCCGCGGAAGCTGCACTGAGTAGTATG 
o8 XbaI_dTRP1_rv 5'-CCCCTCTAGAACTTGCTGGGTATTATATGT 
o9 XbaI_URA3_fw 5'-CCCCTCTAGATTTTTTGTTCTTTTTTTTGA 
o10 BamHI_hr40-URA3_rv 5'-CCCCGGATCCACTTGCTGGGTATTATATGTGTGCCCAATAGAAAGAGA 
ACGGGTAATAACTGATATAATT 
o11 ClaI_dTRP1up_fw 5'-GGGGATCGATTTCTTAATCGGCAAAAAAAG 
o12 XhoI_dTRP1up_rv 5'-TTTTCTCGAGAAACGTGCACCCGCCCGTCT 
o13 XbaI_STE2_fw 5'-AAAATCTAGAATGTCTGATGCGGCTCCTTC 
o14 STE2-G56A_rv 5'-CAGCTGCACCACATCTGACAGCAAACATAA 
o15 STE2-G56A_fw 5'-TTATGTTTGCTGTCAGATGTGGTGCAGCTG 
o16 HindIII_lin_STE2-304_rv 5'-GGGGAAGCTTGAACCTCCGCCACCTGATTTGGATGCATTATTAGCAG 
o17 STE2-G60A_rv 5'-CAGCTGCAGCACATCTGACACCAAACATAA 
o18 STE2-G60A_fw 5'-TTATGTTTGGTGTCAGATGTGCTGCAGCTG 
o19 STE2-G56AG60A_rv 5'-CAGCTGCAGCACATCTGACAGCAAACATAA 
o20 STE2-G56AG60A_fw 5'-TTATGTTTGCTGTCAGATGTGCTGCAGCTG 
o21 STE2-G56L_rv 5'-CAGCTGCACCACATCTGACAAGAAACATAA 
o22 STE2-G56L_fw 5'-TTATGTTTCTTGTCAGATGTGGTGCAGCTG 
o23 STE2-G60L_rv 5'-CAGCTGCAAGACATCTGACACCAAACATAA 
o24 STE2-G60L_fw 5'-TTATGTTTGGTGTCAGATGTCTTGCAGCTG 
o25 STE2-G56LG60L_rv 5'-CAGCTGCAAGACATCTGACAAGAAACATAA 
o26 STE2-G56LG60L_fw 5'-TTATGTTTCTTGTCAGATGTCTTGCAGCTG 
o27 SpeI_STE2_fw 5'-GGGGACTAGTATGTCTGATGCGGCTCCTTC 
o28 EcoRI_lin_STE2-304_rv 5'-GGGGGAATTCGGAACCTCCGCCACCTGATTTGGATGCATTATTAGCAG 
o29 FIG1N_200bp_fw 5'-TAAGATTATGATGGTTTCATGTATGTGTCA 
o30 FIG1C_200bp_rv 5'-TTAGTCGCTCATCAAGGTGACAGTAAATAA 
o31 dSTE2up-URA3_fw 5'-TTTCTTTTCACCTGCTCTGGCTATAATTATAATTGGTTACTTAAAAATGC 
ACCGTTAAGAACCATATCCAAGAATCAAAATTTTTTGTTCTTTTTTTTGA 
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o32 dSTE2up-URA3_rv 5'-TCTTAACGGTGCATTTTTAAGGGTAATAACTGATATAATT 
o33 dSTE2dn_fw 5'-AATTATATCAGTTATTACCCTTAAAAATGCACCGTTAAGAACCATATCCA 
AGAATCAAAATCAAAATTTACGGCTTTGAAAAAGTAATTTCGTGACCTTC 
o34 dSTE2dn_rv 5'-AAGATTAACTGTATATATTGCCTGAGAGTTCTAGATCATG 
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selectable marker, and FIG1 terminator was PCR-amplified from pMR-FIG1GF 
(Togawa et al., 2010) with oligonucleotides o29 and o30, and the amplified fragment 
was introduced into MI-50. After confirming the correct integration, the URA3 marker 
was “popped-out” by homologous recombination using counter-selection with 
5-fluoroorotic acid (5-FOA, Fluorochem, Derbyshire, UK). The resultant strain was 
designated MIF-50. 
To provide leucine auxotrophy, the LEU2 marker located at the ste2Δ locus of the 
IMFD-50 strain (Togawa et al., 2010) was eliminated using marker recycling. The first 
half of a DNA fragment, consisting of the upstream region of the STE2 gene and the 
URA3 selectable marker, was PCR-amplified from pGK406 (Ishii et al., 2009) using 
oligonucleotides o31 and o32. The second half of the fragment, consisting of the 
downstream region of STE2 and the sequences upstream of the STE2 chromosomal 
locus (to facilitate excision of the URA3 marker) was PCR-amplified from BY4741 
genomic DNA using oligonucleotides o33 and o34. These two amplified fragments were 
combined using overlap PCR, and the resulting linear construct was transformed into 
IMFD-50. After confirming integration of the fragments at the correct positions, the 
URA3 marker was “popped-out” by counter-selection with 5-FOA, resulting in strain 
IMFD-250. 
To construct the recombinant yeast strain in which the genomic TRP1 gene was 
replaced by the E2-Crimson reporter gene, the DNA fragment obtained by digesting 
pBlue-URA3-(lexAop)8-E2-Crimson-TRP1 with SacII and XhoI was transformed into 
MIF-50 and IMFD-250. After confirming correct integration, the URA3 marker was 
“popped-out” by counter-selection with 5-FOA. The constructed strains were designated 
MIFLE-50 and IMFDLE-250, respectively.  
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Fluorescence microscopy imaging 
Yeast transformants were grown in SD medium (supplemented as needed) at 30 °C 
overnight, and the cells then were inoculated into 5 mL of the respective fresh SD 
medium to give an initial optical density of 0.03 at 600 nm (OD600 = 0.03). The cells 
were incubated at 30 °C on a rotary shaker at 150 rpm for up to 18 h and then harvested, 
washed, and resuspended in distilled water. The cell suspensions were observed using a 
BZ-9000 fluorescence microscope (Keyence, Osaka, Japan). Green fluorescence images 
were acquired with a 470/40 band-pass filter for excitation and a 535/50 band-pass filter 
for emission. Red fluorescence images were acquired with a 620/60 band-pass filter for 
excitation and a 700/75 band-pass filter for emission. Exposure times were 0.2 and 1 s 
for green and red, respectively. 
 
Flow cytometric analysis 
EGFP and E2-Crimson were detected using a BD FACSCanto II flow cytometer 
equipped with both a 488-nm blue laser and a 633-nm red laser, respectively (Becton, 
Dickinson and Company, Franklin Lakes, NJ, USA); the data were analyzed using BD 
FACSDiva software (v5.0; Becton, Dickinson and Company). The EGFP fluorescence 
signal was collected through a 530/30 nm band-pass filter, and the GFP-A mean of 
10,000 cells was defined as ‘green fluorescent intensity’. The E2-Crimson fluorescence 
signal was collected through a 660/20 nm band-pass filter, and the APC-A mean of 
10,000 cells was defined as ‘far-red fluorescent intensity’. 
 
Ste2p assays 
Yeast strains transformed with the wild-type or mutated Ste2p expression plasmids 
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were grown in SD medium (supplemented as needed) at 30 °C overnight, and the cells 
then were inoculated into 5 mL of the respective fresh SD medium to give an initial 
OD600 = 0.03. The cells were incubated at 30 °C on a rotary shaker at 150 rpm for up to 
18 h and harvested, washed, and resuspended in water to give an OD600 = 10. The 
resulting yeast cell suspensions were added (at 10 μL /well; to give an OD600 = 1) to the 
wells of 96-well cluster dishes containing fresh SD medium (80 μL/well) supplemented 
(10 μL/well) with 10 μM α-factor (Zymo Research, Orange, CA, USA) or distilled 
water (no α-factor control). The plates were incubated at 30 °C with shaking (150 rpm) 
for 4 h. After incubation, the samples containing the yeast cells were diluted with 1 mL 
per well of sheath fluid, and fluorescence was analyzed by flow cytometry. 
 
hSSTR5 assay 
Cultivation conditions for the hSSTR5 assay were modified from a previous report 
(Ishii et al., 2012a). Briefly, yeast strains transformed with the hSSTR5 expression 
plasmids were grown in SD medium (supplemented as needed) at 30 °C overnight, and 
were inoculated into 5 mL of the respective fresh SD medium to give an initial OD600 = 
0.03. The cells then were grown at 30 °C on a rotary shaker at 150 rpm for up to 18 h 
and harvested, washed, and resuspended in water to yield an OD600 = 10. The resulting 
yeast cell suspensions were added (at 10 μL /well; to give an OD600 = 1) to the wells of 
96-well cluster dishes containing fresh SDM71 medium (80 μL/well) supplemented (10 
μL/well) with 10 μM somatostatin (SST) (Calbiochem, Darmstadt, Germany) or 
distilled water (no SST control). The plates were incubated at 30 °C with shaking (150 
rpm) for 4 h. After incubation, the samples containing the yeast cells were diluted with 1 
mL of sheath fluid, and fluorescence was analyzed by flow cytometry. 
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Halo bioassay to test growth arrest response to G-protein signal 
An agar diffusion bioassay (halo assay), performed as described previously (Ishii 
et al., 2006), was used to measure the response to and recovery from 
pheromone-induced cell-cycle arrest. Briefly, yeast transformants were grown in SD 
medium at 30 °C overnight. Sterilized paper filter disks (6 mm in diameter) were placed 
on square size Petri dishes and various amounts of α-factor pheromone were spotted 
onto the disks. Fifty milliliters of SD medium containing 20 g/L agar (and maintained at 
50 °C) was inoculated with the yeast cells to an initial OD600 of 5×10
–4
, and the 
suspension was used to overlay the paper disk-containing plate. The plates were 
incubated at 30 °C for 4 days. 
 
 
Results and Discussion 
General strategy 
The aim of this study was to establish a method, using recombinant yeast strains, that 
permitted simultaneous analyses of dimerization and of signaling by GPCRs. Such a 
technique is expected to provide various advantages for GPCR studies. To achieve this 
goal, we designed a dual-color fluorescent reporter detection system based on the 
combination of a previously reported split-ubiquitin two-hybrid system (Stagljar et al., 
1998) with a G-protein signaling assay system (Iguchi et al., 2010; Togawa et al., 2010). 
As detection readouts, we selected red and green fluorescent reporter genes for 
monitoring dimerization and signaling events of GPCRs, respectively. An outline of our 
strategy is shown in Figure 1. 
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Fig. 1. Schematic illustration of the strategy for simultaneous analysis of 
dimerization and signaling by GPCRs. (A,B) No-dimerization pairs. (C,D) 
Dimerization pairs. (A,C) Without agonistic ligand. (B,D) With agonistic ligand. The 
yeast pheromone signaling pathway is shown, along with the regulatory changes of 
fluorescence reporter genes in response to ligand. This pathway is extensively used for 
the GPCR assay. Agonistic ligand binding to the GPCR leads to activation of 
heterotrimeric G-proteins. The activated G-proteins subsequently induce activation of 
the mitogen-activated protein kinase (MAPK) cascade, resulting in expression of the 
EGFP reporter gene. In the split-ubiquitin yeast two-hybrid system, NubG efficiently 
interacts with Cub only when the proteins to which the two split tags are attached 
interact with each other, resulting in the formation of a NubG/Cub complex. This 
complex is recognized by ubiquitin-specific proteases (UBPs), which release the 
artificial transcription factor (TF; LexA-VP16) from the Cub-containing construct. The 
TF then enters the nucleus via diffusion and binds to the lexA-binding sites upstream of 
the E2-Crimson reporter gene. 
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The yeast split-ubiquitin two-hybrid system has been applied most recently to the 
detection of homo- and hetero-dimerizations of human GPCRs (Nakamura et al., 2013). 
The developed system successfully identified candidate heterodimer partners for target 
human GPCRs. Briefly, separate constructs were used to encode proteins that fused 
either the N- or C-terminal moiety of a split-ubiquitin to the C-terminus of a GPCR 
(Figure 1). Notably, the N-terminal moiety of the split-ubiquitin included an I13G 
mutation (NubG), while the C-terminal moiety of the split-ubiquitin included an 
artificial transcription factor domain (Cub-LexA-VP16). Upon in vivo protein-protein 
interaction, the reconstituted ubiquitin served as a substrate for the action of 
ubiquitin-specific proteases (UBPs), resulting in the release of the LexA-VP16 
transcription factor. The transcription factor then entered the nucleus and induced the 
transcriptional activation of growth and colorimetric reporter genes (ADE2, HIS3, and 
lacZ). Therefore, the system permitted monitoring of dimerization by GPCRs. In the 
present study, the assay was modified to incorporate the red fluorescent reporter gene as 
the assay read-out. 
The yeast-based GPCR signaling assay is a previously developed approach to 
monitoring the pheromone signaling machinery (Ishii et al., 2010). Specifically, 
heterologous GPCRs were expressed on yeast cell surface membranes; binding of 
agonistic ligands to the receptors triggered the activation of the mitogen-activated 
protein kinase (MAPK) cascade via yeast endogenous or chimeric G-proteins (Minic et 
al., 2005) (Figure 1). The signal led to the phosphorylation of transcription factor 
Ste12p, inducing the expression of reporter genes in a pheromone-responsive manner. 
Several laboratories have reported the use of an EGFP gene (placed under the control of 
the pheromone-responsive FIG1 or FUS1 promoter) to detect G-protein signaling 
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(Fukuda et al., 2011; Hara et al., 2012; Ishii et al., 2012a; Ishii et al., 2012b). This 
detection approach permitted a variety of applications, including ligand screening and 
mutational analysis (Ishii et al., 2012b; Ladds et al., 2005; Minic et al., 2005). 
Based on these techniques, we designed a red and green dual-color detection 
method combined with flow cytometry, which permitted high-throughput cell sorting, 
facilitating simultaneous analyses of GPCR dimerization and signaling. 
 
Determination of two fluorescent proteins for dual-color fluorescent reporter 
system 
To allow dual-color flow cytometric analyses, we explored the combined use of two 
fluorescent proteins harboring chromophores with sufficiently distinct emission peaks. 
One of these, enhanced green fluorescent protein (EGFP) (excitation maximum, 490 
nm; >90% efficiency at 488 nm; emission maximum, 510 nm) (Lybarger et al., 1998), 
has been widely used as a reporter gene for flow cytometry. As the partner for 
dual-color detection, we employed a recently described far-red variant of 
DsRed-Express2 (E2-Crimson) (excitation maximum, 611 nm; ≈42% efficiency at 633 
nm; emission maximum, 646 nm) (Strack et al., 2009). 
To test whether E2-Crimson and EGFP are suitable for the flow cytometric 
dual-color detection, we first generated the autonomous replicating plasmids 
pGK426-E2-Crimson and pGK425-EGFP to express constitutively each fluorescent 
protein under the control of the PGK1 promoter. Yeast BY4741 wild-type strains 
harboring these plasmids or mock vectors were generated, and their far-red and green 
fluorescence was evaluated. 
Using fluorescence microscopy, the two fluorescence signals were cleanly 
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resolvable and never interfered with each other’s emission spectra (Figure 2). 
Subsequently, we measured the fluorescence level of each yeast cell under the condition 
of simultaneous 2-laser excitation (488 and 633 nm line) with the flow cytometer 
(Figure 3). As expected, fluorescence signals from these two proteins could be 
completely distinguished by the flow cytometry with standard optical systems. In 
addition, the average fluorescence of cells co-expressing E2-Crimson and EGFP was 
equivalent to that of cells expressing either reporter alone. Thus, we concluded that 
combination of far-red and green fluorescent proteins (E2-Crimson and EGFP) are 
optimally fitted to dual-color fluorescent detection. 
 
Evaluation of LexA-VP16-responsive E2-Crimson reporter gene expression 
To permit the far-red fluorescence-based split-ubiquitin yeast two-hybrid assay, we 
constructed the yeast strains MIFLE-50 and IMFDLE-250, in which the E2-Crimson 
reporter gene was expressed in response to the release of LexA-VP16 transcription 
factor (Table 1). Because the MIFLE-50 or IMFDLE-250 strains originally harbored 
EGFP (as single- or double-copy reporters), these strains were expected to permit 
dual-color fluorescent detection of dimerization and signaling by GPCRs. 
To check the expression of the E2-Crimson reporter gene, we determined the mean 
intensity of fluorescence per yeast cell by flow cytometry. The yeast strains harboring 
mock vectors pBT3-C and pPR3-C were used as negative controls, and those harboring 
pCCW-Alg5 and pAI-Alg5 (which express Alg5-NubI and Alg5-Cub-LexA-VP16, 
respectively) were used as positive controls (Table 1). Alg5-NubI is a yeast membrane 
protein modified with a wild-type Nub tag. The NubI tag usually interacts 
spontaneously with any Cub tag-containing construct (Iyer et al., 2005; Kittanakom et 
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al., 2009). As shown in Figure 4, the E2-Crimson fluorescence of positive controls was 
much higher than that of negative controls, indicating that the E2-Crimson reporter gene 
was expressed. These data demonstrated that reconstitution of the split-ubiquitin and 
release of the LexA-VP16 transcription factor led to expression of the E2-Crimson 
reporter gene. 
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Fig. 2. Fluorescence microscope images of yeast strain BY4741 harboring 
pGK426-E2-Crimson and/or pGK425-EGFP. All transformants were grown in SD 
selective medium for 18 h. (A-C) pGK426/pGK425-containing cells are shown as 
viewed under red (A) or green filters (B) or presented as a merged image (C). (D-F) 
pGK426-E2-Crimson/pGK425-containing cells are shown as viewed under red (D) or 
green (E) filters or presented as a merged image (F). (G-I) 
pGK426/pGK425-EGFP-containing cells are shown as viewed under red (G) or green 
(H) filters or presented as a merged image (I). (J-L) 
pGK426-E2-Crimson/pGK425-EGFP-containing cells are shown as viewed under red 
(J) or green (K) filters or presented as a merged image (L).  
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Fig. 3. Dual-color flow cytometric analysis of yeast strain BY4741 harboring 
pGK426-E2-Crimson and/or pGK425-EGFP. All transformants were grown in SD 
selective medium for 18 h. Solid bars: Cells were excited at 633 nm and emission 
detected at 660/20 nm (E2-Crimson). Open bars: Cells were excited at 488 nm and 
emission detected at 530/30 nm (EGFP). The relative E2-Crimson fluorescence units 
(red-RFU) were normalized by dividing the red fluorescent intensities of each yeast 
strain by those of a yeast strain harboring pGK426-E2-Crimson/pGK425. The relative 
EGFP fluorescence units (green-RFU) were normalized by dividing the green 
fluorescent intensities of each yeast strain by those of a yeast strain harboring 
pGK426/pGK425-EGFP. Data are presented as the mean ± standard deviation of 
separate runs (n = 3 each). 
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Fig. 4. Induction of E2-Crimson reporter gene by LexA-VP16. To check induction of 
the E2-Crimson reporter gene by LexA-VP16 from split-ubiquitin, yeast strains 
expressing Cub/NubG (negative control) or Alg5-Cub/Alg5-NubI (positive control) 
were constructed. All transformants were grown in SD selective medium for 18 h. 
Values represent the mean far-red E2-Crimson fluorescence signal for 10,000 cells, as 
measured by flow cytometry. Data are presented as the mean ± standard deviation of 
separate runs (n = 3 each). (A) MIFLE-50, (B) IMFDLE-250. 
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Simultaneous detection for dimerization and signaling by Ste2p 
To validate the application of our method for simultaneous analyses of both 
dimerization and signaling by GPCRs, we first analyzed homo-dimerization and 
signaling by the yeast endogenous GPCR (Ste2p). Previous studies of dimerization 
reported the use of a truncated Ste2p receptor (lacking the C-terminal tail; Ste2ΔC) to 
reduce the distance between the C-termini of the receptor pair (Gehret et al., 2006; 
Nakamura et al., 2013). Therefore, we transformed our IMFDLE-250 yeast strain with 
pPR3-STE2ΔC and pBT3-STE2ΔC to provide co-expression of the proteins encoded by 
Ste2ΔC-NubG and Ste2ΔC-Cub-LexA-VP16. As a control, pPR3-C split-ubiquitin 
mock vector was used in place of pPR3-STE2ΔC (Table 1). The resulting transformants 
were cultivated in the presence and absence of 10 M α-factor (a Ste2p agonist), and the 
fluorescence level of each strain was measured by flow cytometry (Figure 5). 
In the dimerization assay with the Ste2ΔC-encoding constructs, the cells 
co-expressing Ste2ΔC-NubG and Ste2ΔC-Cub-LexA-VP16 displayed an increase in 
E2-Crimson fluorescence (Figure 5A); an equivalent elevation of far-red fluorescence 
was not seen in cells harboring the mock prey plasmid, suggesting that expression of the 
E2-Crimson reporter gene reflected dimerization of Ste2ΔC. Concurrently, we also 
verified that our system permitted the detection of Ste2p signaling. As expected, 
addition of 10 M α-factor increased the EGFP fluorescence intensity in both cells 
(Figure 5B). Thus, we confirmed the validity of this platform for simultaneously 
analyzing dimerization and signaling by the yeast Ste2p receptor. 
Similarly, we conducted an equivalent experiment using MIFLE-50, a strain that 
harbors a single-copy EGFP reporter gene. Compared with the IMFDLE-250 strain, the 
MIFLE-50 strain exhibited almost the same mean E2-Crimson intensity and a lower 
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EGFP intensity (Figure 6). 
 
 
Fig. 5. Simultaneous detection of dimerization and signaling by truncated yeast 
Ste2p receptor (lacking the carboxy-terminal tail; Ste2ΔC) in IMFDLE-250 strain. 
The IMFDLE-250 yeast strain was transformed with plasmids encoding the indicated 
protein pairs. All transformants were grown in SD selective medium for 18 h. The cells 
then were incubated for another 4 h in SD selective medium with or without 10 M 
α-factor. The mean E2-Crimson (A) and EGFP (B) fluorescence of 10,000 cells was 
measured by flow cytometry. Data are presented as the mean ± standard deviation of 
separate runs (n = 3 each). 
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Fig. 6. Simultaneous detection of dimerization and signaling by truncated yeast 
Ste2p receptor (lacking the carboxy-terminal tail; Ste2ΔC) in MIFLE-50 strain. 
The MIFLE-50 yeast strain was transformed with plasmids encoding the indicated 
protein pairs. All transformants were grown in SD selective medium for 18 h. The cells 
then were incubated for another 4 h in SD selective medium with or without 10 M 
α-factor. The mean E2-Crimson (A) and EGFP (B) fluorescence of 10,000 cells was 
measured by flow cytometry. Data are presented as the mean ± standard deviation of 
separate runs (n = 3 each). 
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Simultaneous detection of dimerization and signaling using Ste2p mutants 
Subsequently, mutated Ste2p receptors with dimerization-defective and/or 
signaling-defective point mutations were analyzed to confirm the validity of the method. 
Reports suggested that the first transmembrane domain (TM1) forms a component of 
the interface between the two receptors in the Ste2p dimer (Overton and Blumer, 2002; 
Overton et al., 2003; Wang and Konopka, 2009). Additionally, the replacement of either 
or both glycine residues (Gly56 and Gly60) in TM1 by alanine or leucine (G56A(L) 
and/or G60A(L)) was shown to convert the Ste2p receptor into a dimerization-defective 
protein (Overton et al., 2003). The substitution of the glycine residues with bulky 
hydrophobic leucine residues resulted in stronger dimerization defects than those seen 
with Gly-to-Ala substitutions, presumably because of steric clashing (Overton et al., 
2003). Moreover, the Gly-to-Leu mutants (G56L and/or G60L) showed 
signaling-defective characteristics, whereas the Gly-to-Ala mutants (G56A and/or 
G60A) still retained some ability to transduce the α-factor signal response (Overton et 
al., 2003). Therefore, these mutants were used to verify the utility of the method 
developed in the present paper. 
To check the signaling properties of strains harboring each of the 6 constructed 
mutated genes, we performed halo bioassays (agonist-induced growth arrest) and 
checked for zones of growth inhibition. The yeast strain IMFDLE-250 expressing the 
G60A mutant exhibited normal signaling properties (Figure 7). The cells expressing the 
G56A single mutant or the G56A/G60A double mutant were able to transduce the signal, 
albeit with reduced efficacy (Figure 7). In contrast, cells expressing any of the leucine 
substitution mutants (G56L, G60L, or G56L/G60L) exhibited strong signaling defects 
(Figure 7). These results confirmed that our detection method yielded results consistent 
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with those reported previously with known ste2 mutants (Overton et al., 2003). 
Next, we assessed these mutants in the dual-color detection system to validate the 
feasibility of simultaneous analyses of dimerization and signaling by the Ste2p mutant 
proteins. The fluorescence of the E2-Crimson and EGFP reporters in IMFDLE-250 
strains expressing these Ste2p mutants was quantitatively evaluated by flow cytometry. 
As shown in Figure 8, the Ste2p receptors with G56A and/or G60A mutations displayed 
significantly reduced E2-Crimson fluorescence while exhibiting essentially intact EGFP 
fluorescence (Figure 8A and 8B). These results indicated that these mutant proteins 
were impaired in homo-dimerization but retained meaningful signaling function. On the 
other hand, the Ste2p receptors with G56L and/or G60L mutations exhibited decreases 
in both E2-Crimson and EGFP fluorescence, showing that these Leu-substituted mutants 
were impaired for both dimerization and signaling. These assays were consistent with 
the results of the halo assays and those of the previous report (Overton et al., 2003). 
Thus, our simultaneous detection system was validated for the evaluation of GPCR 
mutants. 
 
Simultaneous detection of dimerization and signaling by human SSTR5 
Somatostatin (SST) is a cyclic neuropeptide known as a growth hormone 
release-inhibiting factor; SST receptors are therapeutic targets for treatment of 
acromegaly, Cushing’s disease, and Alzheimer’s disease (Ben-Shlomo and Melmed, 
2008; Lamberts et al., 1994; Saito et al., 2005). Heterologous expression of the human 
SST receptor subtype-5 (hSSTR5) in yeast has been shown to activate pheromone 
signaling via endogenous yeast G-protein in response to the native ligand SST (Togawa 
et al., 2010). 
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Fig. 7. Effects of substitutions at either or both glycine residues (Gly56 and Gly60) 
in TM1 on Ste2p receptor signal transduction. The IMFDLE-250 yeast strain was 
transformed with the plasmids encoding the indicated wild-type or mutant receptors. 
Halo bioassay (agonist-induced growth arrest) was performed with synthetic α-factor 
pheromone spotted onto filter disks at the amounts indicated in the schematic diagram. 
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Fig. 8. Simultaneous analysis of dimerization and signaling by Ste2p mutant 
receptors in IMFDLE-250 strain. The IMFDLE-250 yeast strain was transformed with 
plasmids encoding the indicated Ste2p mutant receptors. All transformants were grown 
in SD selective medium for 18 h. The cells then were incubated for another 4 h in SD 
selective medium with or without 10 M α-factor. The mean E2-Crimson (A) and EGFP 
(B) fluorescence of 10,000 cells was measured by flow cytometry. Data are presented as 
the mean ± standard deviation of separate runs (n = 3 each). 
  
204 
 
 
Fig. 9. Simultaneous detection of homo- and hetero-dimerization and signaling by 
human somatostatin receptor subtype-5 (SSTR5) in IMFDLE-250 strain. The 
IMFDLE-250 yeast strain was transformed with plasmids encoding various 
GPCR-NubG constructs (indicated below each graph; “Y-NubG”) and 
SSTR5-Cub-LexA-VP16 (“X-Cub”). All transformants were grown in SD selective 
medium for 18 h. The cells then were incubated for another 4 h in SDM71 selective 
medium with or without 10 M SST. The mean E2-Crimson (A) and EGFP (B) 
fluorescence of 10,000 cells was measured by flow cytometry. Data are presented as the 
mean ± standard deviation of separate runs (n = 3 each). Statistical significance was 
assessed by the t-test (ns, not significant, **P < 0.01). 
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Yeast strain IMFDLE-250, which had been engineered to express hSSTR5, was 
cultivated in the presence and absence of 10 M SST, and the fluorescence of each 
strain was measured by flow cytometry (Figure 9). In the dimerization assay, cells 
co-expressing hSSTR5-NubG and hSSTR5-Cub-LexA-VP16 (Table 1) displayed 
increased E2-Crimson fluorescence compared with mock control cells (co-expressing 
hSSTR5-Cub-LexA-VP16 and NubG) (Figure 9A, P < 0.01, t-test), consistent with the 
detection of hSSTR5 homo-dimerization. In cells co-expressing hSSTR5-NubG and 
hSSTR5-Cub-LexA-VP16, as in control cells, growth in the presence of 10 M SST 
increased EGFP fluorescence (Figure 9B), confirming the detection of SST-induced 
G-protein signaling. However, cells co-expressing hSSTR5-NubG and 
hSSTR5-Cub-LexA-VP16 exhibited increased EGFP fluorescence compared with mock 
control cells (Figure 9B). This elevation in green fluorescence suggests that signaling 
levels are enhanced in cells co-expressing hSSTR5-NubG and 
hSSTR5-Cub-LexA-VP16 because of the greatly enriched expression level of hSSTR5 
receptor derived from hSSTR5-NubG expressing prey vector (harboring multi-copy 
origin and robust ADH1 promoter). 
Finally, we engineered IMFDLE-250 yeast cells co-harboring human SST receptor 
subtype-2 (hSSTR2), human β2-adrenergic receptor (hADRB2), or Ste2p expression 
prey plasmid (fusion forms with NubG) with the hSSTR5-Cub-LexA-VP16 expression 
bait plasmid. These combinations have included the previously reported 
hSSTR2/hSSTR5 and hADRB2/hSSTR5 heterodimer pairs (Grant et al., 2008; 
Somvanshi et al., 2011). After cultivation in the presence and absence of 10 M SST, 
the fluorescence of each strain was measured by flow cytometry (Figure 9). Cells 
co-expressing hSSTR5-Cub-LexA-VP16 and hSSTR2-NubG or hADRB2-NubG (Table 
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1) exhibited E2-Crimson fluorescence (P < 0.01, t-test), while the cells co-expressing 
hSSTR5-Cub-LexA-VP16 and Ste2p-NubG and the mock control cells did not exhibit 
fluorescence (Figure 9A). Our experiments clearly showed that hSSTR5 could not 
co-oligomerize with Ste2p. In contrast, hSSTR5 could interact with hSSTR2 and 
hADRB2. In the signaling assays, all cells displayed SST-induced EGFP fluorescence, 
even though the hADRB2-NubG expression plasmid did not enhance the fluorescence 
levels upon SST exposure (as in the case with the mock control strain; Figure 9B). 
Taken together, these results indicated that hSSTR5 could form heterodimers both by 
congeneric interactions (between hSSTR5 and hSSTR2 moieties) and by heterogeneic 
interactions (between hSSTR5 and hADRB2 moieties). Both classes of 
hetero-dimerization are consistent with the previous reports (including our earlier 
results) (Grant et al., 2008; Nakamura et al., 2013; Somvanshi et al., 2011). Our results 
also suggest that the hetero-dimerization between hSSTR5 and hADRB2 did not change 
the signaling properties induced by SST stimulation. In addition, the strain harboring 
hSSTR5-Cub-LexA-VP16/Ste2p-NubG could give a slightly increased green 
fluorescent signal when treated with SST (compared with the mock control strain; 
Figure 9B). This suggested that co-expression of Ste2p-NubG with 
hSSTR5-Cub-LexA-VP16 increased the transactivation of EGFP by Ste12p upon the 
addition of non-relevant SST ligand. These events might be due to the enrichment of the 
expression level or the localization level to the membrane within the hSSTR5 receptor, 
although Ste2p would not be probably concerned in its mechanism directly on the 
ground of the evidence for non-interacting ability with hSSTR5. 
Thus, our simultaneous detection system was validated for the heterologous 
expression and evaluation of human GPCRs. This system would be useful for 
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identifying an agonist bound to the heterodimer by screening (within a compound 
library or a plasmid-based peptide library) for ligand candidates that specifically 
activate the cells co-expressing components of the heterodimer pair. 
 
Conclusion 
In this study, we designed a dual-color fluorescent detection method for flow 
cytometry using EGFP and E2-Crimson. This technique combined a yeast 
split-ubiquitin two-hybrid system with a yeast G-protein signaling assay to provide a 
platform for simultaneous analysis of both dimerization and signaling by GPCRs. Using 
the yeast Ste2p, in both native and mutated forms, as a model for GPCR dimerization, 
we demonstrated that our technique provides a simple mechanism for simultaneously 
detecting both dimerization and signaling. In addition, we validated our experimental 
system by simultaneously monitoring homo- and hetero-dimerization and SST-induced 
signaling based on heterologously expressed human SSTR5 somatostatin receptor. 
Since budding yeast S. cerevisiae can functionally express human GPCRs (Minic et al., 
2005), our system is expected to serve as a powerful tool for defining the mechanisms 
and functions of GPCR dimerization for uncovering new GPCR heterodimers that 
participate in regulating physiological functions, and for identifying potential targets for 
the development of new therapeutic agents. 
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GENERAL CONCLUSION 
 
This thesis was carried out with the aim to develop the yeast-based approaches for 
monitoring signal transmission and heterodimer formation for human GPCRs. Because 
these biosensors allowed facile detection of not only dimeric receptors but also 
agonistic ligands, it is applicable to the identification of obscured heterodimer partners 
and the screening of new peptidic agonists for target human GPCRs. Additionally, we 
integrated these two systems into a single yeast strain to permit the simultaneous 
detections of dimerization and signaling of human GPCRs. The constructed yeast 
biosensors will promote the elucidation of mechanisms and roles in the machinery of 
GPCR dimerizations, and the discovery of GPCR heterodimer pairs and peptidic 
sequences as potential therapeutic targets. 
 
In part I, in order to extend the ranges of applicable GPCRs, we constructed an 
improved fluorescence-based microbial yeast biosensor that can monitor the activation 
of human GPCR signaling responding to its agonist using tetrameric Zoanthus sp. green 
fluorescent protein (ZsGreen) as a reporter. Since our system is applicable to not only 
hSSTR5 but also hSSTR2 and hNTSR1, this system can likely be extended to other 
human GPCRs, which comprise one of the most important types of drug targets being 
pursued today. In addition, we established a highly sensitive ligand detection system 
using yeast cell surface display technology that is applicable to peptide screening, and 
demonstrate that the display of various peptide analogs of neurotensin can activate 
signaling through the neurotensin receptor in yeast cells. Application of this method will 
allow the identification of lead peptides from combinatorial peptide libraries to provide 
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starting points for drug screening. 
Moreover, using the refined fluorescence biosensor, we successfully applied to 
antagonist characterization and site-directed mutagenesis analyses of human HTR1A 
receptor. To examine the sensing abilities of yeast-based fluorescence reporter system 
for HTR1A antagonist characterization, we measured antagonist inhibition of the 
agonist-induced activating HTR1A. In addition, we adopted the yeast-based biosensor 
to site-directed mutagenesis. Through this work, these results clearly show the 
importance of the DRY motif for HTR1A function. This yeast-based system using a 
fluorescent reporter gene will be available for other human GPCRs and be beneficial for 
simplifying experimental procedures in a GPCR signaling study. 
Furthermore we introduced a single mutation at the position of Asn295 on human 
AGTR1 and used yeast-human chimeric Gα to exert the functional activation of AGTR1 
in the recombinant yeast cells that allow the signaling assay with fluorescence reporter. 
The engineered yeast cells successfully displayed the functional activation of the 
AGTR1-mediated signaling in response to its agonists, permitting easy monitoring of it 
with fluorescence reporter assay. In addition, we demonstrated that the autocrined Ang 
II peptide and its analogs that were produced in the engineered yeast cells by 
themselves also could activate the AGTR1-mediated signaling. This means that the 
construction of genetic library and its screening would be viable strategy for the human 
AGTR1 assay in yeast, and thus the constructed yeast biosensor integrating 
Asn295-mutated AGTR1 receptor will be applicable to the screens of angiotensin 
agonists and drug designs. 
This study showed that our strategy could apply to various human GPCRs by 
improving the sensitivity of detection system and modifying the human GPCRs. 
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In part II, we have developed a specialized method to screen candidate 
heterodimer partners for target GPCRs based on the split-ubiquitin membrane yeast 
two-hybrid method. This modified system permitted the rapid and facile detection of not 
only the heterodimer formation of target human GPCRs, but also the ligand-mediated 
conformational changes in living yeast cells. Since budding yeast S. cerevisiae can 
functionally express human GPCRs, construction of a large prey library would be 
beneficial for the identification of heterodimer candidates as the partners of target 
human GPCRs. Our system will be a useful tool to assist in the intermolecular mapping 
of interactions among GPCRs and uncover potential targets for the development of new 
therapeutic agents. 
Finally, we designed a dual-color fluorescent detection method for flow cytometry 
using EGFP and E2-Crimson. This technique combined a yeast split-ubiquitin 
two-hybrid system with a yeast G-protein signaling assay to provide a platform for 
simultaneous analysis of both dimerization and signaling by GPCRs. Using the yeast 
Ste2p, in both native and mutated forms, as a model for GPCR dimerization, we 
demonstrated that our technique provides a simple mechanism for simultaneously 
detecting both dimerization and signaling. In addition, we validated our experimental 
system by simultaneously monitoring homo- and hetero-dimerization and SST-induced 
signaling based on heterologously expressed human SSTR5 somatostatin receptor. Our 
system is expected to serve as a powerful tool for defining the mechanisms and 
functions of GPCR dimerization for uncovering new GPCR heterodimers that 
participate in regulating physiological functions, and for identifying potential targets for 
the development of new therapeutic agents. 
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In conclusion, we established the yeast-based approaches for elucidating the 
relationship between functions and structures of human GPCRs. For evaluating GPCR 
functions, we improved the system to monitor signal transmission for human GPCRs. 
For examining GPCR structures, we developed the system to monitor heterodimer 
formation among different types of human GPCRs. Finally, we combined these two 
systems to simultaneously monitor the dimerization and the signaling. The findings of 
physiologically relevant GPCR dimers raise the prospect of developing new drugs 
against a wide range of diseases by focusing on the machinery of targeted dimers. This 
study is expected to provide a helpful tool for the elucidating of molecular biological 
functions of GPCR dimers and for the screening of GPCR dimer-specific agonistic 
ligands. 
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